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Substantial epidemiological evidence correlates low weight or thinness at birth with
increased risk of disease in later life; notably insulin resistance, hypertension and
ischaemic heart disease. This concept of intrauterine life events having permanent
influences upon later health has been termed 'programming'. Whilst the molecular
mechanisms linking these effects are unknown, overexposure of the foetus to
glucocorticoids has been implicated. Treating pregnant rats with dexamethasone
(DEX), a synthetic glucocorticoid commonly used in obstetric practice, results in
offspring born of low weight, who subsequently develop adulthood hypertension,
glucose intolerance and insulin resistance. Whilst prenatal DEX-programmed
glucose intolerance is associated with permanently increased hepatic activity of a key
gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK), mechanisms
underlying the programming of hypertension remain unidentified. DEX-programmed
hypertension occurs in both sexes, whilst hyperglycaemia/hyperinsulinaemia has
only been demonstrated in male offspring. Principally, this thesis investigates the
role of the renin-angiotensin (RAS), and sympathetic nervous systems (SNS) in
determining programmed hypertension, and seeks to determine whether
programming effects are sexually dimoiphic. ft further examines the impact of
dietary manipulations, and environmental noise stress, on prenatally-treated offspring
phenotypes.
DEX administration in the last week of gestation reduces offspring birth
weight and programmes adult cardiovascular and metabolic physiology in a sex
specific manner. In male offspring, prenatal glucocorticoid exposure programmes
elevated basal circulating corticosterone, elevated PEPCK activity, and produces
adulthood post-glucose hyperglycaemia and hyperinsulinaemia. Whilst in female
offspring, prenatal DEX programmes elevated hepatic angiotensinogen mRNA
expression, elevated plasma angiotensinogen and renin activity, and produces
hypertension, when measured by tail-cuff plethysmography.
A 4-fold reduction in dietary sodium intensifies this RAS dysregulation in
female DEX-treated offspring; however this does not exacerbate their programmed
blood pressure phenotype. Conversely, the lower sodium diet results in hypertension
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in prenatally vehicle treated animals, and supports a role for both the HPA and RAS
in mediating this. Furthermore, acute exposure to the lower sodium diet is sufficient
to cause glucose intolerance and insulin resistance in female adult rats, irrespective
of their prenatal treatment.
Unlike previous studies, offspring blood pressure was subsequently assessed
with radiotelemetry, which is unmarred by any stress artefact. We now show that
prenatal DEX-treated male and female offspring actually display lower basal blood
pressure in adulthood; with the commonly expected hypertensive phenotype only
being noted when these offspring are subjected to any stressor, regardless of its
apparent banality. Moreover, DEX-treated offspring sustain this stress-induced
hypertension for longer. These hypertensive responses are mediated by alterations in
the responsivity of the sympathetic nervous system, being ameliorated by the
inhibition of catecholamine synthesis, and further exaggerated by the promotion of
systemic catecholamine release. Additionally, we demonstrate that DEX-treated
offspring display greater sensitivity to various vasoconstrictors in the isolated
mesenteric vasculature.
Finally, perinatal exposure of pregnant rats to environmental noise pollution
results in vehicle-treated offspring with a phenotype analogous to prenatal DEX-
treated offspring i.e. lower birth weight, hypercorticosteronaemia, hypertension, and
features of the insulin resistance syndrome. Conversely, exposure of DEX-treated
offspring to the same perinatal noise stressors does not appear to further influence
their phenotype. Therefore, perinatal stress produces a similar phenotype to prenatal
glucocorticoid over-exposure.
These findings demonstrate that in utero over-exposure to glucocorticoids
actually results in stress-induced hypertension, and support a role for both RAS and
SNS in mediating this. Furthermore, it appears that the programming of
cardiovascular physiology may reflect distinct processes in each gender, whilst the
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During the 9 months of gestational life, a fertilised egg, and later a foetus must negotiate a
plethora of biological milestones, which are sculpted by its intrauterine environment. For
example, without enough folate, a foetus can't build and seal a spine; a deluge of alcohol can
interfere with the delicate wiring of its nervous system; and certain medications taken by the
mother can be detrimental to foetal limb development. However, some effects of gestational
sculpting may lie dormant for decades before rearing their heads.
Such was the conclusion drawn by Professor David Barker, who collected detailed birth
records made by midwives early in the 20th century, and followed up the individuals
concerned until middle age. Unexpectedly, adults who had been born with birth weights at
the lower end of the normal range were found to have a higher risk of a constellation of adult
disease, including hypertension and type II diabetes (Barker et al. 1989; Barker 1990). It was
a startling idea. For years, it was commonly accepted that adulthood cardiovascular disease,
such as hypertension, was due to the interplay between an adverse lifestyle and the
individual's genetic background. Barker's pioneering epidemiological studies now suggested
that the foetal environment is potentially as important as the adult one. His resulting 'Foetal
origins of disease' hypothesis stated that "Foetal undernutrition in middle to late gestation,
which leads to disproportionate foetal growth, programmes later.. ..disease" (Barker 1995).
A flurry of research subsequently focused on the likely physiological and molecular
mechanisms underlying these early life 'programmed' events. In our laboratory, we utilise a
rodent model of foetal over-exposure to glucocorticoids to explain this phenomenon
(Edwards et al. 1993; Seckl et al. 1999b). And indeed, the phenotype of our model
recapitulates many of the features revealed by the human epidemiological studies, including
low birth weight; adulthood hypertension, glucose intolerance, insulin resistance and altered
behavioural responses (reviewed in Seckl 2001; Welberg & Seckl 2001; O'Regan et al.
2001). The aim of this thesis was to investigate the molecular mechanisms underlying the
hypertension associated with prenatal glucocorticoid treatment, and to further determine
whether programmed cardiovascular and metabolic events are sexually dimorphic.
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1.2 Foetal Origins of Adult Disease
1.2.1 Governors of in utero development
In utero growth and development is principally governed by the genetic composition of the
foetus, maternal physiology, and the placenta, which is not only responsible for selective
change of materials between the two, but also serves as an endocrine organ. Placental
function is paramount in delivering adequate oxygen and metabolic substrates to the foetus,
whilst simultaneously removing any waste products. Growth of the placenta and foetus are
not always synchronous, thereby varying demands on the placenta throughout gestation
(Robinson et al. 1995). Whilst placental derived luteinising hormone, progesterone, and
oestrogen are important in maintaining pregnancy, the placenta also secretes other hormones,
amongst them corticotrophin releasing hormone (CRH) (Goland et al. 1993).
The foetal endocrine system is also crucial in governing intrauterine development. Whereas
pituitary growth hormone assumes greater importance after birth, glucocorticoids, insulin and
thyroid hormones all have vital prenatal effects. Insulin, which has little effect on tissue
differentiation, stimulates foetal growth by increasing the mitotic drive and nutrient
availability for tissue accretion (Fowden 1992). In contrast, thyroid hormones affect
differentiation and proliferation of different tissues at different times during gestation,
thereby having an asymmetric effect on growth. Glucocorticoids are mainly concerned with
tissue differentiation and maturation aimed at preparing the foetus for postnatal life (Liggins
1994). They promote surfactant production, allowing postnatal lung inflation (Liley et al.
1988); mature the gastrointestinal tract (Trahair & Sangild 1997); and induce PEPCK
transcription, essential to perinatal gluconeogenesis (Liggins 1976). Their levels rise towards
the end of pregnancy, and are further involved in the initiation of parturition (Whittle et al.
2001). Endocrine effects most probably operate though the IGF system. Both IGF I
(dominant after birth) and IGF II (dominant pre-birth) stimulate growth (Sara & Hall 1990),
and glucocorticoids are essential to induce the switch between the two isoforms (Fowden
1995). Foetal hormones, therefore, promote growth and development in utero by altering
both the metabolism and gene expression of foetal tissues. These endocrine actions ensure
that foetal growth is proportionate to nutrient supply, and that prepartum maturation occurs in
preparation for extrauterine life.
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1.2.2 Early life origins of adult disease
Myriad epidemiological studies suggest that factors operating in early life are important
determinants of the risk of common cardiovascular and metabolic disorders of adult life.
Studies in distinct populations initially in the UK, but later also elsewhere in Europe, Asia,
Australia, Africa, the Caribbean and the USA, have shown that low weight or thinness at
birth increase the subsequent prevalence of hypertension, dyslipidaemia, insulin resistance/
Type 2 diabetes and ischaemic heart disease deaths in adult life (Barker 1990; Barker et al.
1993; Curhan et al. 1996a; Curhan et al. 1996b; Fall et al. 1995; Lithell et al. 1996; Leon et
al. 1996; Forsen et al. 1997; Rich-Edwards et al. 1997). These 'early life' associations appear
to be important predictors of adult disease increasing by 40% to 300% the risk of adult
degenerative disease (Curhan et al. 1996a; Curhan et al. 1996b; Barker 1990).
1.2.3 Proposed hypotheses for and against the early life origins of adult
disease
During critical periods of development, when cells are rapidly dividing, tissues become more
susceptible to the effects of external stimuli, thereby creating 'windows' of opportunity for
the environment to affect development (Widdowson & McCance 1975). These stimuli can
permanently affect a wide range of physiological processes, ultimately resulting in later
dysfunction and disease (Edwards et al. 1993; Barker 1999; Benediktsson et al. 1993). This
phenomenon, referred to as 'programming', was first demonstrated in the late 1960s; when a
single dose of androgen was discovered to permanently modify physiology, through altered
development, but only if it was administered during one of these 'windows' (Arai & Gorski
1968).
Whilst the accumulation of epidemiological evidence linking low birth weight with adult
disease continues to increase, we remain relatively ignorant of the underlying programming
mechanisms. Nonetheless, certain alterations in maternal physiology have recently been
demonstrated to be linked to, or cause, intrauterine growth retardation (KJGR) and
subsequent deranged physiology and disease. Amongst the first and perhaps most renowned
of these implicated maternal malnutrition (Godfrey et al. 1996; Roseboom et al. 2001b), and
is discussed later (see section 1.3.3). However, a plethora of other programming factors have
since been demonstrated; some acting prenatally e.g. cytokines (Dahlgren et al. 2001), and
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others operating within the early postnatal period e.g. endotoxin treatment (Shanks et al.
2000) and physical handling of pups (O'Donnell et al. 1994).
Ifwe recall the importance of endocrine control on foetal growth and development, we might
expect perturbations in intrauterine hormone levels to act as programmers of disease. And,
indeed, altered androgen (Gustafsson & Stenberg 1974a), oestrogen (vom Saal et al. 1997),
and thyroid (Castello et al. 1994) levels all have permanent effects on reproduction, brain or
metabolic function. However, perhaps the most intriguing and wide-ranging influences of
hormonal programming are observed with prenatal overexposure to glucocorticoids
(Benediktsson et al. 1993; Seckl 2001; O'Regan et al. 2001), which is discussed further
below.
The 'Foetal Insulin Hypothesis' (Hattersley & Tooke 1999), provides an alternative
explanation to the above. It suggests that specific genetic polymorphisms result in increased
insulin resistance and impaired growth, and that it is these polymorphisms that underlie the
association of birth weight and adult cardiovascular disease. Of course, this mechanism could
operate in tandem with the previously discussed environmental effects. The role of genetics
in linking birth weight to later disease is discussed in section 1.3.1.
Alternatively, it has been proposed that those who suffered intrauterine adversity and failed to
grow, continue to be exposed to an adverse environment in childhood and later life and it is
this later unfavourable environment that produces the effects attributed to programming in
utero (Wannamethee et al. 1996). However, there is scanty evidence to support this
contention. Rather, associations between low birth weight and elevated blood pressure or
insulin resistance, are found in each social group, and are independent of adult 'lifestyle'
influences such as smoking, alcohol intake and obesity (Barker 1995). These 'lifestyle' risk
factors are additive to the influences of early life, such that, for example, the highest
prevalence of Type 2 diabetes mellitus is seen in those people whom were small at birth but
became obese in adulthood (Hales & Barker 2001).
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1.3 Potential mechanisms for the early life origins of disease
1.3.1 A genetic explanation for programming?
We have already introduced the 'Foetal Insulin Hypothesis' as one potential genetic
mechanism linking low birth weight and later diabetes. Following studies, mainly by Davey
Smith et al have added an extra twist to this hypothesis. They have illustrated a relationship
between offspring of low birth weight and an increased risk of diabetes and cardiovascular
disease in their parents (Davey et al. 1997; Lawlor et al. 2002; Smith et al. 2001; Smith et al.
2000). As discussed previously, the relationship between low birth weight and later risk of
disease in adulthood may be explained by the programming effect of the intrauterine
environment, but the relation between a baby's low birth weight and its parents' risk must
have a different explanation; could a common genetic factor link this transgenerational
association of birth weight and cardiovascular disease? Could the Foetal Insulin Hypothesis
be correct? Lawlor et al are the first group to provide support for Hattersley and Tooke's
hypothesis, by demonstrating an inverse relationship between the first-born birth weight and
mothers' insulin resistance in late adulthood (Lawlor et al. 2002). Naturally, definitive
support for the hypothesis would require the identification of genes or specific
polymorphisms that are associated with low birth weight and diabetes or cardiovascular
disease. Recent explorations have begun to scratch at this frontier, revealing some potential
candidates (Casteels et al. 1999; Hattersley et al. 1998), though they still fall short of fully
explaining the association (Ong et al. 2000; Hattersley et al. 1998). In the interim, Lawlors'
study indicates that at least some of the association between low birth weight and disease
may be genetic, or as in the case of 'lifestyle' risks, additive to the effects of an adverse
intrauterine environment.
1.3.2 The environmental case for programming?
Stronger evidence suggests that it is the maternal environment, rather than genetic factors,
that is the dominant influence on birth size. This concept was first aired in the 1950s when it
was demonstrated in half-sibling studies that there was a stronger correlation between the
birth weights of half-siblings sharing the same mother, than those sharing the same father
(Morton 1955). Most interestingly, recent studies explain these findings as a conflict between
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maternal and paternal alleles. In simple terms, paternally expressed imprinted genes, such as
Ig/2, promote foetal growth, thereby commandeering as many maternal resources as possible;
whereas, maternally expressed genes inhibit foetal or placental growth thereby limiting the
resources allocated to any one conceptus (Tycko & Efstratiadis 2002; Constancia et al. 2002).
The importance of the maternal environment is further supported by embryo transfer
experiments; a foetus transferred to a lager uterus will attain a larger birth size (Snow 1989).
In monozygotic twin studies, the smaller one at birth has higher blood pressure (Levine et al.
1994) and the greatest risk of Type 2 diabetes (Poulsen et al. 1997). As these twins share the
same genetic background, the differences in birth weight must be independent of genetic
factors. In fact, more than 60% of the variation in birth weight between individuals is
attributed to environmental factors (Penrose 1954). Moreover, the occurrence of associations
between early life environmental manipulations and later physiology and disease risk in
isogenic rodent models strongly implicates environmental factors (Holness & Sugden 2001;
Seckl 2001). Finally, postnatal 'catch-up' growth is also a risk factor for subsequent
hypertension (Barker et al. 1989b; Levine et al. 1994), ischaemic heart disease (Osmond et
al. 1993) and insulin resistance (Leon et al. 1996), implying that smallness at birth due to
intrauterine environmental growth restriction, rather than genetic smallness, is more
important in determining the risk of adult disease.
1.3.3 Programming; the role of nutrition
Whilst maternal malnutrition during pregnancy is a popular explanation for the association of
low birth weight and subsequent cardiovascular disease, the key evidence includes "severe"
animal experiments, as few human studies verify the assertion.
The majority of the animal studies have utilised the rat, guinea pig, or sheep, and typically
involve either restriction of food availability (Woodall et al. 1996; Persson & Jansson 1992);
protein intake (Hales 1997) or availability (Whorwood et al. 2001); and sodium intake
(Battista et al. 2002). In general terms, these models tend to mirror the profile of human in
utero growth restriction. Thus in line with the 'Thrifty phenotype hypothesis' (Hales &
Barker 2001), the undernourished foetus makes physiological adaptations from which it
benefits in the short term by increasing substrate availability; but these changes become
permanently programmed and ultimately counterproductive in post-natal life when nutrients
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are readily available. When rats are fed a low protein diet (reduced by 55-67%), offspring
have reduced birth weight, undergo catch-up growth (Vehaskari et al. 2001; Ozanne 2001)
and develop insulin resistance (Ozanne & Hales 2002) and hypertension in adulthood
(Langley-Evans et al. 1996). However, as we will later discuss, the characteristics of this
common nutritional model may be mediated by more fundamental mechanisms, including
foetal glucocorticoid overexposure.
As mentioned, there is rather sparse human evidence for the influence of maternal nutrition
on the early life origins of disease. One study of Dutch adults conceived or born during late
1944 and early 1945, when the Nazi army halted food transport to occupied areas of the
Netherlands, found that the offspring were of lower birth weight and developed glucose
intolerance in adulthood (Ravelli et al. 1998). During this period food consumption
plummeted from 1800 to 400 calories a day. Perhaps surprisingly, not every study of this
time period revealed offspring of low birth weight (Roseboom et al. 2001). Furthermore, a
cross-sectional study of people born during and after the extreme siege of Leningrad in World
War II, failed to demonstrate an association between maternal undernutrition and subsequent
diabetes mellitus or hypertension (Stanner et al. 1997). Finally, one prospective study
examining maternal food intake showed no relationship between birth or placental weight,
and any macro-nutrient (Mathews et al. 1999).
Clearly, severe malnutrition of various origins can programme adult disease in animals.
However, the potential impact of subtle nutritional variations (as opposed to extreme
starvation) of First World mothers on offspring health remains to be clarified.
1.3.4 Hormonal Programming
In response to undernutrition or prenatal stress, increases in the foetal levels of catabolic
hormones (glucocorticoids, catecholamines, P-endorphins), and concurrent decreases in
anabolic hormones (insulin, thyroxine, IGFs) help to modify foetal and placental metabolism,
thereby maintaining fuel availability and foetal growth. However, many of these hormones
have well documented life-long programming effects. This is particularly the case for
steroids, illustrated by androgen's ability to programme adult levels of hepatic steroid
metabolising enzymes, the development of sexually-dimorphic structures in the anterior
hypothalamus as well as sexual behaviour (Gustafsson & Stenberg 1974b). These effects can
only occur during a specific perinatal period, but then persist throughout life, largely
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irrespective of any sex steroid manipulations. Similarly, several features of foetal
glucocorticoid overexposure suggest a role in the early life programming of adult
cardiovascular and metabolic disorders (Figure 1.1). This hypothesis is built on several pieces
of evidence.
















® Structural (bone, fat etc.)
Figure 1.1 Programming of the Hypothalamic-Pituitary-Adrenal axis
Introduction -9-
1.4 Prenatal programming by glucocorticoids
Chapter 1
1.4.1 Glucocorticoids and foetal growth
Life without glucocorticoids is eventually unsustainable. We have already reviewed their
pivotal role in foetal life (section 1.2.1), and in the adult they are key players in the regulation
of fluid and electrolyte homeostasis, blood pressure, the immune system, metabolism and
physiological responses to stress. However, whilst some glucocorticoid is good, more is not
necessarily better. Excessive foetal glucocorticoid exposure retards foetal growth and results
in low birth weight offspring in humans as well as other primates and mammalian species
(Reinisch et al. 1978; Novy & Walsh 1983). Foetal Cortisol levels are increased in fetuses
showing IUGR or in pre-eclampsia, implicating endogenous Cortisol in retarded foetal growth
(Goland et al. 1993). Placental 1 ip-hydroxysteroid dehydrogenase type II (ll(3-HSD-2) is
responsible for maintaining lower foetal levels of circulating glucocorticoid (discussed
further in section 1.4.2b), by inactivating endogenous hormone (Benediktsson et al. 1993).
Activity of this enzyme correlates with birth weight. In rats, lower placental lip-HSD-2
activity, and therefore greater foetal exposure to maternal glucocorticoids, is seen in the
smallest fetuses (Benediktsson et al. 1993). Similar associations between birth weight and
placental ll|3-HSD-2 have been demonstrated in humans (Stewart et al. 1995), though not all
studies have found this (Rogerson et al. 1997). Furthermore, humans homozygous for
mutations of the lip-HSD-2 gene, the rare 'syndrome of apparent mineralocorticoid excess',
show greatly reduced birth weight compared to their unaffected sibs (Dave-Sharma et al.
1998). Finally, in pregnant rats, inhibition of the enzyme with licorice-derived drugs, such as
carbenoxolone, reduces offspring birth weight (Lindsay et al. 1996a; Lindsay et al. 1996b).
When viewed together, the above data provides compelling evidence for the importance of
foetal glucocorticoid load during development.
The mechanisms by which glucocorticoids retard foetal growth are poorly understood, but
most probably involve other hormones and growth factors, such as the insulin-like growth
factors (IGFs). Glucocorticoids inhibit IGF production (Luo & Murphy 1989) and increase
IGF binding protein (IGFBP) expression (Luo & Murphy 1990), thereby antagonizing IGF
action and retarding foetal growth. Transgenic mice overexpressing IGFBP 1 are of low birth
weight and interestingly develop hyperglycaemia in adulthood (Rajkumar et al. 1995).
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Together, these data promote the IGF system as one pathway through which prenatal
glucocorticoids could affect both birth weight and metabolism.
There is also evidence that this pathway may underlie the actions of other programming
agents, notably malnutrition. As mentioned (see section 1.3.3), severe dietary protein
restriction during rat pregnancy produces offspring of low birth weight that subsequently
develop hypertension in adulthood (Langley-Evans et al. 1996; Vehaskari et al. 2001).
However, this model of programming is dependent on the actions of glucocorticoids.
Furthermore, it has been shown that maternal undernutrition elevates Cortisol levels (Fowden
1995) and suppresses foetal IGF-1 levels (Oliver et al. 1993). Interestingly, another study has
shown that maternal protein restriction inhibits placental 1 ip-HSD-2 activity (Langley-Evans
et al. 1996). Thus, a weakened placental barrier together with increased maternal Cortisol
production would significantly increase the foetal glucocorticoid load. Conclusively, in the
rodent model, offspring may have their hypertension prevented by giving either the mother or
her offspring inhibitors of glucocorticoid synthesis (Gardner et al. 1997; Langley-Evans
1997). Not only that, but the hypertension may be recreated by the concurrent replacement of
corticosterone (Langley-Evans 1997), further emphasising the potential role of
glucocorticoids as mediators of the effect ofmaternal malnutrition on foetal programming.
Thus, it is clearly evident that, glucocorticoids are central to mediating programming effects
and that the foetal glucocorticoid load is a crucial factor in development. As to provide a
more comprehensive understanding of the consequences of foetal glucocorticoid excess, we
should firstly discuss the mechanisms of glucocorticoid action.
1.4.2 Mechanisms of glucocorticoid action
1.4.2a Synthesis, transport and metabolism
Glucocorticoids (Cortisol in humans and other mammals, corticosterone in rodents) are
synthesised in the mitochondria and endoplasmic reticulum of cells of the zona fasciculata/
reticularis in the adrenal cortex, under the regulation of the hypothalamic pituitary adrenal-
axis (HPA-axis; Figure 1.2). Adrenocorticotrophin releasing hormone (ACTH), produced by
corticotrophs in the anterior pituitary, binds to adrenal cortex cell surface receptors coupled to
Introduction -11-
Chapter 1
adenyl cyclase. This rapidly activates the first, and rate limiting step in the synthesis of
steroid hormones i.e. removal of the cholesterol side-chain by side-chain cleavage enzyme to
form pregnenolone. Cortisol formation further requires the presence of endoplamic reticulum
cytochrome p450-linked 17a-hydroxylase and 21-hydroxylase, and mitochondrial 11 (3-
hydroxylase, which are only present in the adrenal zona fasciculate/ reticularis, thereby
limiting glucocorticoid synthesis to this organ (Figure 1.3).
ACTH is regulated by CRH and arginine vasopressin (AVP). In basal states, levels of CRH,
AVP and ACTH and Cortisol are released in a pulsatile and circadian fashion, regulated by
the suprachiasmatic nucleus of the hypothalamus. In man and other diurnal animals, peak
secretion occurs in the early morning, while the nadir is usually around midnight, while in
rodents, the cycle is reversed, reflecting their nocturnal activities. Glucocorticoid secretion is
auto-regulated by a negative feedback loop, whereby glucocorticoids regulate the secretion of
CRH and ACTH by binding to receptors in the hippocampus, hypothalamus and pituitary
(Genuth 1992a).
Once secreted, glucocorticoids are predominantly protein bound to transcortin/ corticosteroid
binding globulin (CBG; 70-75%) and albumin (15-20%), whilst only 5-10% circulates as free
steroid (Genuth 1992b). Secreted molecules become bound to a receptor, or are degraded
mainly within the liver and have a half-life of ~ 90 minutes. Metabolism is performed by a
variety of enzymes including 5a and P reductases and lip HSD-2. Conjugation of products
in the liver by glucuronidation or sulphatation precedes excretion through the bile (mainly
rodents) or kidney (mainly humans).
1.4.2b Pre-receptor modulation; 1ip-hydroxysteroid dehydrogenase
enzymes
Access to steroid receptors is regulated by the local activity of the 11 P-HSDs, which are
found in two isoforms. lip-HSD type I is NADPH-dependent and is a predominant
reductase, converting cortisone to Cortisol in man, and 11-dehydrocorticosterone to
corticosterone in rodents. Conversely, 1 lp-HSD-type II is NAD-dependent, and operates in
the opposite direction i.e. type II enzyme is responsible for the de-activation, and type I
enzyme the re-activation of glucocorticoids (Seckl & Chapman 1997).
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I l(3-HSD-typel is abundantly expressed in the liver and adipose tissue, where it acts to
amplify the effect of glucocorticoids (Chapman et al. 1997). Its expression is under the
regulation of glucocorticoids (Jamieson et al. 1999) and other hormones (Gomez-Sanchez et
al. 2003), and its absence diminishes glucocorticoid-inducible responses (Kotelevtsev et al.
1997).
lip-HSD type II is expressed in sites also expressing the mineralocorticoid receptor (MR),
including the kidney and placenta (Krozowski et al. 1995). This enzyme prevents exposure of
MR to active glucocorticoids, which act as a ligand for MR, and circulate in higher
concentration than aldosterone. Absence, mutation or inhibition of this isoform results in
mineralocorticoid mediated salt retention and hypertension (Krozowski et al. 1999;
Tomlinson & Stewart 2001; Stewart 1999; Kotelevtsev et al. 1999). Placental 11P-HSD type
II is responsible for protecting the foetal HPA-axis from the much greater maternal levels of
circulating glucocorticoids (Benediktsson et al. 1993). The implications of this are discussed
in sections 1.4.1 and 1.5.
1.4.2c Glucocorticoid receptors; transcriptional activation and
regulation of expression
Receptors for glucocorticoids are members of the steroid-thyroid-retinoid receptor super-
family. Two cytoplasmic receptors bind glucocorticoids with differing affinity; the lower
affinity Type 2 or glucocorticoid receptor (GR) is widely distributed in the brain and
periphery, whereas the Type 1 receptor or mineralocorticoid receptor (MR) has a high affinity
for glucocorticoids but is more restricted in anatomical localisation e.g. to the distal nephron,
colon, hippocampus and sweat glands (reviewed by Bamberger et al. 1996; Funder 1997a;
DeRijk et al. 2002).
Recently, an alternate splice variant of GR (or GRa), called GRp, has been identified.
However, the importance of this receptor isoform remains to be established (Bamberger &
Chrousos 1995; Hecht et al. 1997), and given its absence in rodents (Otto et al. 1997), is
somewhat controversial. Furthermore, in human cell lines, the presence of an alternately
translated form of GRa has been found, resulting in further subdivision of human GRa into
types A and B, with the latter being twice as efficient at trans-activation (Yudt & Cidlowski
2001; de Castro et al. 1996).
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As glucocorticoids are fat-soluble, they enter cells by simple diffusion and activate the
cytoplasmic receptor via a ligand-binding domain (Figure 1.2). This process involves
dissociation from the heat-shock proteins (HSPs) that form a complex with unbound receptor
(Bronnegard et al. 1995), and translocation of the hormone ligand complex across the nuclear
membrane (Hache et al. 1999). Once its nuclear effect has been achieved, the receptor is
recycled to the cytopolasm, where it re-associates with HSPs (Yang & Defranco 1996).
Ligand receptor classically exerts an effect through dimerisation and attachment of the DNA
binding domain to specific sequences ofDNA in the promoter regions of target genes, known
as glucocorticoid response elements (GREs) (Reichardt & Schutz 1998). It can further
achieve an effect by protein-protein interactions with other transcription factors, which bind
DNA (Reichardt & Schutz 1998). Binding of GR and other transcription factors initiates
chromatin remodeling and modulates the assembly of the transcriptional machinery, such that
target gene transcription is activated or repressed (Reichardt & Schutz 1998). GREs have
been identified in a variety of genes related to cardiovascular (e.g. angiotensinogen; Feldmer
et al. 1991) and metabolic (e.g. PEPCK; Hanson & Reshef 1997) physiology.
As well as regulating the transcription from other genes, the expression of GR itself is
regulated, mainly through the binding of transcription factors to response elements within its
own promoter region, and also through post-translational mechanisms (Dong et al. 1988).
A further mechanism of GR regulation could be through the usage of alternate promoter
regions of the gene (McCormick et al. 2000). The GR gene consists of 9 exons, the
untranslated first containing the promoter region, and the remaining translated or protein
encoding exons 2-9 (Funder 1997b). Multiple transcription initiation sites have now been
identified within exon 1 of rats (McCormick et al. 2000), mice (Cole et al. 1993) and humans
(Breslin et al. 2001) that yield transcripts with different 5' untranslated sequences, permitting
transcriptional control through different specific response elements within the promoter
region. This permits considerable complexity of the tissue (Kalinyak et al. 1989), age (Tohgi
et al. 1995), sex (Owen & Matthews 2003), and metabolic (Burnstein et al. 1991) specific
variation of control of GR expression and, potentially, programming (McCormick et al. 2000;
O'Regan et al. 2001).
Introduction -- 14 -
Chapter 1








































Figure 1.3 Summary of steroid synthetic pathway of the adrenal cortex
Cortisol and corticosterone are synthesised from cholesterol in the endoplasmic reticulum
and mitochondria in the zona reticularis and zona fasciculata of the adrenal cortex.
Aldosterone production occurs exclusively in the zona glomerulsoa.
Abbreviations: SCC: side cleavage chain, 17aH: 17a-hydroxylase, 21H: 21-hydroxylase,
lipH: 1 ip-hydroxylase, 3PHSD: 3P-hydroxysteroid dehydrogenase, 17PHSD: 17p-
hydroxysteroid dehydrogenase, A: aromatase, El: oestrone, E2; oestradiol.
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1.4.2d Glucocorticoid induced insulin resistance and diabetes mellitus
Diabetes mellitus is a series of diseases classified by a lack of control over glycaemia. Type I
diabetes is characterised by early onset and an inability of the pancreatic p-cells to secrete
sufficient insulin, whereas, Type II or non insulin-dependent diabetes mellitus (NIDDM) has
a typical onset in middle-age, and is related to poor glucose tolerance. Most patients with the
latter form of diabetes are resistant to insulin-stimulated glucose uptake, as are ~ 25% of non-
obese individuals with normal oral glucose tolerance, and require their pancreatic P-cells to
sustain a permanent state of hyperinsulinaemia in order to prevent deterioration of glucose
intolerance (Reavan 2000).
Insulin resistance reflects a reduced capacity for many tissues to respond to insulin (sometime
referred to as the 'Insulin resistance syndrome'). In this scenario, hepatic gluconeogenesis is
increased, whilst peripheral glucose uptake is significantly decreased (Boden 2001; Abel et
al. 2001).
There are myriad potential sites of action for glucocorticoids to affect insulin sensitivity
(reviewed by Andrews & Walker 1999). The principle effects of glucocorticoids are broadly
antagonistic to those of insulin in the regulation of carbohydrate, lipid and protein
metabolism by effects on three major sensitive tissues of liver, skeletal muscle and fat.
Glucocorticoids increase blood glucose by mobilising substrates for hepatic gluconeogenesis.
They stimulate the release of amino acids from skeletal muscle, fatty acids and glycerol from
adipose tissue, and increase the expression of gluconeogenic enzymes such as PEPCK
(Hanson & Reshef 1997), thereby enhancing gluconeogenesis in the liver. They also
stimulate glycogen synthesis by activating glycogen synthase and inactivating the glycogen-
mobilising enzyme glycogen phosporylase. Peripheral glucose uptake and utilisation is
further inhibited by glucocorticoids, by decreased translocation of the GLUT 4 glucose
transporter to the cell surface (Weinstein et al. 1998). Glucocorticoids additionally prevent
glucose-stimulated insulin secretion from pancreatic P-cells (Delaunay et al. 1997).
Moreover, given the adverse effects of glucocorticoids on endothelium-dependent
vasodilatation (see section 1.4.2e); it is conceivable that the resulting altered blood flow
would reduce glucose delivery to skeletal muscle.
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Therefore, by increasing gluconeogenesis and inhibiting peripheral glucose uptake and
insulin secretion, glucocorticoids are in a prime position to produce both insulin resistance
and NIDDM. Unsurprisingly then, that clinical cases of Cortisol excess or deficiency are
associated with the most pronounced glucocorticoid mediated effects on glycaemic
homeostasis. In Cortisol deficiency, caused by hypopituitarism or hypoadrenalism (Addison's
disease), tissue sensitivity to insulin is increased. Conversely, in Cortisol excess (Cushing's
syndrome); patients develop glucose intolerance, as well as hypertension and central obesity
(referred together as the 'Metabolic Syndrome' or 'Syndrome X'). More interestingly though,
it has been proposed that lesser perturbations within the HPA-axis, that push Cortisol levels to
the upper limit of normal, may contribute to the pathology of the Metabolic Syndrome
(Bjorntorp & Rosmond 1999), a concept we'll elaborate on later.
1.4.2e Glucocorticoid induced hypertension and cardiovascular disease
In most Westernised countries, cardiovascular disease is the leading cause (almost 50%) of
death in adults, as well as one of the leading reasons for major morbidity, social disruption
and loss of income (Whelton 1984). In the United States alone, nearly 1 million people (or
more than twice the population of Edinburgh) die each year from cardiovascular related
disease. Three times as many suffer a serious clinical event and many more suffer
unrecognized complications, such as silent myocardial infarction, which increase the
individual's risk of subsequent morbidity and mortality. Hypertension is not only one of the
most important predictors of cardiovascular disease but is also a major modifiable risk factor
(Stamler et al. 1986). As with insulin resistance and NIDDM, glucocorticoids play a pivotal
role in the regulation of blood pressure.
Blood pressure (BP) sensitivity to glucocorticoids is present from before birth in both humans
(Kari et al. 1994) and other mammals (Berry et al. 1997), and hypertension is a common
feature associated with the hypercortisolism of Cushing's syndrome (Sasano et al. 2002).
Rats are particularly sensitive to glucocorticoids, with very low doses of dexamethasone
(DEX) (a synthetic glucocorticoid commonly used in clinical practice) increasing blood
pressure within a few days (Tonolo et al. 1988). The cardiovascular effects are associated
with a marked reduction in body weight gain and even weight loss at supraphysiological
doses. Short-term treatment of normal human volunteers with Cortisol produces an effect akin
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to that of mineralocorticoid excess, which differs markedly from the iatrogenic effects of
synthetic steroids or the clinical consequences of Cushing's syndrome (Connell et al. 1987).
Glucocorticoid induced-hypertension is most probably mediated by alterations in: renal
physiology, vascular reactivity, the bio-synthesis of vasoactive hormones, the renin-
angiotensin-system (RAS) and the sympathetic nervous system (SNS) (Figure 1.4).
Glucocorticoids affect renal function by two main processes. DEX ( which is a poor substrate
for llp-HSD type II, but is a greater GR than MR agonist), at concentrations which are
unlikely to evoke a mineralocorticoid response, have been shown to cause a kaliuresis and to
affect cation transport across the colon (Nickerson et al. 1969). The significance to BP
control of this glucocorticoid response, which is presumably GR mediated, remains to be
elucidated. Additionally, as we have previously discussed, if 11P-HSD type II is congenitally
absent or inhibited pharmacologically, then physiological glucocorticoids are free to access
renal MR causing sodium retention and hypertension.
Glucocorticoids also directly alter vascular responsiveness to circulating vasoactive agents
(e.g. to noradrenaline (Russo et al. 1990) and angiotensin II (Sato et al. 1994; Grunfield
1990). For example, mesenteric arteries from DEX-treated rats are more sensitive to the
effects of noradrenaline compared to controls (Russo et al. 1990). Furthermore, inhibition of
nitric oxide synthesis (Wallerath et al. 1999) and decreased levels of both prostaglandin (a
powerful paracrine vasodilator) and its mediator adenylate cyclase (Handa et al. 1984; Handa
et al. 1983) have been demonstrated in adult rats with DEX-induced hypertension.
Glucocorticoids also decrease the biosynthesis of atrial natriuretic peptide (ANP) (Whitworth
et al. 1995), which has vasodilator and natriuretic properties, thereby contributing to their
pressor effects. There is also evidence for inhibition of components of the vasodilatory
kallikrein-kinin-system (Mantero & Boscaro 1992).
The RAS is a key regulator of BP (reviewed in Lavoie & Sigmund 2003; Jan Danser 2003).
In adult rats, glucocorticoids regulate all of the principle components of the RAS including
renin secretion (Burris et al. 1986), angiotensinogen synthesis and expression (Bunnemann et
al. 1993), angiotensin converting enzyme activity (Mendelsohn et al. 1982), angiotensin II
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(Sato et al. 1994) and mineralocorticoid receptor expression (Reul et al. 1989). Their greatest
effect on the RAS is to increase the hepatic production of angiotensinogen (Mantero &
Boscaro 1992). Furthermore, in the fetal rat, hepatic angiotensinogen expression is also
regulated by glucocorticoids (Everett et al. 1991).
Increased sympathetic nerve activity has also been proposed as a mechanism to explain the
pathogenesis of glucocorticoid-induced hypertension. This could arise from changes in
neuronal or extraneuronal uptake of noradrenaline. Decreased neuronal uptake normally
potentiates vasoconstriction caused by catecholamines (Dusting & Li 1986).
Additionally, glucocorticoids have also been shown to directly increase cardiac output in man
(Pirpiris et al. 1993), and to promote sodium influx into vascular smooth muscle cells (Kornel
etal. 1993).
Indirectly, glucocorticoid-induced hyperinsulinaemia may itself promote hypertension.
Insulin resistance is a common feature of essential hypertension (DeFronzo 1992), and
several lines of evidence suggest that insulin resistance per se or hyperinsulinaemia can result
in increased sodium reabsorbtion (DeFronzo et al. 1975; DeFronzo 1981), enhanced vascular
tone and activate the adrenergic nervous system (DeQuattro & Feng 2002), thereby driving
hypertension.
In summary, glucocorticoids potentiate the pressor activity of vasoconstrictors, increase the
activity of the RAS and SNS, and reduce the activity of a number of potent vasodilators.




f Vasoconstriction 4 Vasodilation
(| Renin-angiotensin-system activity





t adrenergic activity .











Figure 1.4 Mechanisms of glucocorticoid-induced hypertension
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As briefly mentioned, the 'metabolic syndrome' (or 'syndrome X') is a cluster of
abnormalities that are risk factors for the development of ischaemic cardiovascular disease
(Reaven 2000; Reaven 2002). These include insulin resistance with compensatory
hyperinsulinaemia, glucose intolerance, increased plasma triglycerides, decreased high-
density lipoprotein cholesterol, hypertension (Reaven 2002), and frequently obesity
(Bjorntorp & Rosmond 1999).
We have previously discussed how glucocorticoids can impact individually on each of these
variables, but more recent studies have focused on the influences of Cortisol secretion on
these collective cardiovascular risk factors. In cross-sectional and case-control studies, higher
blood pressure, glucose intolerance, insulin resistance and hyperlipidaemia are associated
with elevated Cortisol levels, measured in blood, saliva and urine (Phillips et al. 2000; Fraser
et al. 1999; Walker et al. 1998; Phillips et al. 1998; Stolk et al. 1996; Filipovsky et al. 1996)
or impaired peripheral inactivation ofCortisol (Walker et al. 1998).
Tissue sensitivity to glucocorticoids is partially mediated by the density of GR expression,
and can be assessed clinically by measuring the intensity of dermal blanching after topical
administration of DEX. Individuals with cardiovascular risk factors reveal altered peripheral
glucocorticoid sensitivity. Thus, increased vasoconstrictor responses are found in men with
glucose intolerance and insulin resistance (Walker et al. 1998), essential hypertension
(Walker et al. 1996) or with a familial predisposition to hypertension (Walker et al. 1998).
This response is also enhanced in healthy individuals with GR gene polymorphisms
(Panarelli et al. 1998), also associated with familial predisposition to hypertension (Watt et
al. 1992) and greater hyperinsulinaemia (Weaver 2001).
Tissue sensitivity to glucocorticoids may also be adjusted by the lip-HSDs (see section
1.4.2b), and several strands of evidence suggest that lip-HSD type I plays a role in
coordinating metabolic control (reviewed in Seckl and Walker 2001). Recent studies suggest
that impaired 1 ip-HSD type I activity contributes to the pathogenesis of obesity, a feature of
the metabolic syndrome. In the leptin-resistant Zucker obese rat, 1 lp-HSD type I activity is




consequences of the obesity (Livingstone et al. 2000). However, this may also activate the
HPA axis to compensate for the increased clearance of glucocorticoids through reduced
hepatic regeneration. Furthermore, tissue-specific enhanced lip-HSD type I activity may
also promote adverse metabolic effects. For example, whilst Zucker obese rats have impaired
hepatic lip-HSD type I activity, they show enhanced activity of lip-HSD type I in their
omental adipose tissue (Livingstone et al. 2000). Interestingly, this very same pattern of 1 ip~
HSD type 1 dysregulation (i.e. impaired in liver, enhanced in adipose) has been demonstrated
in human obesity (Rask et al. 2001).
Clearly this evidence suggests that altered HPA-axis activity i.e. increased circulating levels
of glucocorticoids together with increased GR sensitivity, contributes to the pathogenesis of
insulin resistance and the development of cardiovascular risk factors. Given the wealth of
evidence from epidemiological studies highlighting the association between low birth weight
and the development of these cardiovascular risk factors; it hardly surprising that
glucocorticoids have been proposed to link low birth weight and the predisposition to disease
in adult life (Edwards et al. 1993; Benediktsson et al. 1993; Seckl et al. 1999). In fact the
'low birth weight syndrome', resembles an attenuated metabolic or Cushing's syndrome
phenotype (diabetes, hypertension, heart disease). This hypothesis continues to be endorsed
by an ever-growing number ofboth animal and human studies, reviewed below.
1.5 Adult phenotype of prenatal glucocorticoid programming
Several groups have begun to examine the effect of prenatal glucocorticoid exposure on long-
term health and metabolism, considering glucocorticoid sensitive physiological systems.
In rats, prenatal exposure to excess exogenous (dexamethasone; DEX) or endogenous
(inhibition of lip-HSD type II by carbenoxolone) glucocorticoids (Figure 1.5) results in
offspring of low birth weight (by 10-16%) (Nyirenda & Seckl 1998; Welberg et al. 2001a;
Levitt et al. 1996; Sugden et al. 2001), that in adulthood have elevated circulating basal
corticosterone levels (Levitt et al. 1996; Welberg et al. 2001a), develop hypertension
(Benediktsson et al. 1993), and glucose intolerance and insulin resistance (Nyirenda & Seckl
1998; Nyirenda et al. 2001), i.e. all the major components of the metabolic syndrome.




heart (Langdown et al. 2001), immune system (Bakker et al. 1998) and brain (Welberg et al.
2001a), which will be discussed further in the next section.
Similar effects of prenatal glucocorticoid treatment have also been noted in guinea pigs (Liu
et al. 2001) and the sheep; where repeated DEX treatment in early pregnancy programmes
hypertension (Dodic et al. 1998), and in mid to late gestation produces glucose intolerance
(Gatford et al. 2000).
The existence of glucocorticoid programming in humans is just beginning to be appreciated.
High-dose glucocorticoid treatment during human pregnancy reduced birth weight (Reinisch
et al. 1978). In rhesus monkeys, brief high doses of DEX in the last trimester affects
hippocampal structure and Cortisol levels in the offspring (Uno et al. 1994). Clinical evidence
concerning the effects of low-dose in utero glucocorticoids is rather sparse. Substrates for
11 p-HSD type II (Cortisol and prednisolone) would be anticipated to have little effect.
Conversely, synthetic, non-11 P-HSD type II substrate glucocorticoids are used in obstretics
for two distinct indications. DEX, betamethasone or triamcinolone are often given to
accelerate foetal lung maturation (thereby preventing respiratory distress syndrome) when
preterm labour threatens (Ward 1994). DEX is rarely administered throughout gestation,
except in cases of congenital adrenal hyperplasia; DEX attenuates adrenal androgen excess,
thereby reducing virilisation (Speiser 1999). In this scenario birth weight has been reported as
normal (Forest et al. 1993), but as we've previously commented, birth weight is only a crude
indicator of an adverse intrauterine environment. As children, these individuals display
altered psychosocial behaviour being shyer and more emotional (Trautman et al. 1995), as
well as demonstrating delayed psychomotor development (Lajic et al. 1998). More
interestingly, late trimester DEX has been shown to be associated with a relative increase in

























Figure 1.5 The placental barrier, and mechanisms of in utero glucocorticoid over¬
exposure
Foetal levels of corticosterone are much less than the maternal circulating levels due to the
enzyme 11 |3-hydroxysteroid dehydrogenase-type II (11 fl-HSD type II), which inactivates the
majority of maternal glucocorticoid diffusing across the placenta. Foetal over-exposure to
glucocorticoids may occur if dexamethasone (DEX), which is a poor substrate for the




1.6 Physiological mechanisms of prenatal glucocorticoid
programming
1.6.1 HPA-axis programming
A series of studies have examined administration of ACTH or Cortisol to pregnant rats. Since
neither ACTH nor physiological corticosteroids freely pass the placenta, the results have been
unsurprisingly modest and discordant, probably a reflection of the doses used than any
consistent pattern of effects (reviewed by Welberg & Seckl 2001). In contrast, prenatal
exposure to DEX, which readily passes the placenta, reduces brain weight (DeKosky et al.
1982) and alters adult behaviour (producing behavioural inhibition and reduced coping in
adverse situations) (Welberg et al. 2001a), though the outcome depends upon the timing of
gestational exposure. These effects may reflect altered amygdala gene expression and
function with CRH, GR and MR genes implicated (Welberg et al. 2001a), so far in specific
nuclei of this region underpins fear and learning as well as driving HPA activity.
Prenatal DEX also affects HPA-axis activity in the rat. Both long and short term exposure to
DEX in utero result in adult rats with elevated basal glucocorticoid levels (Levitt et al. 1996;
Welberg et al. 2001a). However, the mechanisms underlying the increased HPA-axis activity
appears to differ depending upon the timing of exposure. DEX exposure in the final trimester
of pregnancy increases CRH mRNA in the hypothalamic PVN and reduces hippocampal MR
and GR (Welberg et al. 2001a), whereas DEX throughout gestation does not alter
hippocampal GR or MR, but increases receptor expression in the amygdala, a structure which
stimulates the HPA-axis (Levitt et al. 1996; Welberg et al. 2001a). Thus late gestational
exposure to DEX may permanently alter the 'set point' of the HPA-axis at the level of the
hippocampus, reducing feedback sensitivity, whereas continuous exposure to DEX
throughout gestation may increase forward drive of the HPA-axis at the amygdala. Thus,
distinct neural mechanisms appear to modulate the common outcome of altered HPA-axis
activity following prenatal glucocorticoid exposure. Similar heterogeneity of effects has been




How might such mechanistically distinct effects come about with exposure during different
times? As mentioned previously, it is intuitive that programming can only occur during the
development of a tissue. Thus, glucocorticoid exposure in the last days of gestation in the rat
can only target those actively developing CNS regions, such as the hippocampus, whilst those
regions that are yet to develop or are already in their final state are protected. Of course the
long and complex pre-and postnatal ontogeny of the brain make it a prime target for
programming. Complex patterns of expression of the key candidate genes GR, MR and 11 p-
HSDs in the brain may underlie this (Diaz et al. 1998; Matthews 1998). Indeed, lip-HSD
type II is highly expressed in mid-gestation CNS and the outcome for the HPA-axis and
behaviour of its inhibition during pregnancy appears to encompass some aspects of both early
and late DEX exposure, consistent with this notion (Welberg et al. 2001a). Whilst the details
of ontogenic patterns are species-specific (for example near term the guinea-pig shows a
dramatic reduction in PVN GR (Matthews 1998), whereas the sheep shows reduced
hippocampal GR (Andrews & Matthews 2000), perhaps both necessary to facilitate the
glucocorticoid surge necessary for parturition in these species (Challis et al. 2001), the broad
spectrum of tissues protected from or allowed timed exposure to glucocorticoids appears a
tenable interpretation of these complex patterns of gene expression. Clearly glucocorticoids
(whether endogenous or exogenous) can only have developmental effects on specific target
genes and systems during their individual ontogenic windows of susceptibility.
The evidence for programming of the HPA-axis in humans has only begun to be investigated.
Intriguingly, birth weight correlates closely with HPA-axis measures from infancy (Clark et
al. 1996), through young adulthood (Levitt et al. 2001) to old age (Phillips et al. 1998;
Phillips et al. 2000). Low birth weight associates with both increased basal and ACTH-
stimulated Cortisol levels (Levitt et al. 2001). Even though roles for MR and GR remain to be
fully elucidated, evidence supporting a physiological role for MR in human central feedback
includes the observation that MR antagonists potassium canrenoate and spironolactone both
increase plasma Cortisol (Heuser et al. 2000; Arvat et al. 2001). Whether prenatal exposure to
DEX or liquorice derivatives have similar human HPA-axis programming effects is
unknown, though fludrocortisone decreases plasma Cortisol levels, hinting at impaired central
negative feedback (Mangos et al. 2000) (of course positive HPA-axis drive could be equally




1.6.2 Programming of insulin-glucose metabolism
In rats, prenatal DEX reduces adulthood glucose-induced insulin secretion (Holness &
Sugden 2001), probably due to a programmed reduction in |3-cell mass (Petrik et al. 1999),
thereby causing impaired pancreatic function. Whilst the molecular changes underpinning
this remain to be fully documented, recent studies suggest increases in pancreatic GR are at
least partially responsible (Sugden & Bulmer 2001).
Permanent up-regulation in the activity of a key hepatic gluconeogenic enzyme, PEPCK, has
also been reported (Nyirenda & Seckl 1998). This effect is confined to the gluconeogenic
periportal region of the hepatic acinus, where strikingly, GR expression is also increased
(Nyirenda & Seckl 1998). Thus, it is likely that hypercorticosteronaemia in these animals, act
on higher hepatic levels of GR to increase PEPCK activity, thereby promoting increased
gluconeogenesis. Moreover, increased GR and attenuated fatty acid uptake, specifically in
visceral adipose (a key clinically important metabolic depot) is consistent with insulin
resistance, and could contribute to the increased hepatic glucose output in this model
(Cleasby et al. 2003). Finally, the window for these programmed effects is restricted to the
last trimester (Nyirenda & Seckl 1998), and operates directly on the foetus / neonate, rather
than via indirect effects on maternal postnatal nursing behaviour (Nyirenda et al. 2001).
1.6.3 Programming blood pressure regulation
Whilst much work has elucidated the mechanisms of programmed insulin/ glucose
metabolism, relatively little is known of the mechanisms ofDEX programmed hypertension.
In rats, prenatal DEX, largely in the last trimester, affects the development and maturation of
specific organs related to blood pressure control and maintenance. Specifically, prenatal
glucocorticoids or stress affect the developing heart, vasculature, kidney and brain. Effects
include permanent induction of the pattern and balance of alpha and beta adrenergic receptor
expression (Huff et al. 1991) and potentiation of adenylate cyclase (Bian et al. 1993); either
might alter the subsequent vascular responsivity to vasoconstrictors, though this awaits
investigation. Development of the heart and its biochemistry are also programmed by
prenatal DEX (Bian et al. 1993), as is the sympathetic innervation of some organs (Navarro




endothelin-1 sensitivity (Docherty et al. 2001). Yet, to what extent these and other possible
perturbations in local and/ or the systemic SNS mediate DEX programmed hypertension
remains unknown.
Some data in sheep have implicated the renin-angiotensin-aldosterone system (RAS) (Moritz
et al. 2002; Dodic et al. 2002). For example, foetal sheep directly infused with Cortisol
become hypertensive and show increased pressor responses to angiotensin II (Tangalakis et
al. 1992). In the rat, it is unknown whether prenatal DEX-induced changes in RAS also
occur, or if they have life long cardiovascular implications. As mentioned previously,
glucocorticoids regulate all aspects of the RAS in the adult rat (see section 1.4.2e), and more
importantly, in the foetal rat, they regulate hepatic angiotensinogen expression (Everett et al.
1991).
Finally, most blood pressure studies in the rat have utilised either tail-cuff plethysmography
or carotid cannulation (Benediktsson et al. 1993; Levitt et al. 1996; Lindsay et al. 1996a).
Both techniques are marred by serious technical artifacts (see Chapters 2 and 5 for further
discussion); moreover, measurements are recorded during the daytime, when offspring are in
their quiet phase of their circadian rhythm. Therefore, non-stressful and physiologically
accurate 24 hour blood pressure and haemodynamic profiling is clearly required. Only then,
will we be fully equipped to comprehend the true nature and real impact of prenatal
glucocorticoid treatment on cardiovascular physiology.
1.6.4 Effect of perinatal stress on programming
Prenatal environments exert profound influences on the development of an organism and can
predispose it to adaptive disturbances in later life. For example, maternal stress, particularly
during the final trimester, has been shown to have long term programming effects on rat
offspring (Peters 1982; Dunn & Berridge 1990). Interestingly, these effects are analogous to
those seen in adult offspring of dams treated with DEX during the last week of pregnancy
i.e.: hyperactivation of the HPA-axis (Hennessy et al. 1999), altered corticosterone secretion
(Henry et al. 1994; Reul et al. 1994), altered GR expression (Koehl et al. 1999), increased
tissue sensitivity to glucocorticoids (McCormick et al. 1995) and increased stress




secretion of glucocorticoids (Selye 1976), it is most probable that endogenous increases in
foetal glucocorticoid exposure during stress are responsible for the similarities shared
between the two prenatal models. Additionally, elevated maternal glucocorticoid levels may
further modify glucocorticoid secretion in the offspring by acting on developing
noradrenergic systems (Barbazanges et al. 1996). Indeed, prenatal stress increases the
turnover of brain noradrenaline in adult rats (Takahashi et al. 1992)(as does prenatal DEX;
Slotkin et al. 1992), and noradrenaline exerts a direct inhibitory control on hippocampal
corticosteroid receptors, thus facilitating corticosterone secretion (Maccari et al. 1992 ; Yau
& Seckl 1992).
Programming effects are not just restricted to prenatal manipulations, as 'neonatal handling'
(Meaney et al. 1996 ;0'Donnell et al. 1994) and stress (Meaney et al. 1996) have also been
shown to exert long-term effects on stress susceptibility. In the 'neonatal handling' paradigm,
15 minutes of daily 'handling' of pups during the first week or two of life permanently
increases hippocampal GR, thereby potentiating the HPA-axis sensitivity to glucocorticoid
negative feedback (Meaney et al. 1988); ensuring low levels of plasma glucocorticoids, a
state compatible with good adjustment to environmental stress (Meaney et al. 1992).
Neonatal glucocorticoid exposure appears to have similar effects (Catalani et al. 1993).
Neonatal handling further enhances maternal care-related behaviours, which correlates with
offspring HPA-axis physiology and hippocampal GR expression (Liu et al. 1997). Moreover,
the long-term effects of some prenatal programming can be considerably modified in the very
early postnatal period (Maccari et al. 1995).
Therefore, by operating through distinct developmental 'windows', similar early life events
can produce manifold differing manifestations, that are wholly dependent on the degree,
duration, developmental timing or sequence of events. This equally applies to programmed
human pathophysiology (Seckl 2001). However, the long-term cardiovascular and metabolic
consequences of any form ofperinatal stress remains to be elucidated.
1.6.5 Effect of gender on programmed phenotypes
In several other paradigms, perinatal manipulations that permanently alter adult HPA-axis
function are sex-specific (Weinstock et al. 1998; Mathews et al. 1999), and the importance of




(Adair & Cole 2003) and rodents (Ortiz et al. 2003 ; Khan et al. 2003) . Moreover, there is no
reason to assume that if a similar programmed phenotype is obtained that identical
mechanism underlie it. Indeed, early or late gestation DEX or 1 ip-hydroxysteroid
dehydrogenase inhibition all produce HPA axis hyperactivity but involve distinct central
mechanisms (Welberg et al. 2001a; Welberg et al. 2001b; Welberg et al. 2000). However,
little work has been done on the effects of prenatal steroids and peripheral programming
phenotypes. Recently, gender-specific patterns of programmed insulin resistance have been
observed in the male offspring of dams, whose diet was protein restricted during pregnancy
and lactation (Sugden & Holness 2002). DEX-programmed hypertension occurs in both
sexes, but may reflect distinct processes in each gender, whilst





Against this background, we hypothesised that prenatal DEX given in the last week of
pregnancy would result in permanent alterations in both the RAS and SNS, which in
adulthood would produce altered cardiovascular and metabolic phenotypes. We further
hypothesised that these altered phenotypes would be gender specific.
1.8 Objectives and Aims
In examining our hypothesis we addressed the following key questions:
H; What are the effects of perinatal stress upon the cardiovascular and metabolic
phenotypes of in utero DEX and control treated rats?
<d Are there gender differences in the prenatal glucocorticoid programming of
cardiovascular and metabolic physiology?
d Does prenatal DEX treatment programme offspring RAS, and, if so, does this
contribute to their cardiovascular phenotype?
Do alterations in dietary sodium affect the metabolic and cardiovascular phenotypes
of in utero DEX and control treated rats?
d What are the circadian blood pressure, haemodynamic and activity profiles of a rat,
programmed by prenatal over-exposure to glucocorticoids?


















All other solid chemicals
Becton Dickinson, Crowley, Oxon, UK.
BDH-Merck, Poole, Dorset, UK.
Brights, UK.
Hayman Ltd., Witham, Essex, UK.
Roche Diagnostics Ltd., Lewes, East
Sussex, UK.
Sigma-Aldritch Company Ltd., Poole,
Dorset, UK.
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TaqMan™ primers and probes
TaqMan™ PCR core reagent kit
NICK sephadex G-50 DNA column
Zeta-Probe® GT, Nylon membrane
Agarose
PicoFluor 40 Scintillant fluid
NTB-2 photographic emulsion
Kodak D19 developer
Amfix high speed fixer
lkb DNA Ladder
First strand buffer





Amersham Pharmacia Biotech, Little
Chalfont, Buckinghamshire, UK.





H.A. West, Edinburgh, UK.
Invitrogen Life Technologies/Gibco
BRL, Paisley, UK.
Phillip Harris Scientific, Ashby-de-la
Zouch, Leicestershire, UK.









p-GEM-T Easy Vector cloning kit
Taq DNA Polymerase and buffer
Wizard Plus Miniprep DNA purification
System Promega Ltd., Southhampton, Hants,
UK.
Qiagen PCR purification kit Qiagen Ltd., Crawley, West Sussex,
UK.




Kodak Biomax MS film
Kodak Biomax MR film Sigma.
Oligonucleotides TAGN, Newcastle-Upon-Tyne, UK.
2.1.3 Protein Reagents
Bradford Protein Assay Reagent Bio-Rad Laboratories Ltd.
2.1.4 Antibodies
Anti-Angiotensin 1 antibody
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Wistar rats were purchased form Harlan Orlac, Bicester, Oxon, UK.
Standard chow was supplied by Special Diet Services (SDS), Witham, Essex, UK, and
contained 61.9% carbohydrate, 18.8% protein, 3.4% oil and 0.6% salt.
Scientific Diet Service, a division of SDS supplied the Normal Sodium (0.3%), Low
Sodium (0.03%) and High Sodium (3%) diets, which contained the same
carbohydrate, protein and oil as standard chow.
2.1.7 Drugs




(Nalbuphine Hydrochloride) Du Pont, UK.
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Halothane-VET Merial Animal Health Ltd., Dublin,
Ireland.
Sagatal
(sodium pentobarbitone, 60mg/ml) Rhone Merieux, Essex, UK.
Multiparin®




[Arg8] Vasopressin Acetate salt
Reserpine
D-amphetamine Sigma
2.1.8 Materials for plasma assays
Anti-rabbit scintillation proximity assay
reagent Amersham Pharmacia Biotech.
Rat Insulin ELISA Kit
(Containing Antibody-coated microplates, 2.56ng lyophilised rat insulin standard,
sample dilutent, Anti-Rat Insulin Enzyme Conjugate stock solution, Enzyme
conjugate dilutent, enzyme substrate (TMB) solution, enzyme reaction stopping
solution (IN Sulphuric acid), X20 concentrated washing buffer stock solution)
Crystal Chem Inc., Chicago, Illinois,
USA.
Count-A-Coat Aldosterone Radioimmunoassay
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(Containing 200 Aldosterone Ab-coated polypropylene tubes, lyophilised iodinated
aldosterone, 8 lyophilised processed human aldosterone calibrators)




(Containing 7 lyophilised ACTH calibrators in human plasma matrix, [ I]-ACTH
Ab, C-terminal anti-ACTH, coupled to sheep anti-rabbit coated tubes, X20 wash
concentrate.) Euro-Diagnostica B. V., Arnhem, The
Netherlands.
Oestradiol ELISA
(Containing 96 microtiter wells, coated with anti-oestradiol serum, estradiol
conjugated to horseradish peroxidase, reference standard set, 0-2000pg/ml, substrate
solution (TMB), stop solution and X40 wash solution.)
Steroid free human serum.
Immunodiasgnostic Systems, Tyne &
Wear, UK.
Infinity Glucose Reagent
(Containing 2.1mM ATP, 2.5mM NAD, >1500U/L yeast hexokinase, >3200 U/l
Glucose-6-phosphate dehydrogenase)
P-Hydroxybutyrate Assay kit
(Containing P-HBA reagent (4.6 mM NAD, oxamic acid and buffer, pH 7.6), 50
units/ml P-hydroxybutyrate dehydrogenase, pH7.6, 50mg/ml D-P-Hydroxybutyrate
Calibrator)
10, 25 & 75mg/ml D-P-Hydroxybutyrate Calibrators
Sigma Diagnostics
Angiotensinogen and Renin Assays
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Norit Charcoal Norit N. V, Amersfoort,
The Netherlands
Dextran T70 Pharmacia AB, Uppsala, Sweden.
Porcine Kidney Renin
(1U; liberates lOOpg ofAngiotensin II
from Angiotensinogen per hour at pH 6
and 37°C) Sigma
RIA cups
(No. 73.1055) Sarstedt, Beaumont Leys, Leicester,
UK.
Angiotensin I standard (lpg/ml)
Anti-Angiotensin I Ab
Renin Inhibitor
Bilaterally nephrectomised rat plasma Generous gifts from Dr. C.J. Kenyon
2.1.9 Materials for Animal Surgery
Alzet® Mini-Osmotic Pumps,
Model 2002 (0.5pl/Hr for
14 days)
All surgical instruments
Alza Corporation, Palo Alto, CA 94303,
USA.
Fine Science Tools, Haverhill, Suffolk,
UK.
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Catheters for Carotid Cannulation
(Non-sterile polythene tubing (o.d. 0.38mm, i.d. 1.09mm; ref. 800/110/120) inserted
a distance of 0.2cm into the flared end of a translucent thin walled PVC tube (o.d.
0.63mm, i.d. 1.4mm;ref. 800/010/100/800). Portex Ltd., Hythe, Kent, UK.
Harvard Apparatus Vet Fluosorber
Fluovac International Market Supply Shirley Aldred & Co. Ltd., Bradwell,
Sheffield, UK.
All syringes, hypodermic needles,
venflons and suture material. Surgical Supplies Services Ltd.,
Cumbernauld, Glasgow, Scotland, UK.
2.1.10 Equipment
TaqMan™ ABI Prism 7700 Sequence
Detector™ Applied Biosystems, UK.
MacClassic II/ MacLab/4e




GeneQuant RNA/DNA Calculator Amersham Pharmacia Biotech.
Berthold LB 2111 y-counter Berthold Technology Ltd., St. Albans,
Herftfordshire, UK.
Thermacage Incubator
(utilised to warm rats prior
to tail-cuffplethsymography) Beta Medical and Scientific, Sale, UK.





(utilised for maxi-preps and the
preparation of competent cells) Beckman Instruments, High Wycombe,
Buckinghamshire, UK.
Electrophoresis Power Pac 300
Model 583 Gel Dryer
EL 312e Bio-Kinetics Microplate
Reader
Dage MTI CCD72S imaging camera
Elcomatic EM 720, pressure transducer
(utilised in mesenteric perfusions)
Bio-Rad Laboratories Ltd.
Bio-Tek Instruments Inc., Winooski,
Vermont, USA.








FSA Laboratory Supplies, Fissons pic.,
UK.
Fuji Photo Film Company Ltd., Toyko,
Japan.
Peristaltic pump
(utilised to perfuse mesenteric vasculature) Gilson Minipuls, Villiers, France.
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Labofuge 400R Centrifuge
(utilised for 15 and 50ml volume Falcon tubes)
Heraeus, Brentwood, Essex, UK.
Ultra-Turrax T8 auto-homogeniser Ika, Labortechnik, Staufen, Germany.
Northern light B95 Precision Illuminator
IEC-Centra-8R centrifuge





(chart recorder that was coupled to pressure
transducer) Lectromed, Letchworth, UK.
Leica Cryostat Leica Microsystems, UK.
Phosphoimager FLA-2000
SensorNor 840, Physiological Pressure
Transducer.





SensoNor a.s., Horten, Norway.
Shimadzu Europa, Milton Keynes,
Buckinhamshire, UK.
Skatron Instruments, Dolasketta, Lier,
Norway.





(utilised for extraction of steroids
from rat serum)
1450 Microbeta Plus Liquid Scintillation
Counter
(utilised for standard cpm counting)
2.1.11 Software
Sequence Detector 1.6.3 software
Dataquest™ A.R.T.™ 2.1
MCID-M4 Image Analysis V.3.0 Rev 1.5
MacLab Chart V 3.3.5
Fujifilm Fluorescent Image Analyser
FLA-2000 V.1.0
Aida 2.0 Auto Image Data Analyser
Stastistica v.5.0
Mulitcalc Advanced v2.0




Data Sciences International, MN, USA.
Imaging Research Inc.
ADInstruments Ltd.
Raytest Scientific Ltd., Sheffield, UK.
Statsoft, Tulsa, Oklahoma, USA.
Wallac Oy.
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Borate Buffer: 8.25g Boric Acid and 2.7g sodium hydroxide dissolved in 11 dH20
and set to pH 7.4 with hydrochloric acid.
Caesium chloride/TE buffer: lOOg CsCl dissolved in 100ml TE buffer.
Charcoal: 6.07g of TRIZMA base added to 0.51 distilled water, 5ml 5M HCL, 2g
neomycin sulphate, 1.85g EDTA, 5g BSA, made up to 11, pH 7.4 and stored in
100ml aliquots at -80°C. Prior to use; 0.062g Dextran T70 dissolved in 5ml of the
above buffer. Final solution containing 0.6g Norit charcoal, 95ml buffer and 5ml
Dextran T70 solution, kept at 5°C.
Deionised Formamide: 150ml formamide mixed with 15g mixed bed ion-exchange
resin for >lhr, filtered twice and stored protected from light.
DEPC-treated water: Distilled water mixed with diethylpyrocarbonate (DEPC; 1
drop/ 100 ml), shaken and left for 1-24 hours prior to autoclaving.
1Kb DNA ladder: 20pg 1Kb ladder (Gibco, UK), in 200pl distilled water with 10%
(v/ v) loading buffer.
GTE: 50mM glucose, 25mM tris, lOmM EDTA in dH20, adjusted to pH 8 with
hydrochloric acid.
Loading buffers: (a) 40% sucrose w/ v, 0.25% bromophenol blue (w/ v) in dH20; (b)
0.35% w/v orange G, 40% glycerol in dH20.
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LB Agar: LB broth plus 15g of agar/1 added prior to autoclaving.
LB broth: lOg bactotryptone, 5g bacto yeast extract, 5g sodium chloride in 11 dH20,
autoclaved immediately.
10X MOPS buffer: 42g MOPS, 16.6ml 3M sodium acetate and 20ml 0.5M EDTA
dissolved in 11 dH20; adjusted to pH 7.
Phosphate buffered Saline (PBS): 0.1M phosphate buffer with 137mM NaCl,
2.7mM KC1 in distilled water, pH 7.4, autoclaved before use.
Physiological Salt Solution (PSS; 'Krebs' bicarbonate solution): 123mM NaCl,
2.65mM KC1, 1.2mM KH2P04, 1.29mM CaCl2, 1.2mM MgS04, 25mM NaHC03 in
distilled water, pH 7.4. Stored at 4°C and supplemented with ll.lmM glucose and
18pM ascorbic acid glucose immediately before use, continuously oxygenated by
bubbling 95% 02: 5% C02.
5M Potassium acetate: 245.6g potassium acetate dissolved in 300ml dH20, 57.5ml
glacial acetic acid and 142.5 ml water (final volume 500ml).
lOx Reverse Transcription buffer: 0.1M Tris-HCl, 0.5M KC1, 1% Triton X (ready
mixed from Promega).
SDS solution: 0.2M sodium hydroxide, 1% w/v SDS.
Thermophilic DNA polymerase lOx reaction buffer: 500mM KC1, lOOmM Tris-
HCl and 1% Triton X (ready mixed from Promega).
SxTranscription optimised buffer: 200mM Tris-HCl, 50mM NaCl, 30mM MgCl2,
and lOmM spermidine (ready mixed from Promega).
IOxTBE buffer: 0.9M TRIZMA base, 0.9M Boric acid, 20mM K2-EDTA in
distilled water.
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TE buffer: lOmM tris, ImM EDTA, adjusted to pH 8 with concentrated hydrochloric
acid; autoclaved prior to use.
50mM Tris buffer: 12.14g of TRIZMA base added to 11 distilled water, 10ml 5M
HCL, 3.5g neomycin sulphate, 1.75g Human serum albumin, made up to 21, pH7.4,
stored in 10ml aliquots at -80°C.
Ultra-pure water: d^O, UV-treated and autoclaved.
2.1.12 Drugs used in Mesenteric Perfusion Studies
Arginine Vasopressin acetate (A VP): 216.8mg dissolved in 20ml-distilled water
(final concentration 10"4). 1ml aliquots stored at -20°C. AVP was diluted to
concentrations between 0.2 and 20nM in PSS prior to use.
Noradrenaline (NA): 95.79mg dissolved in 30ml-distilled water (final concentration
10~2M). 1ml aliquots stored at -20°C. NA was diluted to concentrations between 0.2
and 20pM in PSS immediately prior to use.
2M Potassium Chloride (KCl): 14.91 g dissolved in 100ml distilled water. Stored at
4°C. Prior to use, this solution was substituted for NaCl in the PSS to a final
concentration of potassium between 25 and 125mM.
2.1.14 Drugs used in surgery
Nubain: One ml volume of strawberry jelly per average weight of rat was given, i.e.
0.5mg ofNubain/ml ofjelly/250g rat. The jelly recipe was prepared as directed to the
part where the jelly is dissolved in hot liquid. The volume of dissolvent used was
reduced by the volume of Nubain to be added. When the mixture was <30°C, the
Nubain was added, and once the jelly had set, it was placed on the cage floor.




All animal procedures were performed under the terms of the Animals (Scientific
Procedures) Act 1986 and Project Licence number 60/2466. I was responsible for the
maintenance of and prenatal injections given to the rats, with assistance from Mr.
Keith Chalmers, Mr Donald Hay, MrWilly Mungall and Ms Sharon Rossiter.
Animals were principally under my care, with assistance from the animal technicians
of the Biomedical Research Facility throughout all experiments. Wistar rats were
utilised in each experiment. All rats were maintained under controlled conditions of
light (lights on 08.00 h - 20.00 h) and temperature (21-22°C), and allowed free
access to standard chow and drinking water. Adult and post weaning rats were kept
up to a maximum of 8 per cage and cleaned out weekly. Rat pups were kept with
their mothers until postnatal day 21 and were not cleaned during this period.
"Bought in" rats were allowed to acclimatise to their new environment for a
minimum of one week before mating. Single virgin females were housed with a male
for the purposes of mating which was deemed successful when an expelled vaginal
plug was observed. This was designated day zero of pregnancy. Males were used to
impregnate a maximum of two females. Pregnant females were housed singly during
gestation. Litters were weighed individually at birth and culled to eight, retaining
either as many males as possible or in latter cohorts equal numbers of males and
females. Pups were weaned at postnatal day 21 and separated according to sex for
housing with littermates where possible. Offspring were weighed at this time and at
regular intervals throughout postnatal life. In all experiments offspring were selected
randomly from as many litters as possible, when this was impossible, a maximum of
two animals from each litter were utilised per experiment.
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Prenatal administration of dexamethasone was preformed as previously described
(Nyirenda et al. 1998). Briefly, dams were treated with daily morning subcutaneous
injections of dexamethasone (lOOpg/kg/d) in 0.9% saline / 4% ethanol during the last
week of gestation i.e. day 15 to day 21 inclusive. Control animals received
equivalent injections of vehicle (1 ml/kg, 0.9% saline / 4% ethanol) during the same
time period.
Following successful pregnancy and birth, all "bought in" breeding pairs were
sacrificed by cervical dislocation. Subject offspring were killed in a similar fashion
or by decapitation. Relevant tissues were dissected, cleaned and weighed when
necessary and quickly frozen on dry ice. Trunk blood was collected into a plastic
tube containing ~0.1ml of lOOmM EDTA via an EDTA-coated funnel, and quickly
placed on ice. The tubes were then centrifuged at 2000g for 10 minutes, and the
supernatant plasma transferred to Eppendorf tubes. Plasma and tissue were stored at -
80°C.
2.3.2 Staging the oestrous cycle
To stage the oestrous cycle, 1ml of sterile saline was introduced to the rat's vagina
and epithelial cells were aspirated and placed on a glass slide for microscopic
inspection. The oestrous cycle was then staged according to the Journal of Animal
Technicians Association, 12.No.l. Staging was independently verified by at least one
other researcher/animal technician.
2.3.3 Glucose tolerance tests
Rats were fasted from 17.00h to 09.00h, weighed and a basal blood sample (t = 0)
taken by tail tip (i.e. removal of the distal 5-10mm of their tails). The rats were then
administered 2g/kg glucose by gavage and returned to their cages. At 30 and 120
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mins post glucose administration, additional blood samples were taken by 'tail-
milking' (i.e. massaging the tail distally). All blood samples were collected into
heparinised Eppendorf tubes, and treated as outlined above for the collection of
plasma. Samples were frozen at -80°C. At the end of the glucose tolerance test and
after bandaging their tails, the rats were allowed free access to food and water.
2.3.4 Pre- and post-operative care of animals
Prior to each surgical procedure, all animals were anaesthetised with Halothane and
the appropriate surgical sites shaved and swabbed with ethanol. The rat was then
placed on a warm plate, to maintain body temperature; additional heat was provided
by the use of angle poise lamps. Immediately before the first incision and at regular
intervals during the procedure, the depth of anaesthesia was determined by pinching
the rat's foot tightly and observing any changes in respiration.
Postoperatively, all animals were placed in a cage on their own, under an infrared
light. Each cage contained dishes of water, food and analgesia in jelly (nubain),
thereby allowing the rat to self-medicate. The following day the animals were closely
inspected for any signs of infection/discomfort and if healthy, were moved to an
appropriate experimental cage.
2.4 Procedures for Blood Pressure Measurement
Both indirect and direct methods of blood pressure measurement were utilised. Blood
pressure measurements were made in the first instance when the animals were three
months old, to test for the programming phenotype, and then during subsequent
experimental procedures.
Materials and Methods -49-
2.4.1 Tail Cuff Occlusion Plethysmography
Chapter 2
In general, the indirect blood pressure measurement techniques used for rats allow
the investigator to measure systolic blood pressure over a long period of time in the
same conscious animal without the need for surgical operation or anaesthesia.
However, its accuracy is limited by any movement of the animal, the necessity for
preheating the rat, and of course, stress. Such indirect systems require an appropriate
cuff for occluding the arterial supply to the tail. The inflatable cuff, which is applied
to the proximal end of the tail, is connected to a mercury manometer and the pulse
wave generated is viewed on a computer screen. The apparatus used is as described
by Evans, who found high correlation between the BP values obtained by
plethysmography and arterial cannulation (Evans et al. 1994).
Before using the tail cuff, the animals were placed in a heating chamber at 37°C for
~3-10mins. This was to ensure release of the arterial sphincter at the base of the tail,
thereby allowing arterial pulsations to be easily detected by the sensor. The animal
was then wrapped in a towel to restrict movement and placed on a hot pad to
maintain tail arterial vasodilation. An average of four deflation pressures were used
to determine the animal's BP. If there was a difference of lOmmHg between the
highest and lowest readings, the measurement was repeated. It should be noted that
no degree of familiarisation was observed with this technique, and furthermore, no
differences in BP values were noted between measurements at the beginning or end
of the week.
2.4.2 Carotid Cannulation
Direct measurement of arterial pressure in the rat involves surgical cannulation of a
major artery; in our case the left carotid artery was utilised, with the cannula later
connected to a pressure transducer. This approach provides accurate measurements
of both systolic and diastolic pressure (and therefore calculation of the mean arterial
blood pressure). However, since these experiments are acutely performed, the blood
pressure will be influenced to some degree by the surgery and anaesthesia. Therefore
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in these experiments, the first measurements of BP were taken at least 30hrs
following implantation of the cannula, when there were no remaining anaesthetic
effects. Readings were taken over a period of lOmins, with the animal in a quiescent
and unrestrained state.
The characteristics of an ideal catheter include: thromboresistance, ease of insertion,
long-term tolerance, infection control and favourable mechanical and convenience
factors. For these experiments, the catheters were made from polyethene material, as
they have good flexibility, can be easily moulded and are rigid enough to be handled
easily. Their main disadvantage is that they cannot be autoclaved for sterilisation.
Catheters were prepared as follows: 2cm of non-sterile Portex® polythene tubing
(o.d. 0.38mm, i.d. 1.09mm) was inserted a distance of 0.2cm into the flared end of a
translucent thin walled Portex® PVC tube (o.d. 0.63mm, i.d. 1.4mm). The tubing
was flushed and filled with sterile saline and clamped distally with forceps, ready for
use.
The carotid artery lies medial to and below the jugular vein and was exposed by
blunt dissection between the sternohyoid, syternomastoid and omohyoid muscles.
Extreme care was taken to gently dissect the vagus nerve away from the artery (any
damage to the nerve is readily visible post-operatively, as the rat displays signs of
pstosis). In general the left carotid was employed as passage of the catheter along the
right carotid may result in it emerging in the left ventricle, thereby causing
arrhythmias. A catheter in the artery on the left side will pass into the aortic arch with
no ensuing problems. An occluding ligature was placed as anteriorly as possible and
a loose posterior ligature was positioned several millimetres away. A small bulldog
clip was placed on the most distal end of the artery to stop the flow of blood. Using
microscissors, a small incision was made in the artery and the catheter was fed
through. The posterior ligature was lightly tightened round the artery and the catheter
was pushed towards the heart while the clamp was released. The posterior ligature
was then tied and secured around the artery and catheter. To exteriorise the catheter,
a trocar of 18G was passed subcutaneously from the site of site of entry of the
catheter to emerge in the dorsal nape of the neck. The end of the catheter was then
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passed subcutaneously through the trocar needle. It was ensured that a loop of
catheter was prepared near the neck incision site, to allow for normal body
movements; without it, there is danger of the animal asphyxiating or pulling the tip
of the catheter back or out of the vessel. After exiting, the catheter was then trimmed
to ~25mm, stoppered with a pin fashioned from a suitably sized hypodermic needle
and sutured into position. These sutures were further secured by the application of
surgical glue, to prevent the animal from chewing or pulling at the exteriorised
portion of the catheter. Finally, the various neck muscles were sutured back into their
original positions and all skin incisions were either sutured or stapled.
To ensure and maintain catheter patency, it was flushed in the first instance with
0.2ml heparin (20 units heparin/ml) post-exteriorisation and then every day following
BP measurement.
2.4.3 Radio-telemetry
Whilst the above techniques are commonly used to monitor blood pressure and heart
rate in experimental models of hypertension, they are far from ideal. The use of
tethers (to secure exteriorised vascular catheters) and both the warming and restraint
required for 'non-invasive' tail cuff measurement, introduce a significant stress
artefact, with well documented elevations of plasma Cortisol and cathecholmaines.
These problems may be overcome by using radio-telemetry, which measures BP
(systolic, diastolic, and mean arterial blood pressure), heart rate and provides an
estimate of activity in unrestrained conscious animals. It further affords the ability to
collect data continuously over long periods of time, without the stress of human
contact. Also, since rats are nocturnal animals, measuring their blood pressure at
nighttime may prove more physiologically relevant and identify greater differences
between the programmed and control animals.
The monitoring system consists of a surgically implanted transmitter (Data Sciences
International PA11-C40), receiver and personal computer with accompanying
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software (Dataquest Software) to decode the signal and measure the animals'
activity, heart rate and systolic, diastolic and mean arterial BP.
Surgical implantation of the transmitter was kindly performed by Mrs G. Brooker.
All animals were prepared for surgery and anaesthetised as described before.
Following laporotomy, sterile saline soaked cotton wool was used to retract the gut
in order to expose the abdominal aorta, which was separated gently from the vena
cava. Two ties were placed as far proximally and distally as possible on the
abdominal aorta in order to place tension on the vessel. A 21G needle was angulated
at 45° and used to pierce the vessel wall and to introduce the probe. Once the tip of
the probe was satisfactorily in place, the needle was withdrawn, the vessel sealed
with a patch of cellulose (supplied with the transmitter) and the ties removed. The
activity and position of the probe was tested by sweeping an active standard AM/FM
Radio over the vessel; the implantation was considered successful if the probe
disrupted the radio's signal. The transmitter's battery was then sutured firmly to the
left abdominal wall, the intestines were repositioned and the surgical site closed with
sutures and staples. Animals were cared for postoperatively as previously described.
No measurement was recorded until preliminary tests revealed that the heart rate and
blood pressure had stabilised post-operatively. Animals were housed singly and each
cage was placed over an individual receiver panel. Each cage and its associated
receiver panel were housed in a specially designed steel rack, preventing any cross¬
talk between the radio-signals of neighbouring animals. The rack was stored in a
quiet room within the animal facility, dedicated to telemetry measurement.
Haemodynamic data was then continuously sampled every 30mins for periods of 10
seconds.
2.5 Mesenteric Perfusions
Isolation of the mesenteric vasculature was kindly perfonned by Ms. Sharon
Rossiter. Pairs of rats (one control, one prenatally treated with Dex) were
anaesthetised with sodium pentobarbitone and laparotomised, exposing the
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intestines, aorta and subsequently the superior mesenteric artery. The aorta was
ligated proximally to the superior mesenteric artery in order to minimise bleeding
and the superior mesenteric artery was cannulated using a 18G Venflon, that was tied
in place and perfused continuously with oxygenated PSS at a rate of 3ml.min"1, using
a peristaltic pump.
The vasculature was isolated as previously described by McGregor in 1965
(McGregor 1965). Briefly, the mesentery was dissected and the gut removed from
the duodenum to the end of the ileum using surgical scissors. The gut itself was then
removed and the remaining isolated superior mesenteric arterial cascade was
removed to a petri dish, which was kept at 37°C by a water bath. On alternate days,
mesenteric preparations from each treatment group were attached to alternate
transducers to exclude the possibility of any positional artefact. Tissues were
maintained in buffer in covered Petri dishes while perfusions were carried out.
Perfusion pressure into the mesenteric vasculature was measured continuously
through an Elcomatic EM 720 transducer (calibrated with a mercury
sphygmomanometer) and decoded and recorded on a MacLab Chart V3.3.5.
programme. Following a 15min equilibration period, a brief 'wake-up' bolus of
20nM NA was administered. In every experiment the expected minimal response of
an 80mmHg rise in pressure was observed.
2.5.1 Vascular responses to NA, AVP & KCI
A pair of mesenteric vasculature preparations was simultaneously tested with
increasing concentrations of agonists in the following order: NA (0.1, 0.2, 1, 2, 5, 10
and 20pM), AVP (0.5, 1, 2 5, 10, 20 nM) and KCI (25, 45, 65, 85, 105 and 125mM),
all prepared in PSS. Vasculatures were perfused with increasing concentrations of
agonist for three mins. Between tests, the vasculatures were infused with PSS alone,
during which time the perfusion pressure returned to basal values. A recovery period
of at least 30mins was allowed between each agonist.
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2.6 Induction of stress by disturbance, weighing, and restraint
procedure.
To assess responses to stress, offspring were subjected to a series of graded stressors
from simple disturbance (a researcher entering their room), to being weighed, and
placed in a Perspex cylinder for 15min. To evaluate the stress response to weighing,
haemodynamic measurements were recorded prior to removal of the rat from its
cage, and again immediately and at 5min post-weighing, when the animal was
replaced in its home cage. For the restraint procedure, haemodynamic measurements
were collected prior to the rat being placed in the cylinder, throughout the 15min
restraint period, and at 15min post-restraint, when the animal was returned to its
cage. A rest period of two days was allowed between experiments.
2.7 Haemodynamic responses to alterations in catecholaminergic
mechanisms.
Haemodynamic responses were analysed 2 hr following the depletion of
catecholamines by i.p. reserpine (0.5mg.kg_1), and during a 15 min restraint test,
performed 4 hr post-resperine administration. After a 1-week recovery period,
haemodynamic responses were collected for 15 min following a low dose of i.p. d-
amphetamine (0.5mg.kg_1), aimed to cause systemic catecholamine release.
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2.8 Plasma Assays
2.8.1 ACTH Immunoradiometric Assay
ACTH IMRA was performed using a commercially available kit (ACTH, coated tube
system; Euro-Diagnostica, UK). All plasma samples were collected and stored as
previously described, from the same animals used to obtain plasma for corticosterone
measurement (see below).
Concentrations of ACTH in the range of 0-1250pg/ml were prepared in order to
construct a standard curve. Standards (50pl) in duplicate and samples (50pl, neat
plasma) in either singulate or duplicate were incubated in coated tubes (C-terminal
anti-ACTH, coupled to sheep anti-rabbit) with 50pl l25I ACTH antibody and left at
125
room temperature overnight. Two tubes were prepared with 50pi I ACTH
antibody alone, in order to give total counts. The tubes were washed twice in 2mls of
the supplied wash buffer before being thoroughly decanted and counted in a in a y-
counter. The concentration of ACTH in the samples was estimated by comparison
with the standard curve. The inter- and intra-assay coefficients of variation were
<10%.
2.8.2 Aldosterone radio-immunoassay
Aldosterone RIA was performed using a commercially available kit (Coat-A-Count
Aldosterone, DPC, USA). A range of concentrations of aldosterone was prepared (0-
3,300 pmol/1) to allow the construction of a standard curve. Standards and samples
were incubated in duplicate aldosterone-specific antibody coated polypropylene
1 9 S
tubes with I Aldosterone (1 ml per sample) at room temperature for 18hrs. Two
tubes were prepared with only 125I Aldosterone to give total counts, and two with a
1 9S
mixture of I Aldosterone and non-specific binding buffer to give non-specific
binding. The tubes were decanted thoroughly before being counted in a y-counter and
the concentration of aldosterone in the samples estimated by comparison with the
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standard curve. The inter- and intra-assay coefficients of variation were <15% and
<10% respectively.
2.8.3 Angiotensinogen Radioimmunoassay
Plasma samples were diluted 1 in 400 in Tris buffer. A range of concentrations of
Angiotensin 1 standards (0-400pg/10pl) was prepared to allow the construction of a
standard curve. lOpl of standard together with 10pl of trapping agent (anti-
Angiotensin 1) were incubated in duplicate in RIA cups at 0°C. 3pl of sample were
also incubated in a similar fashion, with 5pl of a 1 in 30 dilution of Porcine Kidney
Renin, and 10pl of the trapping agent. All standards and samples were centrifuged at
2000rpm in a Centra-8R centrifuge for lmin at 0°C before being transferred to a
preheated 96 RIA cup holder, and shook for lhr at 37°C. The 96 RIA cup holder was
subsequently placed on ice, and 150pl of Tris, containing approximately 4-5000cpm
125I and lOpl of renin inhibitor was added to each cup. Two cups were prepared with
just 150pl of the Tris/125I/renin inhibitor mix in order to calculate the total counts. A
further 2 cups of sample were prepared as outlined above except for the addition of
the Porcine Kidney Renin; this was to ensure that the samples were not generating
Angiotensin I with endogenous renin under the above experimental conditions. All
cups were incubated at 4°C overnight. 250pl of charcoal (continually stirred at 5°C,
on a bed of ice and water) was added to each cup and centrifuged at 2500rpm in a
Centra-8R centrifuge for 15min at 4°C. The supernatant was aspirated fully and the
free charcoal pellet was counted in a y-counter. The concentration of
Angiotensinogen in the samples was estimated by inference from the Angiotensin I
generated from comparison with the standard curve.
2.8.4 Corticosterone Radioimmunoassay
All animals were handled daily for a period of at least two weeks and all blood
samples were obtained by tail nick (described above) between 07.00h and 08.30h
and/or 19.00h and 20.30h.
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Plasma samples were diluted 1 in 10 in borate buffer and denatured at 65°C for
30mins to dissociate corticosterone (B) from its carrier proteins. A range of
concentrations of B were prepared (0-320nM) to allow construction of a standard
curve. Samples and standards were incubated in duplicate with a mixture of [ H]-B
(10,000cpm per sample) and rabbit anti-cort Ab (1 in 10,000 dilution) in borate
buffer in a total volume of 70fil for lh. 50pl of anti-rabbit scintillation proximity
assay beads were then added to each sample and the samples sealed and incubated
overnight. The SPA beads bind to the primary antibody and if the primary antibody
is bound to [3H]-B, the SPA beads cause scintillation of the radioactive signal. As the
concentration of unlabelled B increases, there is competition between binding of the
labelled and unlabelled B to the primary antibody, and the radioactive signal
decreases. Samples were counted on a Wallac Microbeta Plus liquid scintillation
counter and the concentration of B in each sample was determined from a graph of
cpm versus [cort], generated using the Multicalc programme. The inter- and intra-
assay coefficients of variation were <10%, as reported by Dr. C.J. Kenyon, who
developed the assay. There is extremely weak cross-reactivity with progesterone,
deoxycorticosterone and Cortisol (all < 8%) when compared to B (100%) (MacPhee
etal. 1989).
2.8.5 Glucose Assay
Plasma samples were incubated in duplicate with glucose hexokinase reagent for not
less than 5min. The reagent causes any glucose present in the sample to be
phosphorylated and NADH to be generated, thereby resulting in an increase in
absorbance at 340nM. The absorbances of the samples at 340nM were measured
using a Shimadzu uv/ visible recording spectrophotometer with a reagent blank. If
the plasma sample was haemolysed, a plasma blank (prepared by diluting the plasma
sample with water) rather than a reagent blank was used to correct for the colour in
the sample. The amount of glucose in the sample was calculated by comparison with
a standard curve (100-600 mg/dl glucose). The inter- and intra-assay coefficients of
variation were <2%.
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2.8.6 Insulin ELISA
Insulin ELISA was performed using a commercially available kit (Ultra Sensitive
Rat Insulin ELISA Kit, Crystal Chem Inc., Chicago, Illinois, USA). Plasma samples
were diluted 1 in 2 in the supplied buffer before assay. A range of concentrations of
insulin was prepared (0.1 to 12.8 ng/ml) to allow the construction of a standard
curve. Standards and samples (5 pi) were incubated in duplicate in the antibody-
coated microplate with 95pl of samples dilutent at 4°C for 2hrs. Plates were washed
with the supplied washing buffer before the addition of lOOpl of the Anti-rat Insulin
enzyme conjugate. Following 30min incubation at room temperature, the plates were
washed again. lOOpl of enzyme substrate solution was added to each well; the plates
were covered in aluminium foil and left for 40mins at room temperature before the
final addition of lOOpl of enzyme reaction stopping solution. The absorbance of the
plate was measured at 450nm (subtracting wave length 630nm) and the concentration
of insulin in the samples estimated by comparison with the standard curve. The inter-
and intra-assay coefficients of variation were both <10%.
2.8.7 Oestradiol Assay
Oestradiol assay was performed using a commercially available kit (Estradiol
ELISA, IDS, Tyne & Wear, UK.).
Prior to initiating the assay, steroid extraction from rat plasma was performed. 250pl
of plasma was mixed with 1ml of ethylacetate in Corning 12X15mm glass tubes,
vortexed and centrifuged at 2000rpm in a Labofuge 400R centrifuge for 15mins at
RTP. 800pL of the organic supernatant was transferred to a fresh glass tube, without
disturbing the solid layer. All samples were placed on a hot pad and air-dried under a
Sample Concentrator for 20mins. When they were completely dry, the samples were
reconstituted in 75pl of steroid free human serum (zero standard).
25pi of standard and sample were dispensed into the appropriate wells, followed by
200pl of the enzyme conjugate (oestradiol conjugated to horseradish peroxidase).
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(400jil per well per wash). Plate contents were decanted and a lOOpl per well of
substrate solution (TMB) was added. The plate was incubated for 15mins at RTP
before the enzymatic reaction was stopped by the addition of 50pl of stopping
solution. The absorbance of the plate was measured at 450nm and the concentration
of oestradiol in the samples estimated by comparison with the standard curve.
2.8.8 Phosphoenolpyruvate Carboxykinase (PEPCK) Assay
PEPCK is the rate limiting enzyme of gluconeogensis and catalyses the
decarboxylation and phosphorylation of oxaloacetate to form phosphoenolpyruvate.
In this reaction a nucleoside triphosphate is dephosphorylated to diphosphate.
PEPCK can also catalyse the reverse reaction i.e. incorporation of CO2 into
phosphoenolpyruvate to yield oxaloacetate. The mammalian enzyme has a high
specificity for nucleotides, accepting as substrates only inosine, guanosine and
xanthosine nucleotides.
PEPCK activity can be measured by coupling the formation of oxalacetate in the
backward reaction with NADH oxidation in the presence of excess malate
dehydrogenase. However, in crude preparations, the relatively higher levels of tissue
pyruvate kinase interfere in coupled assay system with malate dehydrogenase (IDP
and GDP also being substrated for pyruvate kinase). dGDP has the unique property
of being a good phosphate acceptor for PEPCK but is a poor substrate for pyruvate
kinase, and, is therefore, used in the coupling reaction as shown in Figure 2-1.
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Figure 2-1 Coupled reactions in PEPCK Assay
CO, + dGDP dGTP NADH + NAD'
Oxaloacetate Malatc
PEPCK MDH
Phosphoenolpyruvate is first converted to oxaloacetic by PEPCK. Malatc dehydrogenase
(MDH) then reduces oxaoloacetate to malate using NADH as a co-factor. During this reaction an
equimolar amount ofNADH is oxidized to NAD+. The consequent rate of decrease in absorbance at
340nm is directly proportional to the activity ofPEPCK.
10% (w/v) fresh liver homogenates were prepared in ice-cold buffer (250mM sucrose
and 5mM Hepes, pH 7.4). Homogenates were centrifuged for 10 min (4°C) at
10,000rpm to sediment intact cells, and the resulting supernatant was recentrifuged
for 60min (4°C) at 50,000 rpm in a Beckman Optima TLX ultracentrifuge. The
supernatant (cytosol) was collected and stored at -70°C and later used to assay
PEPCK activity. Protein content of the samples was determined by the Bradford
method.
PEPCK activity was measured at 30°C by coupling the formation of oxalocetate with
NADH oxidation in the presence malate dehydrogenase, as described by Petreseu
(Petrescu et al. 1979). The reaction mixture (1ml final volume) contained 50mM
Hepes (pH 6.5), 50mM sodium bicarbonate, ImM MnCfi, 0.25 mM NADH, ImM
phosphoenolpyruvate, 1.5U malate dehydrogenase and lOOpL of liver cytosolic
preparation. The reaction was initiated in a spectrophotometer, set to 'Kinetic' mode,
with 0.15mM deoxy-GDP and the drop on absorbance at 340nm was followed for
5mins. A reaction mixture lacking bicarbonate was used as control. PEPCK activity
was calculated from the rate of drop in absorbance at 340nm and the molar
absorptivity ofNADH.
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together with 1 OjlxL of trapping agent (anti-Angiotensin I) were incubated in
quadruplicate in RIA cups at 0°C. 2pl of neat plasma sample were also incubated in a
similar fashion, with 8pL of substrate (bilaterally nephrectomised rat plasma), and
1 Op.1 of the trapping agent. All standards and samples were centrifuged at 2000rpm in
a Centra-8R centrifuge for lmin at 0°C. Two of the four cups were incubated for
30mins at 0°C ('cold' standards and samples), whilst the remaining two cups were
transferred to a preheated 96 RIA cup holder, and shook for 30mins at 37°C ('hot'
standards and samples). All cups were subsequently placed on ice, and 150pl of Tris,
containing approximately 4-5000cpm 125I and lOpl of renin inhibitor was added to
each cup. Four cups were prepared with just 150pl of the Tris/'25I/renin inhibitor mix
in order to calculate the total counts. All cups were incubated at 4°C overnight. 250pl
of charcoal (continually stirred at 5°C, on a bed of ice and water) was added to each
cup and centrifuged at 2500rpm in a Centra-8R centrifuge for 15min at 4°C. The
supernatant was aspirated fully and the free charcoal pellet was counted in a y-
counter. A standard curve was constructed using values obtained for the 'hot'
standards and the concentration of Angiotensin I generated by both the 'hot' and
'cold' samples were made by comparison with this curve. To calculate renin activity
in the samples, values for Angiotensin I generated by the 'cold' samples were
subtracted from the values ofAngiotensin I generated by the 'hot' standards.
2.9 Protein concentration by the Bradford method
The concentration of total protein in a solution was determined using the method of
Bradford (1976). The assay is based upon the binding of Coomassie brilliant blue G-
250 to basic and aromatic amino acid residues, and consequent colour change to the
amount of protein of > 3000kDa present. Samples were diluted with buffer to give
solutions in the linear range of 0.05-0.5mg protein/ml, and BSA standards were
prepared in the same buffer to 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 mg/ml. Diluted protein
assay dye reagent (1.96 ml) was added to 40pl of protein standard or appropriately
diluted tissue homogenate in a borosillicate tube, vortexed to mix and left at room
temperature for 15 min-1 hour to allow colour development. Absorbance of samples
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at A,595nm was measured using a Shimadzu UV/ visible recording spectrophotometer
and the concentration of protein in each sample was calculated from the mean
absorbance, the dilution factor, and a graph of [protein standard] versus mean
absorbance at A.595nm.
2.10 Northern Analysis of RNA
2.10.1 RNA Extraction
RNA extraction was perfomed using TRIzol® Reagent - a mono-phasic solution
containing phenol and guanidine isothiocyanate. This reagent maintains RNA
integrity whilst disrupting cells and dissolving cell components.
2.10.2 Homogenisation
To aid initial homogenisation, individual tissue/organs were wrapped in chilled
aluminium foil whilst frozen. 1ml TRIzol® was added per 50-100mg tissue whilst
frozen and samples were homogenised on ice using a mechanical homogeniser.
Samples were centrifuged at 12,000g at 4°C for lOmin to remove insoluble material
and small amounts of unhomogenised tissue. The resulting supernatant was removed
to sterile Eppendorf tubes.
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Following homogenisation, samples were allowed to equilibrate to RTP then left for
5 minutes to allow complete dissociation of the nucleoprotein complexes. 0.2ml
Chloroform per ml TRIzol® used in original homogenisation was added to each
sample. Samples were hand shaken vigorously for 15 seconds then incubated at RTP
for 3 minutes. Samples were centrifuged at 12,000g at 4°C for 15min resulting in a
lower red phenol-containing phase (containing proteins), an interphase (containing
DNA and denatured proteins) and an upper aqueous phase containing RNA.
2.10.4 RNA Precipitation
The upper aqueous phase from each sample was transferred into a fresh eppendorf
and the RNA was precipitated by addition of 500pl isopropanol (per ml TRIzol® in
original homogenisation). Following addition of isopropanol, samples were
incubated at RTP for lOmin prior to centrifugation at 12,000g at 4°C for lOmin. The
RNA precipitate forms a visible gel-like pellet on the side of the tube.
2.10.5 RNA Wash
Following centrifugation the supernatant was removed and the RNA pellet was
washed with 1ml 75% ethanol (per ml TRIzol® in original homogenisation). Pellets
were vortexed and centrifuged at 9000g at 4°C for 5min.
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Following the RNA wash, the ethanol was removed and the pellets were briefly air-
dried for 5min, being careful not to completely dry out the RNA, which greatly
reduces solubility. RNA pellets were dissolved in 10-50pl DEPC-treated water
(depending on pellet size) followed by incubation at 60°C for lOmin. RNA was
stored at -80°C until required.
2.10.7 RNA Quantification
Before use, RNA was quantified using a GeneQuant RNA/ DNA Calculator. RNA
was diluted 1:25-1:100 in DEPC-treated water and the optical density at A260nm and
A280nm was determined to assess concentration and purity. Only RNA with a
A260/A280 ofbetween 1.5 and 1.8 was used.
2.10.8 RNA electrophoresis and capillary transfer
Total RNA was separated by electrophoresis on a 1.2% agarose formaldehyde
denaturing gel. A 100ml gel was prepared by melting 1.2g of agarose in 88ml DEPC-
treated water, adding 40% formaldehyde (2ml) and 10X MOPS buffer (10ml), and
pouring into a gel mould with appropriately sized combs in place. The gel was
allowed to set before being soaked in IX MOPS buffer in a gel tank for 30mins.
RNA was prepared for electrophoresis by aliquoting 20pg of RNA, adding DEPC-
treated water to bring the total volume to lOpl, then adding deionised formamide
(lOpl), 40% formaldehyde (2.5pl) and 10X MOPS buffer (2.5pl) to give a total
volume of 25pl. The sample was mixed and the RNA was denatured by incubation at
65°C for 15mins. Ethidium bromide was added to the loading buffer (lpl per 50pl
loading buffer) and 2pi of this mix was added to each sample of the denatured RNA.
The RNA was loaded into the wells on the gel and electrophoresed at 100V for 2-
4hrs, until the front band of the loading buffer was 3A of the way down the gel. The
gel was photographed under UV light (X = 254nm) with as little exposure as possible
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to minimise RNA damage. The presence of intact 28S, 18S and 5S Ribosomal RNA
bands indicated that the preparation was undegraded. The gel was soaked in 20X
SSC buffer for 15min before blotting onto a nylon membrane. A wick of Whatman
3MM filter paper was placed over an upturned gel mould in a plastic tray containing
20X SSC buffer and the gel placed on top. A piece of nylon membrane cut to the
same size was smoothed on top of the gel and this was covered with 3 layers of 3MM
filter paper and approximately 10cm of paper towels. A glass plate and light weight
was placed on the top to secure the apparatus, and a builder's level was utilised to
ensure "evenness" of the tower. Capillary transfer was allowed to take place
overnight at room temperature. The following day, the membrane was washed in
20X SSC to remove any gel and the efficiency of transfer checked by photographing
both the gel and the membrane under UV light (X = 254nm). The membrane was
dried between two sheets of 3MM filter paper at 80°C for 2hrs, and the RNA cross-
linked under UV light.
2.10.9 Hybridisation to 32P-labelled cDNA
The membrane was soaked in 20X SSC buffer for 5mins before being placed in a
Hybaid hybridisation bottle containing 3mL 20% SDS and 6ml phosphate buffer that
had been pre-heated to 55°C. Denatured Herring testes DNA (lOmg/ml; lOOjul) was
then added to this. The membrane was prehybridised in a Hybaid hybridisation oven
at 55°C for a minimum of 2hrs. The 32P-labelled cDNA probe (prepared as described
in section 2.11) was added to the hybridisation buffer and the membrane was
hybridised with the probe overnight at 55°C. The probe was then disposed of and the
membrane was rinsed with wash buffer one. This was followed by a further two
washes in the same wash buffer at room temperature for 20 mins and one wash in
wash buffer two for 30mins at 55°C. The level of radioactive signal remaining on the
membrane was checked and if this was too high the final wash was repeated as
necessary. The membrane was wrapped in parafilm and exposed to a Fujifilm
imaging screen for a length of time between 5mins-24hrs and the level of hybridised
probe quantified using a Fuji FLA2000 fluorescent image analyser. The membranes
were then rehybridised with U1 cDNA in the same way to control for RNA loading
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and transfer. The level of expression of the RNA of interest was then expressed as a
ratio of the signal of the RNA of interest to the signal for Ul. Membranes were left
for a minimum of one month before reprobing to allow decay of the original signal
and all mRNA species probed were well separated on the membrane. If results
between groups of animals were to be compared all the samples were hybridised in
the same hybridisation bottle with the same probe.
2.11 Preparation of 32P-labelled cDNA probes
2.11.1 Preparation of cDNA templates by PCR
cDNA templates were prepared by PCR for various genes of interest in liver, kidney,
fat and hypothalamus, to be used subsequently for the synthesis of DNA probes for
use in Northern blots. Forward and reverse oligonucleotide primers were designed to
target rat mRNA sequences of interest, based upon published sequences made
available through the BLAST database (National Centre for Biotechnology
Information, National Library ofMedicine, Bethesda, MD, USA.).
2.11.2 Reverse Transcriptase Reaction
First strand cDNA synthesis was performed using Promega's Reverse Transcription
System. 3pg of total RNA was reverse transcribed in a reaction mixture containing
25mM MgCb, 10X reverse transcription buffer, lOmM each of dATP, dCTP, dGTP
and dTTP, 20U RNasin, 0.5pg 01igo(dT)i5 primers and 15U AMV-reverse
transcriptase made up to 50pl in DEPC-treated water. Samples were incubated at
42°C for 50min followed by 5min at 99°C then 5min on ice to inactivate enzymes
and prevent binding to DNA.
Negative control reactions for each RNA sample were performed in parallel (made
up as above but in the absence of AMV-reverse transcriptase) in order to determine
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genomic DNA contamination. A further negative control reaction containing water
instead of RNA was performed to determine RNA contamination of the Reverse
Transcriptase System reagents.
Plasmid DNA (lOpg) was digested with the appropriate restriction enzyme (10 units)
in 1 X restriction enzyme buffer in a total volume of lOOpL for 2hrs at 37°C (see
table). Digestion of the DNA was confirmed by electrophoresis of 3pL of the digest
through a 1% agarose gel (prepared by dissolving 1% agarose in 1 TBE buffer and
adding 1 jlxI ethidium bromide (10mg/ml)). The digest was compared with uncut
plasmid and a lkB DNA ladder containing fragments ranging from 75-12kb under
UV light at X = 254nm. If the plasmid was sufficiently digested the remaining digest
was electrophoresed in a large single well of a 1% low melting point agarose gel
(made as above but using low melting point agarose).
The DNA fragment was visualised under UV light (A, = 254nm), excised from the gel
using a scalpel, purified from the gel using Hybaid's Recovery DNA Purification kit
and resuspended in 50pl DNAase free/ RNAase water. Recovery of the DNA
fragment was assessed by electrophoresis of lpl of the DNA solution through a 1%
agarose gel as described below.
2.11.3 PCR Reactions
5pl of cDNA template was used in each PCR reaction containing 2.5pl of 10X
Thermophilic DNA polymerase Reaction Buffer containing 25mM MgCh and made
up to a final volume of 25pi with DEPC-treated water. A second mixture containing
2.5pl of 10X Thermophilic DNA polymerase Reaction Buffer containing 25mM
MgCb, 2.5mM each of dATP, dCTP, dGTP and dTTP, 15pmol upstream primer, and
15pmol downstream primer was made up to 25pl in DEPC-treated water. 0.25pl of
Taq polymerase was added to each reaction tube just prior to starting the required
PCR programme. A negative control reaction containing DEPC-treated water rather
than cDNA was performed in parallel to determine contamination ofPCR reagents.
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PCRs were performed on an Eppendorf Mastercycler Gradient with a heated lid (set
to 110°C). Samples were heated to 95°C for 3min for initial denaturation, placed
directly on ice for lmin before the addition of the second mixture. All samples then
underwent 35 cycles of PCR amplification (denaturation at 94°C for lmin, primer
annealing at primer-specific temperature for lmin and elongation at 72°C for 2min).
Upon completion of the PCR programme, samples were incubated at 72°C for a
further lOmin to ensure elongation of products to full length and chilled to 4°C prior
to gel electrophoresis. Specific primer sequences and PCR conditions are detailed in
Table 2-1.
2.11.4 Gel Electrophoresis
RT-PCR products were analysed by electrophoresis on a 1.0% agarose gel. Gels
were prepared by melting 1% (w/v) agarose in 0.5X TBE and adding lpl/ 100ml of
ethidium bromide. After pouring into a gel mould with appropriately sized combs in
place, gels were allowed to set at room temperature then placed in 0.5X TBE in a gel
tank.
10pl 1Kb DNA ladder containing fragments ranging from 75-12,000 bases were
loaded into the first well on each gel to allow determination of product size. 2-5pi of
each RT-PCR product was mixed with 2.5pl loading buffer and loaded into
individual wells of the gel. Gels were electrophoresed at 100V for 30-45min until
the loading buffer band was approximately % of the way down the gel and were then
photographed under UV light at 7.260nm.
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(Annealing temperature for all sequences = 56°C; 35 cycles)





Forward primer ttcacttccaagggaagatgaga 818-840




Forward primer cccaccgtgttcttcgaca 52-71
Reverse primer aaagttttctgctgtctttggaact 126-151
Probe caagggctcgccatcagccgt 73-93
M195333 99
(Annealing temperature for all sequences = 59°C, and probes = 69°C; 40 cycles)
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Purified PCR products were ligated into pGem-T Easy plasmid utilising -A/-T
overhangs generated by the Taq polymerase. The volume of purified PCR product
containing an amount of DNA equal to three times the molar quantitiy of vector per
pi in the kit was calculated in each case. This volume was mixed with 5pi of X2
Ligase buffer, lpl linear vector and lpl of T4 DNA ligase and made up to lOpl with
ultra-pure water. Positive and negative control ligations were set up, containing 2pl
of control DNA insert in place of PCR product, or no DNA respectively. The
mixtures were incubated at 4°C overnight.
2.11.6 Cloning of plasmid DNA
Bacterial transformation: Eschericia coli HB101 cells were grown in 100ml of LB
broth at 37°C in a shaking incubator until they reached mid-log phase (A6oo = 0.3-
0.6). They were then centrifuged at 3000g for 5 mins at 4°C, the pellet re-suspended
in cold calcium chloride (0.1M; 20ml) and left on ice between lOmins and 2hrs. The
centrifugation step was repeated to re-pellet the cells and the cells were re-suspended
in cold calcium chloride (0.1ml; 2ml). The competent cells were stored on ice in the
fridge for up to 3 days before transformation.
Competent cells (lOOpl) were mixed with plasmid DNA (50ng) and left on ice in the
fridge for 20mins. The cells were heat shocked at 40°C for one minute and replaced
on ice. The heat shock and the calcium chloride lead to the incorporation of the
plasmid DNA into the cells. The cells were spread onto LB agar plates containing
lOOpg/ml ampicillin, and the plates incubated overnight at 37°C. Only cells that have
incorporated the plasmid DNA will grow on the ampicillin plates, as HB101 cells do
not have inherent ampicillin resistance.
Materials and Methods -71 -
2.11.7 Plasmid DNA preparation
Chapter 2
A single transformed bacterial colony was selected from an agar plate and incubated
overnight at 37°C in 3mL LB containing lOOpg/ml ampicillin. This was then added
to 500ml LB containing lOOpg/ml ampicillin and incubated overnight at 37°C. The
culture was centrifuged at 6000 rpm for 5min at 4°C in a Beckman J14 centrifuge,
and the supernatant discarded. The cell pellet was resuspended in 12ml cold GTE
buffer, 24ml of cold alkaline SDS was added and the mixture left on ice for 1 Omin.
Cold potassium acetate (16ml) was added and the mixture left on ice for a further 10
min before being centrifuged at 6000 rpm for 5min at 4°C in a Beckman J14
centrifuge. The mixture was filtered through sterile gauze to remove the precipitate,
isopropanol (32ml) was added to the filtrate and the mixture was left at room
temperature for 30mins to precipitate the DNA. The DNA was pelleted by
centrifugation at 10,000rpm for 3mins at 4°C in a Beckman J20 centrifuge, and the
supernatant discarded. The DNA pellet was resuspended in 2.2ml TE buffer, 2.9g
CsCl added and dissolved lOOpl ethidium bromide (lOmg/ml) added. The mixture
was transferred to Beckman Quickseal ultracentrifuge tubes and topped up with
CsCl/TE solution and centrifuged at 70,000rpm for 20hrs at 20°C in a Beckman
Optima TLX ultracentrifuge. The DNA was separated into bands that could be
visualised by the pink colour of the ethidium bromide. These DNA bands were
removed by a 21G needle and syringe, transferred to fresh ultracentrifuge tubes,
topped up with CsCl/TE solution and centrifuged at 100,000 rpm for 4hrs at 20°C in
a Beckman Optima TLX ultracentrifuge. The DNA bands were collected as before
and the ethidium bromide was removed by extracting repeatedly with water-saturated
butanol until the pink colour disappeared. The DNA was precipitated with ethanol (2
volumes) for lOmins at room temperature and pelleted by centrifugation for 5mins at
14, OOOg. The supernatant was discarded and the DNA pellet washed with 70%
ethanol then resuspended in 1ml TE buffer. The concentration and purity of the DNA
was assessed spectrophotometrically using the ratio of absorbances at X = 260 and
280nm.
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2.11.8 Restriction enzyme digestion of the plasmid, and
purification of the fragment
Restriction enzyme digestion was used for the linearisation of insert-containing
vector in advance of probe synthesis, the excision of inserts to verify their size and to
determine the orientation of inserts by asymmetric digestion.
GR insert was excised from its pGEM-3 vector (generously donated by Dr. Karen
Chapman) using Ava 1.
U1 insert was excised from its pBluescript KS+ vector (generously donated by Dr.
Matt Sharp) using EcoR 1 and Hind 111.
In general tenns, l-2pl of enzyme was mixed with one-tenth the total volume of the
supplied buffer and l-5pg of DNA, ± BSA, and made up to between 20 and 60pl
total volume with DEPC-treated water. This was incubated for 90 to 180 minutes at
37°C, and an aliquot electrophoresed on a 1% agarose gel to verify linearisation,
orientation and to examine the length of products with reference to a DNA ladder.
2.11.9 Sequencing of cDNA
Was performed by DNAShef, at the Dept. of Haematology, Royal Infirmary,
Edinburgh.
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Roche's random primed DNA labelling kit was used to label the DNA fragments.
Approximately 25ng ofDNA fragment was aliquoted into an Eppendorf, made up to
lOpl with DEPC-treated water and denatured at 100°C for lOmins. The Eppendorf
was cooled on ice and briefly centrifuged. Hexanucleotide primer mix (2pl), dATP,
dTTP, and dGTP (lpl of each), [a32P]-dCTP (4pl) and Klenow (lpl) were added to
give a total reaction volume of 20pl and the reaction incubated at 37°C for lhr.
Unincorporated radioactivity was removed by passing the mixture through a NICK
column. The NICK column was prepared by washing with 3ml TE before application
of the mixture. The column was washed with 400pl TE, the elutant discarded and the
labelled DNA eluted from the column with a further 400pl TE. The activity of the
probe was assessed by mixing 1 pi of probe with 1 ml of Cocktail T scintillant and
counting in a P-counter. The probe was used if the specific activity was greater than
10,000cpm/pl. The DNA probe was denatured before use by heating to 100°C for
5min.
2.12 Real Time PCR
2.12.1 TaqMan™ probe and primer design
TaqMan™ probes and forward and reverse primers were designed using Primer
Express™ software. Four basic rules were used as guidelines when designing and
choosing the optimal sequences i.e.
1. Primers should be > 18 base pairs long.
2. There should be no more than 3 G or C base pairs within the terminal 5 base
pairs of the 3' ends of each primer.
3. Tm of the probe must be > 10°C than the highest primer Tm.
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4. There should be ideally more C than G residues in both the primers and
probe.
All primer and probe sets were designed to run across different exons. BLAST
searches of the probe and primer sequences revealed no significant homology to
sequences other than the specific gene of interest. In any case, TaqMan™ RT-PCR
will not give any measurable signal without all 3 of the probe/primers working for
any one target. Prior to beginning the assay, the quality of the primers was assessed
by amplifying the genes of interest by standard RT-PCR. Specific primer and probe
sequences are outlined in Table 2-2.
2.12.2 TaqMan™ Real-Time RT-PCR Assay
The TaqMan™ assay requires both forward and reverse primers as well as a
fluorogenic probe that anneals between the forward and reverse sites. The probe has
a fluorescent reporter dye at the 5' end and a quencher dye at the 3' end. During PCR
cycling the probe is cleaved by the 5'-3' nuclease activity of Taq polymerase, the
reporter and quencher dyes become separated resulting in an increase in
fluorescence. The ABI 7700 measures the accumulation of PCR product by
continuously monitoring the increase in fluorescence during cycling. Cycle threshold
(Ct) is set to a level above the baseline fluorescence and once chosen, sets the point
at which the sample PCR amplification plot crosses threshold. The Ct value in turn is
predictive of the quantity of input cDNA. The more of the target gene present in the
sample the earlier it will be detected in the PCR cycles and the lower the Ct. Ct
detection is converted into number of gene copies in the starting material and a
standard curve is constructed using known amounts of rat genomic DNA. Test gene
mRNA values are extrapolated from the standard curve and expressed in arbitrary
units. The assay has been described in full elsewhere (Gibson et al. 1996; Heid et
al. 1996; Lie et al. 1998).
Materials and Methods -75-
Chapter 2
For the assay, 500ng of sample RNA was prepared and reversed transcribed as
previously described. 5pi of cDNA from each sample was collected and used to form
stock cDNA, from which a standard curve was created. All sample cDNAs were
diluted 1:4 with nuclease-free water.
One TaqMan™ cDNA plate was used per test gene. For each gene of interest a
primer/probe mix was created, consisting of (for 100 reactions): 30pl of 25pM
forward primer, 30pl of 25pM reverse primer, lOOpl of 5pM probe and 540pl of
nuclease-free water. 550pl of this mix was added to 550pl of a cyclophilin
primer/probe mix (internal control) and 1250pl TaqMan™ PCR core reagent, to form
a master mix. Each sample was assayed in triplicate; 67.5pl of the master mix was
added to 7.5pl of sample cDNA, and 24pl of this final mixture was added to three
wells of the cDNA plate. In order to generate a standard curve; serial 1:10 dilutions
of the stock cDNA were added to the master mix and added to the plate in a similar
manner. Three no-template negative controls were constructed by substitution of
nuclease-free water for cDNA. Four negative RT controls were further added to the
cDNA plate. Three wells contained a 1 in 4 dilution of the stock cDNA and acted as
quality control. Plates were analysed on a TaqMan™ ABI Prism 7700 Sequence
Detector™. Cycling parameters: 50°C for 2mins, 95° for lOmins, 40 cycles of 95°C
for 15s, 60°C for lmin. Data acquisition was processed with Sequence Detector 1.6.3
software. All controls and a selection of samples, chosen at random were
electrophoresed on a 1% Agarose gel to verify specific amplification and to examine
the length of products with reference to a DNA ladder.
2.12 35S In Situ Hybridisation
Please note: The hepatic GR in situ hybridisation was kindly performed by Mrs.
Karen Anderson and evaluated by Dr. Megan C. Holmes.
In situ hybridisation allows the visualisation of the exact cellular and/ or structural
location of specific mRNAs (indicating transcription of the corresponding gene) by
hybridisation of a 35S-labelled 'antisense' RNA probe to the mRNA of interest. 35S-
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UTP labelled RNA 'sense' probes of similar length, nucleotide content and specific
activity were included in the experiment in order to assess the specificity of the
hybridisation reaction.
Only RNase free, sterile solutions and equipment were used for in situ hybridisation
experiments in order to prevent degradation of target mRNA by exogenous RNases.
2.13.1 Slide Preparation
Prior to use, glass microscope slides were coated in 3-aminopropyltriethoxysilane in
order to prevent section dehiscence. Slides were racked and washed in the following
series of solutions; 0.2M HC1 for 3min, DEPC-treated water for 3min, 2% 3-
aminopropyltriethoxysilane in acetone (filtered through NaS04) for 10s, acetone for
3min (twice), and finally DEPC-treated water for 3min. Slides were air-dried for 30-
60min before baking at 50°C for 4-16 hours. Dried slides were wrapped in
aluminium foil and stored for up to 3 months.
2.13.2 Tissue section preparation
Liver from female rats aged 6mo were frozen immediately on powdered dry ice and
stored at -80°C until required.
Frozen tissue sections were cut using a Leica cryostat. Tissues frozen at -80°C were
placed in the cryostat chamber at -20°C and allowed to equilibrate for approximately
30min. Following equilibration, tissues were embedded in Cryo-m-bed embedding
compound and positioned in the correct orientation for sectioning. 15pm thick
sections of brain were transferred to aminopropyltriethoxysilane-coated slides, and
stored at -80°C until required.
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2.13.3 Synthesis of 35S-UTP Labelled Ribo-Probes
See Table 2-3 for specific characteristics of probe generation.
Table 2-3 Characteristics of Probe Generation for In Situ Hybridisation






5 = sense; as = antisense; nt = nucleotide.
0.5-lp.g of linearised plasmid (described in section 2.11.8) was transcribed by
incubation at the appropriate temperature for 60-90min with ATP, CTP and GTP
(lOmM each), 35S-UTP (s.a. 800Ci/ mmol), lOmM dithiothreitol (DTT), 0.5pl RNase
inhibitor, and lpl appropriate polymerase in a total volume of lOpl IX transcription
optimised buffer. Following incubation, lpl DNase 1 (RNase free) was added and
reactions incubated at 37°C for a further 15min to degrade the DNA template, after
which probes were placed on ice for l-5min and purified using NICK columns, to
remove unincorporated radioactivity. The column was prepared by washing through
with 3ml TE buffer. The probe mixture was then applied to the column. The column
was washed with 400pl TE buffer and the initial elutant discarded. Labelled probe
was eluted in an additional 400pl TE buffer.
For each probe, the total activity was estimated by counting lpl of probe in 1ml
PicoFluor 40 scintillant fluid in duplicate in a p-counter (minimum activity required
2xl05 cpm/ pi). Probes were stored at -20°C until required, for a maximum of 7 days.
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2.13.4 Fixation Protocol
Slides were removed from the -80°C freezer and kept on dry ice until the start of the
fixation procedure. Slides were fixed in ice cold 4% paraformaldehyde in 0.1M
phosphate buffer for lOmin, rinsed twice in lx PBS for 5min, acetylated in 0.1M
triethanolamine with 0.25% acetic anhydride for lOmin to prevent loss of signal and
rinsed in lx PBS for 3min. Following dehydration through a series of ethanol
solutions (70, 80 and 95% ethanol in DEPC-treated water) slides were air dried for
30min.
2.13.5 Pre-hybridisation & Hybridisation Steps
Following fixation, slides were pre-hybridised with 200pl/ slide of 2x pre-
hybridisation buffer diluted 1:1 with deionised formamide, at 50°C for 2h.
Dampening two layers of Whatmans No.3 chromatography paper with box buffer
humidified the slide boxes, hence preventing tissue sections from drying out.
Sense and antisense probes were thawed and added to 2x hybridisation buffer diluted
1:1 in deionised formamide to give a final probe concentration of 20x10"6 cpm/ml.
Probes were denatured at 90°C for lOmin and placed on ice before addition of lOmM
DTT. Pre-hybridisation buffer was drained from slides and 200pl appropriate probe
was applied to slides. Slides were hybridised in sealed, humidified boxes at 50°C for
an optimum of 16 hours.
2.13.6 RNase Treatment & Washes
Following hybridisation, slides were washed three times in 2x SSC for 5min and
carefully wiped dry around the sections with lens tissue. 200pl of RNase A (30mg/
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ml in RNase buffer) were applied to each slide and slides were incubated at 37°C for
1 hour in humidified boxes (1 layer of Whatman No.3 chromatography paper
dampened with RNase buffer) to remove unhybridised probe.
Following RNase treatment, slides were washed in 2x SSC at room temperature for
30min, then twice in O.lx SSC at 60°C for 60min. After washes, slides were
dehydrated through a series of ethanol solutions containing 0.3M ammonium acetate
(2min in each of 50, 70 and 90% ethanol) and air-dried.
2.13.7 Visualisation of Hybridisation
Slides were exposed to Kodak Biomax-MR film for 2-7 days. For hepatic sections,
slides were individually dipped in NTB-2 photographic emulsion (diluted 1:1 with
DEPC-treated water at 42°C) and exposed in light-tight boxes for 5 days to 12 weeks
at 4°C. Slides were developed in D19 solution (diluted 1:1 with water) at 15°C and
fixed in Amfix solution (diluted 1:5 with water at 15°C). The hybridisation signal
was quantified by counting silver grains in the liver under bright field illumination
using a computer driven image analysis system (Carl Zeiss, Welwyn Garden City,
UK). The analysis was carried out blind to prenatal treatment. For each animal, 20
hepatocytes were assessed. Results were calculated as mean number of grains per
hepatocyte after background counted over non-specific areas was subtracted.
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2.14 Statistics
All values are expressed as mean ± standard error of the mean. Results were taken to
be significant with p < 0.05. All analysis was performed using the Statistica
programme.
The difference between the mean values of measurements made on two comparable
treatment groups was tested by Student's t-test, and between multiple groups by One-
Way ANOVA. When multiple separate treatment types were involved, Two or
Three-Way ANOVA was performed, with post-hoc comparison of means testing
using the LSD test or planned comparison. If measures were repeated, this was also
taken into consideration.
As revealed by Figure 2-2, the systolic blood pressures obtained for both prenatally
DEX and vehicle treated animals at 3 months of age, illustrates that their BP follows
a Normal (or Gaussian) distribution.
Figure 2-2 Graph of Normal distribution for systolic blood pressure
Data taken from Figure 3-2 (page 89); mean (p): 131 mmHg, Standard Deviation (5):
5.7mmFlg, N = 12, with 6 from each prenatal treatment group.
119mmHg 125mmHg 131mmHg 137mmHg 143mmHg
(M- -25) (p-18) (p) (p + 15) (p + 25)
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n= (z)2(S)2/ (d)2
where: z = confidence coefficient
§ = standard deviation
d = interval
It is fair to assume an interval of about 8 units wide, that is, the estimate should be
within about 4 units of the true value in either direction. We also assume a
confidence coefficient of 0.95, and from Figure 2-2, we know that the standard
deviation is 5.7mmHg. Therefore, z = 1.96, 8 = 5.6, and d = 4.
On making the proper substitutions, the value of n is found to be:
n — (1.96)2(5.7)2/ (4) 2
= 7.53
Therefore, a sample size of 8 is justified for our experiments.
Note: A full derivation of the above equation, and the table of Normal Curve Areas are
available in 'Biostatistics: A foundation for analysis in the health sciences' by Wayne W.
Daniel, Pages 97-88, 143-145 and 491, 3rd edition, published by John Wiley & Sons.
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Perinatal environmental stress profoundly affects
glucocorticoid programming experiments
3.1 Introduction
As research institutions expand, and respond to ever-changing building and animal
welfare regulations, they are required to undergo either new construction and / or
renovation. However, such structural changes are associated with a plethora of
nuisances, such as noise, vibration, and alterations in temperature and air-flow; and each
disturbance is capable of powerfully stimulating the HPA axis (Dallman et al. 1999).
The auditory system is permanently open - even during sleep. Its rapid and overshooting
excitations caused by noise signals are subcortically connected via the amygdala to the
HPA-axis, resulting in CRH and ACTH release (Spreng 2000a). Animal experiments
show noise-induced changes in the sensitivity of GR by increase of heat-shock proteins
(Spreng 2000a), and ultrastructural changes of the heart (Lenzi et al. 2003) and adrenal
gland (Soldani et al. 1999). Increased Cortisol levels have been found in humans when
exposed to aircraft (Haines et al. 2001) or road traffic noise (Ising & Ising 2002), even
during sleep (de Jong 1993), implying these effects are mainly without mental control.
Of course, increased glucocorticoid and sympathetic neural secretion is a perfect short
term stress response, co-ordinating appropriate metabolic and vascular changes, and
thereby assisting the individual to negotiate the stressor. However, over prolonged time
periods, such persistent noise-induced stress responses can be gravely damaging to
health. The adverse effects of long term increases in Cortisol (human) / corticosterone
(rodent) are manifold: immunosupression (e.g. eospinopenia), insulin resistance (e.g.
diabetes), cardiovascular disease (e.g. hypertension), catabolism (e.g. osteoporosis) and
intestinal problems (e.g. stress-ulcer) (Spreng 2000b; Gamallo et al. 1992; Tomei et al.
1991; Sobrian et al. 1997; Kay et al. 1998). Worse still, may be the widespread
extrahypothalamic effects of CRH/ and/ or ACTH which have the potential to influence
nearly all regulatory systems, causing for example, stress-dysmenorrhea (Spreng 2000b).
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Numerous animal studies have documented the programming effects of pre- and post¬
natal stress on offspring physiology and behaviour, which are remarkably analogous to
those induced by foetal glucocorticoid overexposure. Exposing pregnant dams to
stressful stimuli, results in both maternal and foetal HPA activation (Williams et al.
1999; Hennessy et al. 1999). Moreover, these offspring display an activated HPA axis
till weaning, and as adults are more anxious and stress-responsive (Takahashi et al.
1992). These adverse behavioural effects are associated with altered patterns of brain
GR expression, as well as alterations in the circadian rhythm of corticosterone secretion
(Koehl et al. 1999), consistent with HPA-axis dysregulation. Similarly, prenatal DEX
treatment results in permanent life-long hyperactivation of the HPA-axis (Levitt et al.
1996), also associated with altered brain GR expression and increased anxiety-related
behaviour (Welberg et al. 2001). The SNS further participates in stress responses, even
in foetal life (McMillen et al. 2001), and prenatal exposure to various stressors affects
the development of sympathetic innervation and /or its regulation (Young 2002). A
recent study on the offspring of rats kept in hypoxia during pregnancy showed altered
development of sympathetic centres involved in blood pressure regulation, which
continued to adversely affect offspring blood pressure throughout adulthood (Peyronnet
et al. 2002). In line with these observations, we found that prenatal DEX-treated
offspring display hypersensitive pressor responses to even the mildest stressor, and that
the resulting stress-induced hypertension is mediated by altered sympathetic nerve
responsivity (see Chapter 5). Post-natal manipulations, such as handling new bom pups,
also induces modified stress responses, by reducing anxiety through altered HPA
feedback sensitivity and hippocampal GR expression (Meaney et al. 1989; O'Donnell et
al. 1994).
This chapter reports the phenotypes of offspring treated with either vehicle or DEX
during the last week of gestation, which were unintentionally further subjected to pre-
and / or post-natal stress, as a result of ultrasonic emission from fluorescent strip lights
and / or adjacent constmction work. The facility in which our animals are housed was
refurbished in 1999, with the installation of a new lighting system, and is located next to
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a newly constructed wing of the Western General Hospital, which was completed in
summer 2000; the following cohort of animals were both generated and characterised
during this time period.
3.2 Methods
3.2.1 Animals
Female rats and their litters were maintained, bred, and administered with vehicle or
DEX during their third week of pregnancy as described in Chapter 2. Male offspring
were weighed at 3, 7, 14 and 21 days of age, and at three weekly intervals thereafter
throughout postnatal life.
At 2 and 3 months of age, male offspring underwent 7 consecutive days of systolic blood
pressure measurement by automated tail cuff plethysmography (the last 3 days'
measurements were used in subsequent analysis), or 3 days consecutive days of blood
pressure measurement by carotid cannulation (where BP was measured in the first 10
minutes after connecting the animal to the apparatus), as described in Chapter 2.
Following the discovery of atypical phenotypes for prenatally treated DEX offspring,
adult males, born within the facility, though not subjected to any in utero manipulations,
were utilised as environmental stress monitors. Following cessation of the construction
work, adult naive males were introduced to the animal facility.
3.2.2 Plasma [corticosterone]
[Corticosterone] in plasma obtained by tail nick sampling was measured in male and
female offspring at 3 and 6 months of age, using the method outlined in Chapter 2.
Further plasma corticosterone assays were performed on adult males, that were not
prenatally treated, but who were bom and housed in the animal unit throughout the
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generation of this cohort, and in adult naive males following a month's habituation to the
animal unit.
3.2.3 PEPCK activity assay
Measurement of PEPCK activity was made in cytosol derived from homogenates of liver
obtained from offspring killed at 3 months of age, according to the methods described in
Chapter 2.
3.2.4 Oral glucose tolerance test
Glucose and insulin were assayed in plasma samples from male offspring aged 6
months, collected during the OGTT, using the methods described in Chapter 2.
3.2.5 Assessment of ultrasonic noise pollution
Upon the discovery of atypical phenotypes of prenatally treated animals, a detector used
for identifying and locating bats in the wild (kindly donated by the Dept. of Zoology)
was set to 80 kHz and used to periodically investigate the animal unit for sources of
ultrasound.
3.2.6 Designation of 'Quiet' and 'Noisy' rooms
A motor unit used to power strip lighting within the animals' room was identified as one
potential source of ultrasound pollution. This specialised unit enabled the lights to
operate a 'dawn' and 'dusk' phase, as opposed to simple 'on/off function. It was
replaced with normal strip lighting in one room, which was termed the 'Quiet' room but
left untouched in a second room, which was termed the 'Noisy' room.




As expected, DEX administration throughout the final week of gestation resulted in a
significant decrease in birth weight i.e. vehicle 5.9 ± 0.05g, DEX 5.4 ± 0.05g (n= 67 for
both groups, p < 0.01 by Student's t-test), representing a mean 8.5% reduction in birth
weight as a result of prenatal DEX treatment. No differences in gestation length (Vehicle
and DEX; 22 ± 0 days, n = 8 per group) or litter size (Vehicle; 9 ± 1 pups versus DEX; 8
± 1 pups, n = 67 per group) were noted.
3.3.2 Growth Trajectory
Figure 3-1 reveals that male and female offspring from both treatment groups gained
weight throughout the course of their postnatal life. Contrary to many previous studies,
DEX-treated offspring only exhibited catch-up growth until approximately 3 months of
age, thereafter it ceased and they remained approximately 11% lighter than controls for
the remainder of their life; for example, at 210 days of age, mean body masses were 660
± 14g and 591 ± 12g for vehicle and DEX-treated offspring (n = 34 and 39 respectively,
p < 0.05 by Student's t-test).
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Figure 3-1 Growth trajectory of offspring to 7 months of age
A Growth trajectory of male and female DEX and vehicle treated offspring. Data are
presented as mean ± SEM (note the SEMs are contained with the symbols), n = 34 (DEX)
and 39 (Vehicle). B Catch-up growth of DEX-treated rats: ratio ofmean body weights of
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3.3.3 Systolic Blood Pressure
Although there was a trend for DEX-treated offspring to display elevated systolic blood
pressure when measured by carotid cannulation, this did not reach statistical significance
in the present cohort (see Figure 3-2). Similarly, no effect of prenatal treatment was
revealed by tail-cuff plethysmography at either 2 or 3 months of age (see Figure 3-2).
However, systolic blood pressure did increase significantly between 2 and 3 months of
age in both vehicle (from 120 ± 7 mmHg to 145 ± 5 mmHg,/? < 0.05, 1 way ANOVA
followed by post-hoc test) and DEX (from 128 ± 2.5 mmHg to 146 ± 5.5 mmHg,/? <
0.05, 1 way ANOVA followed by post-hoc test) treated offspring.
Figure 3-2 Offspring systolic blood pressure at 2 and 3 months of age
Systolic blood pressure of vehicle and DEX-treated male offspring at 2 and 3 months of
age, measured by carotid cannulation (average of 2 consecutive days; readings were
taken within the first 1 Omins after connection of the animal to the apparatus) or tail-cuff
plethysmography (average ofmeasurements recorded on the last 3 days of 7 days
consecutive measurements). Data are presented as mean ± SEM, n = 4-6 per group for
carotid cannulation and n= 10 per group for tail-cuff plethysmography, 1 way ANOVA
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3.3.4 Prenatal DEX and glucose homeostasis
Contrary to previous studies, no difference was observed between the prenatal treatment
groups in either plasma glucose (see Figure 3-3A) or insulin (see Figure 3-3B) during
the OGTT, performed at 6 months of age.
Figure 3-3 Plasma glucose and insulin during an oral glucose tolerance
test
Plasma [glucose] and [insulin] quantified in blood taken from 09:00 from the tail-tip of
rats fasted overnight. A Plasma glucose before, and at 30 and 120 mins after an oral
glucose load, measured by hexokinase assay. B Plasma insulin before, and at 30 and 120
mins after an oral glucose load measured by ELISA. Data are presented as mean ± SEM,
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3.3.5 Hepatic PEPCK activity
The lack of effect of prenatal DEX on glucose homeostasis was further associated with
a lack of effect of prenatal DEX on liver PEPCK activity, measured at 3 months (see
Figure 3-4).
Figure 3-4 Hepatic Phosphoenolpyruvate carboxykinase activity.
PEPCK activity measured in microsomal extracts from livers of 3 month old vehicle and
DEX treated offspring. Data are presented as mean ± SEM,






At 3 months of age, both male and female offspring of both prenatal treatment groups
displayed greatly elevated increases in basal morning (08:00) plasma CORT (see Figure
3-6), compared to levels normally achieved in the laboratory (Levitt et al. 1996;
Welberg et al. 2000; Chapter 4).
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Figure 3-5 Offspring basal plasma corticosterone concentrations
Plasma [cort] quantified in blood taken from 08:00 from the tail-tip ofmale and female












3.3.7 Detection of environmental noise pollution
Considerable ultrasound emissions at 80kHz emanated from the fluorescent strip lighting
fitted in the animal rooms of the Biological Research Facility.
It was further noted that the byroad adjacent to the facility was frequently utilised as a
route of access for construction lorries destined for the nearby building site. We further
learned that the construction of the foundations for the site involved 'piling', a process
whereby large steel rods are rammed deep into the ground, resulting in substantial and
widespread underground vibrations.
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3.3.8 Replacement of lighting and monitoring of corticosterone levels
Following the detection of one potential environmental stressor, the lighting was
replaced in one room (termed the 'Quiet' room), and adult males were housed between
this room and an adjacent room, where the lighting remained untouched ('Noisy' room).
However, measuring basal plasma corticosterone in these animals at four, and six weeks
after the lighting was changed revealed no differences between those housed in either
the 'Quiet' or 'Noisy' rooms (see Table 3-1).
Table 3-1 Comparison of basal plasma corticosterone obtained in
adult males housed in either the 'Quiet' or 'Noisy' rooms
Time of basal corticosterone measurement
in adult males Quiet Room Noisy Room
4 weeks after the lights were changed 446 ± 158 nM 440 ±91 nM
6 weeks after the lights were changed 456 ± 142 nM 444 ± 120 nM
3.3.9 Plasma corticosterone levels in vehicle-treated male offspring, and
naive males housed in both 'Quiet' and 'Noisy' rooms.
As demonstrated in Figure 3-7, vehicle treated offspring, aged 8 months, housed in both
the 'Quiet' and 'Noisy' rooms, revealed similar significant reductions in their basal
corticosterone levels, though they still verge on or exceed the upper limit of normal.
Conversely, naive males housed in the 'Quiet' and 'Noisy' rooms had corticosterone
levels of 42.5 ± 5 nM, and 31.5 ± 6 nM respectively (N - 8 per room); both values lying
within the normal basal range for our laboratory. Construction of the foundations of the
new hospital wing was completed at the time of testing.
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Figure 3-6 Corticosterone levels in vehicle-treated male offspring,
housed in either the 'Quiet' or 'Noisy' room
Plasma [cort] quantified in blood taken at 08:00, from the tail-tip of vehicle- treated
offspring aged 8 months. Data are presented as mean ± SEM, n = 8 per group. Shown
also are the previous mean [cort] for these rats when they were 3 months of age
(represented by a solid grey line), the upper limit of normal basal [cort] (represented by a
dashed grey line), and the mean [cort] measured in naive males aged 3 months
(represented by a black dotted line). The downward arrow denotes the reduction in [cort]
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3.3.10 Comparison of offspring phenotypes pre-, during and post-
detection of noise pollution
Characterisation of this cohort revealed a phenotype that differed substantially from
previous and subsequent cohorts of prenatally treated offspring. A summary of the
results highlighting the discrepancies between offspring cohorts generated for this study,
and those before and after the cessation of building work, and modification of the
lighting system, is outlined in Table 3-2. Finally, offspring cohorts generated
simultaneously by Dr. M. Nyirenda at another animal unit elsewhere in the university
revealed the previously reported phenotypes for prenatally vehicle and DEX treated
offspring (data not shown).
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3.4 Discussion
This chapter recounts data acquired during a series of investigations intended to unravel
the molecular mechanisms underlying the hypertensive phenotype of the DEX-
programmed rat. Instead, it reveals how the physiological profile of a prenatal vehicle or
DEX-treated animal is confounded by perinatal stress, induced in this case by
construction noise. Furthermore, during this same time period the animal facility was
frequently but irregularly passed by a plethora of construction lorries and machines
accessing the adjacent building site, which would have involved the emission of
infrasound. Such noise disturbances would have been clearly audible to our cohorts, as
rodents possess a hearing range that incorporates both ultra- and subsonic frequencies.
Moreover, prenatal DEX-treatment programmes greater cochlear sensitivity to noise
stress (Canlon et al. 2003), which is most harmful when emitted irregularly and
unpredictably (Fride & Weinstock 1984). Thus, these sound frequencies may have
induced stress, either pre- and / or postnatally to both vehicle and DEX-treated cohorts
through the maternal and / or foetal HPA-axis and / or SNS.
Despite in utero growth retardation, the other well documented adult characteristics of
the DEX-programmed phenotype were nonexistent. As highlighted by Table 3-2, this
probably reflects alterations in the vehicle-treated offspring that developed a phenotype
analogous to that of DEX-offspring, without any appreciable modification in the
phenotype of the latter. Given the null effect of perinatal stress on the phenotype of the
DEX-treated offspring, it is tempting to speculate that there is an 'upper limit' for the
effects of prenatal glucocorticoids. Whether this 'upper limit' is a result of modified GR
and / or MR expression, or is a function of enhanced glucocorticoid metabolism remains
to be established. Alternatively, it is conceivable that a factor exists, which antagonises
the effects of glucocorticoids, thereby limiting their adverse effects in the long term.
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Birth weights of both cohorts, but especially of vehicle-treated offspring were
significantly reduced when compared to previous (Levitt et al. 1996; Nyirenda et al.
1998) and later (see Chapters 4 and 6) studies , implying that the initiation of noise stress
occurred before birth. Subsequent catch-up growth of DEX-treated offspring also failed
to achieve completeness, and they remained on average 11% lighter throughout
adulthood, when compared to controls; though the implications of this are controversial.
Whilst complete (Nyirenda et al. 1998; Levitt et al. 1996; Desai et al. 1996; Woodall et
al. 1996) and lack of catch-up growth (Welberg et al. 2001; Cleasby et al. 2003; Langley
& Jackson 1994) have been demonstrated in several programming models, each reported
cohort still developed a 'programmed' phenotype. These studies support the present
view that birth weight and therefore, subsequent catch-up growth form relatively crude
markers of exposure to an adverse intrauterine environment, rather than underlying a
specific cause of pathophysiology in the offspring. In Chapter 4, birth weight and
postnatal catch-up growth were observed in both male and female DEX-treated
offspring, yet the adult 'programmed' phenotypes differed substantially, consistent with
this hypothesis.
At 2 and 3 months of age, no differences in systolic blood pressure were detected by
either tail-cuff plethysmography or carotid cannulation. This contrasts with previous
reports that utilised these techniques to demonstrate hypertension in DEX-treated adult
offspring (Benediktsson et al. 1993; Levitt et al. 1996; Lindsay et al. 1996). Whilst there
was an increase in systolic blood pressure between the time of measurement at 2 and 3
months of age, it occurred to the same degree in the offspring of both cohorts, and
possibly reflects perinatal stress programming. Interestingly, it is the vehicle-treated
offspring that demonstrate blood pressure values equivalent to those normally associated
with prenatal DEX-programming (Benediktsson et al. 1993; Levitt et al. 1996; Lindsay
et al. 1996), whilst the DEX-treated offspring display typically expected values, again
suggesting that perinatal noise stress did not add to their phenotype. Alternatively, it is
perhaps tempting to speculate that they in fact resist the effects of stress. In terms of
mechanism for the hypertension associated with perinatal stress programming, it is most
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likely mediated through elevated glucocorticoids (Levitt et al. 1996), altered sympathetic
nerve responsivity (Tonkiss et al. 1998; Chapter 6), and/ or an activated RAS (Everett et
al. 1991; Chapter 4). Furthermore, whilst tail-cuff plethysmography and carotid
cannulation are associated with considerable stress artifacts, the nature of their varying
effects on both vehicle and DEX-treated offspring, does not implicate them as causative
factors in the hypertension detected here (Chapter 6).
In further contrast to previous (Nyirenda et al. 1998; Nyirenda et al. 2001) and
subsequent (Chapter 4) findings, prenatal DEX treatment did not affect plasma glucose
or insulin levels measured at three time points during an OGTT. However, increases in
both these plasma variables following the oral glucose load indicate that nothing went
awry with the procedure (Nyirenda et al. 1998). In line with birth weight and BP data
from the present cohorts, the elevated plasma glucose and insulin concentrations
measured in vehicle-treated offspring mirrored those typically expected of prenatal
DEX-treated offspring. Furthermore, the comparable insulin-glucose profile of these
offspring cohorts is consistent with their identical hepatic PEPCK activities. Such
elevated levels of activity are normally associated with the hyperglycaemia found
exclusively in prenatal DEX-treated offspring (Nyirenda et al. 1998; Nyirenda et al.
2001; Chapter 4).
Highly elevated levels of plasma corticosterone, indicative of stress, were observed in
both cohort offspring, and again, unlike previous (Levitt et al. 1996; Welberg et al.
2001) and later (Chapter 4) findings, no differences between cohorts were detected.
After the removal of the ultrasonic emitting lights in one room, rat corticosterone levels
were assayed at regular intervals, serving as environmental stress monitors. These rats,
though bom in the animal facility, were not subjected to any in utero manipulation.
However, they too repeatedly displayed equivalent levels of corticosterone, regardless of
which room they were housed in, suggesting that perinatal stress had programmed the
HPA-axis of each animal bom within the facility, which could be further acted upon by
construction noises. Indeed, following the cessation of building works, plasma
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corticosterone values fell dramatically, but still remained in excess of the upper normal
basal limit, revealing continued life long HPA dysfunction. At this time na'ive adult
males were introduced to the animal facility, and displayed appropriate basal plasma
corticosterone levels, with no differences observed between animals housed in either
room, suggesting that exposure to the stressors during the perinatal period is critical to
programming later dysfunction. Alternatively, it may suggest that exposure to ultrasonic
noise from the strip-lighting alone was insufficient to programme adult dysfunction, and
that the phenotypes presented here are a result of the construction disturbances.
In conclusion, it is evident that perinatal stress induced by environmental noise is
sufficient to confound prenatal DEX-programming experiments. This perinatal stress
successfully introduced low birth weight, hypercorticosteronaemia, insulin resistance
and hypertension, to vehicle-treated offspring, such that the typical distinctions between
both treatment groups were completely ameliorated. The lack of an additional effect on
DEX-treated offspring is suggestive of an 'upper limit' effect of prenatal stress or
glucocorticoids, serving to prevent against the potentially detrimental effects of
sustained glucocorticoid hyper-exposure. Finally, perinatal stress is further able to
programme HPA-axis dysfunction in offspring that were not additionally subjected to
any other in utero manipulations.
Perspectives
With the demonstrated ability to modify complex physiological systems, it is quite
conceivable, that construction work may serve as a major contributor to reports of
'biological variability'. As the following chapters will illustrate, under well-controlled
conditions, biological variability is actually quite negligible, and those environmental
variables, which may go unnoticed by many researchers (particularly those that utilise
animal tissues harvested by others); can cause pronounced, misleading, and costly
alterations in otherwise robust model systems.
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Glucocorticoid exposure in late gestation permanently
programmes gender specific differences in adult
cardiovascular and metabolic physiology.
4.1 Introduction
Whilst the precise mechanisms underpinning prenatal programming remain elusive, we
hypothesised that excessive fetal exposure to glucocorticoids might be important, based
upon the documented effects of antenatal glucocorticoid administration to reduce birth
weight and alter the trajectory of maturation of specific fetal organs (see Chapter 1 for
more in-depth introduction). In rats, we and others have shown that prenatal exposure to
the synthetic glucocorticoid dexamethasone (DEX) or to endogenous maternal
glucocorticoids by inhibition of the feto-placental 'barrier enzyme', 11 P-hydroxysteroid
dehydrogenase type 2, reduces birth weight and produces permanently impaired glucose
tolerance and hypertension in the adult offspring, associated with increased
hypothalamic-pituitary-adrenal (HPA) axis activity and abnormal behaviour reminiscent
of anxiety (Levitt et al. 1996; Welberg et al. 2000; Welberg et al. 2001; Holness &
Sugden 2001; Sugden et al. 2001). The programming of glucose-insulin dyshomeostasis
only occurs when glucocorticoids are administered in the final week of gestation
(Nyirenda et al. 1998), whereas the programming of hypertension is less time
constrained (Levitt et al. 1996; Benediktsson et al. 1993). Similar findings have been
reported with DEX in the sheep (Dodic et al. 2001; Gatford et al. 2000) and guinea pig
(Persson & Jansson 1992; Jansson & Persson 1990; Liu et al. 2001), although the
particular windows of vulnerability appear species-specific.
In terms of mechanism, whilst prenatal DEX-programmed glucose intolerance is
associated with permanently increased hepatic expression of a key gluconeogenic
enzyme phosphoenolpyruvate carboxykinase (PEPCK) (Nyirenda et al. 1998), the basis
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of DEX programming of hypertension remains unknown, although some data in sheep
have implicated the renin-angiotensin-aldosterone system (RAS) (Moritz et al. 2002;
Dodic et al. 2002). Importantly, in adult rats, glucocorticoids regulate all of the principle
components of the RAS, including renin secretion (Burris et al. 1986), angiotensinogen
synthesis (Bunnemann et al. 1993), angiotensin converting enzyme activity (Mendelsohn
et al. 1982), angiotensin II (Sato et al. 1994) and mineralocorticoid receptor expression
(Reul et al. 1989). Furthermore, in the fetal rat, hepatic angiotensinogen mRNA levels
are regulated by glucocorticoids (Everett et al. 1991).
An additional complexity relates to gender. In several paradigms, antenatal
manipulations that permanently alter adult EIPA axis function are sex-specific
(Weinstock et al. 1992; Liu et al. 2001; Ward & Weisz 1984; Kerchner et al. 1995), and
the importance of gender in determining programmed outcomes has recently been
suggested in both humans (Adair & Cole 2003) and rodents (Ortiz et al. 2003; Khan et
al. 2003). Moreover, there is no a priori reason to assume that if a similar programmed
phenotype is obtained that identical mechanisms underlie it. Indeed, early or late
gestation DEX or 11 (3-hydroxysteroid dehydrogenase inhibition all produce HPA axis
hyperactivity but involve distinct central mechanisms (Welberg & Seckl 2001; Welberg
et al. 2001; Welberg et al. 2000). However, little work has been done on the effects of
antenatal steroids and peripheral programming phenotypes. DEX-programmed
hypertension occurs in both sexes, but may reflect distinct processes in each gender,
whilst hyperglycaemia/hyperinsulinaemia has only been shown in male rats. This study
aimed to determine whether there is sexual dimorphism in the prenatal glucocorticoid
programming of (1) glucose intolerance, and (2) hypertension; and (3) to ascertain
whether the prenatal programming of adult blood pressure by glucocorticoids is
mediated by alterations in the RAS.




Female rats and their litters were maintained, bred, and administered with vehicle or
DEX during their third week of pregnancy as described in Chapter 2. Male and female
offspring were weighed at 3, 7, 14 and 21 days of age, and at three weekly intervals
thereafter throughout postnatal life.
Experiments in which female offspring were utilised, it was ensured that they were all at
the same stage of the oestrous cycle, as outlined in Chapter 2.
At 6-7 months of age, offspring underwent 7 consecutive days of systolic blood pressure
measurement by automated tail cuff plethysmography, as described in Chapter 2.
4.2.2 HPA activity
Morning and evening corticosterone and ACTH levels was measured in plasma obtained
by tail nick sampling from male and female offspring at 3 months of age, using the
method outlined in Chapter 2.
4.2.3 PEPCK activity assay
Measurement of PEPCK activity was made in cytosol derived from homogenates of liver
obtained from offspring killed at 3 months of age, according to the methods described in
Chapter 2.
4.2.4 Oral glucose tolerance test
Glucose and insulin were assayed in plasma samples from offspring aged 6 months,
collected during the OGTT, using the methods described in Chapter 2.
4.2.5 Plasma renin activity, angiotensinogen and oestradiol levels
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Plasma renin activity (PRA), angiotensinogen and oestradiol levels were measured in the
trunk blood of animals aged 8 months, as described in Chapter 2.
4.2.6 Angiotensinogen northern blot hybridisation
Total liver and mesenteric adipose tissue Angiotensinogen (Aogen) mRNA was
quantified by Northern blot controlled for by U1 as described in Chapter 2; results are
ratios ofAogen:Ul mRNA (arbitrary units;AU).
4.2.7 Real-time PCR
Quantities of hypothalamic and renal Aogen were assessed by real time PCR as outlined
in Chapter 2.
4.2.8 Female hepatic GR in situ hybridisation
Livers from 5 prenatal vehicle and DEX-treated females were removed after decapitation
and fragments quickly frozen on dry ice and stored at -80°C. GR in situ hybridisation
was performed as described in Chapter 2.
4.2.9 Statistical analyses
All data are expressed as mean ± SEM. Data were compared using an unpaired Student's
t tests, one-way or multiple ANOVA followed by a LSD post-hoc multiple comparisons
test, where appropriate. Values were considered significant when P < 0.05
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4.3 Results
4.3.1 Gestational weight gain, birth phenotype and catch-up growth
DEX administration throughout the final week of gestation significantly reduced
maternal weight gain (see Table 4-1). There were no differences in the length of
gestation, litter size, ratio of male to female pups born or pup viability. DEX treatment
reduced the birth weight of offspring, similarly in both male and female pups (see Table
4-1).
At weaning (postnatal day 21) and throughout adulthood, body weights of
dexamethasone and vehicle-exposed offspring were similar, both in males and in
females, i.e. full catch-up growth had occurred (see Table 4-2).
Table 4-1 Comparison of gestational and birth parameters in vehicle
and DEX treated cohorts
Maternal weight before treatment, maternal weight gain during the last week of
pregnancy (days 14-21), gestation length, litter size, male: female ratio, and group, male,
and female offspring birth weight. Results are mean ± S.E.M; Student's t-test, * p < 0.05,




Maternal Gestation Litter Male:female







94 ±5 22 ±0 13 ±1.6 0.9 ±0.1 6.4 ±0.06 6.5 ±0.08 6.2 ±0.08
(« = 107) (n = 58) (n = 49)
DEX 373 ±6
0 = 9)
55 ±4* 22 ±0 12 ±1.2 1.2 ±0.2 5.6 ± 0.06t 5.7 ± 0.09f 5.6 ± 0.09f
0=112) 0 = 55) 0 = 57)
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Table 4-2 Comparison of post-natal growth in vehicle and DEX treated
offspring
Offspring body weights (grams) of pregnant rats treated with vehicle (control) or DEX
during the last week of gestation (embryonic days 14-21), measured at weaning
(postnatal day 21), 3 months, and 6 months. Data are presented as mean ± SEM.
Weight at weaning Weight at 3 months Weight at 6 months
(g) (g) (g)
Vehicle
Group 56.4 ±1.7 (« = 51) 390 ±8.6 (« = 34) 532.9 ±10.0 (n = 34)
Male 57.6 ±1.1 (« = 26) 493 ± 9.9 (n = 20) 693.9±12.2 {n = 20)
Female 55.7 ±1.0 (n = 25) 287 ± 7.2 (n=14) 372.0 ±7.8 {n= 14)
DEX
Group 54.0 ± 0.9 (n = 56) 382 ± 11.5 (n = 38) 517.9 ± 16.1 (n = 38)
Male 55.1 ±1.2 (n = 29) 480 ± 11.6 (n = 20) 674.8 ± 22.3 {n = 20)
Female 52.7 ± 1.4 (« = 27) 283 ± 11.5 (w = 18) 361.0 ± 9.9 («=18)
4.3.2 HPA activity in adult offspring
In male offspring, prenatal DEX exposure resulted in significant increases in basal
morning (08:00) plasma ACTH and corticosterone concentrations, whereas levels at the
evening, diurnal peak, (20:00) were unchanged (see Figure 4-1). These hormonal
profiles were not reflected in female offspring treated with DEX, with no differences
observed between either group at either time point (see Figure 4-1). Overall, female
offspring displayed significantly higher basal and peak ACTH and corticosterone
concentrations.
Programming gender specific outcomes - 105 -
Figure 4-1 HPA activity in offspring
Chapter 4
Basal (AM) and peak (PM) adrenocorticotrophin (ACTH) and corticosterone (CORT)
levels in male and female offspring that have been exposed to either vehicle or DEX
during the last week of intrauterine life. Results are mean ± S.E.M, 2-way ANOVA
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4.3.3 Prenatal DEX, glucose homeostasis and PEPCK activity
Male offspring of dams treated with DEX throughout the last week of pregnancy had
permanent reactive hyperglycaemia and hyperinsulinaemia 120 min after an oral glucose
load (see Figure 4-2A). In contrast, their prenatal DEX-exposed female offspring
littermates did not differ from controls in their glucose homeostasis at any time point
pre-, or post-oral glucose load (see Figure 4-2A).
Consistent with previous observations (Nyirenda et al. 1998), prenatal DEX exposed
male offspring had significantly elevated hepatic PEPCK activity, whilst no differences
in enzyme activity were observed in their female littermates (see Figure 4-2B).
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Figure 4-2 Plasma glucose and insulin during an oral glucose tolerance
test, and hepatic phosphoenolpyruvate carboxykinase activity.
A. Insulin: glucose ratios in male and female adult offspring, exposed to vehicle or DEX
during the final week of pregnancy (embryonic days 14-21). Following an overnight
fast, offspring underwent an oral glucose tolerance test. Plasma glucose and insulin was
measured at 0, 30 and 120 after an oral glucose load (2g.kg"'). B. Activity of hepatic
PEPCK, assayed at weaning (postnatal day 21) in fed male and female offspring treated
in utero with vehicle or DEX during the third week of gestation. All results are mean ±
S.E.M, A. 2-way ANOVA (prenatal treatment x gender), B. 3-way ANOVA (prenatal
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4.3.4 Systolic Blood Pressure
As shown in Figure 4-3, only female offspring in the prenatal DEX group showed
elevated systolic BP above vehicle controls, when measured at 6 months by tail-cuff
plethysmography. In this cohort of prenatally DEX treated animals, adult male offspring
systolic BP was not elevated.
Figure 4-3 Offspring systolic blood pressure at 6-7 months of age
Systolic blood pressures, measured by tail-cuff plethysmography, in adult male and
female offspring exposed to vehicle or DEX throughout the final week of intrauterine
life (embryonic days 14-21). Results are mean ± S.E.M, n = 8 per group, * p < 0.05
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4.3.5 Prenatal DEX and tissue Angiotensinogen expression
Prenatal DEX treated female offspring displayed a significant increase in hepatic
angiotensinogen mRNA expression (see Figure 4-4B) in association with the
hypertension. In contrast, DEX exposed males, which were not hypertensive, had
significantly decreased hepatic angiotensinogen mRNA expression (see Figure 4-4A).
The effect on angiotensinogen mRNA in liver was specific to this tissue since expression
of this transcript in female or male mesenteric adipose tissue, kidney and hypothalamus
did not reveal any significant differences (see Figure 4-5). However, renal
angiotensinogen mRNA levels were higher in females (see Figure 4-5A), consistent
with previous reports (Gordon et al. 1992).
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Figure 4.4 Offspring levels of hepatic Angiotensinogen mRNA expression
Hepatic expression of angiotensinogen mRNA, in 8 month old male (graph A) and
female (graph B) offspring, treated with vehicle or DEX during the last week of
gestation (embryonic days 14-21). Data from Northern blots, graphically represented in
arbitrary units (AU) of angiotensinogen mRNA in adult rat liver. Values shown are
normalised to U1 used as loading control. Results are mean ± S.E.M, Student's t-test, n =
6 per group, * p < 0.05 compared with vehicle group. C. Example of a typical Northern




































Hepatic Aogen Expression in adult
female offspring.
• "f;r ' '''■ '• , **
j# "
Mesenteric Aogen Expression in aduftS^
female offspring.
;' "ifil!" •. (nitWf' 'iiii
i
mm-:.:





Programming gender specific outcomes - 109-
Chapter 4
Figure 4-5 Offspring levels of renal, hypothalamic and mesenteric adipose
Angiotensinogen mRNA expression
Renal (graph A), hypothalamic (graph B) and mesenteric adipose tissue (graphs C and
D) expression of angiotensinogen (Aogen) mRNA, in adult male and female offspring,
treated with vehicle or DEX during the last week of gestation (embryonic days 14-21).
Data from real-time PCR (graphs A and B), and Northern blots (graphs C and D),
graphically represented in arbitrary units (AU) of angiotensinogen mRNA in adult
tissue. Values shown for Northern blots are normalised to U1 used as loading control.
Results are mean ± S.E.M, 2-way ANOVA (prenatal treatment x gender) (graphs A and
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4.3.6 Plasma angiotensinogen, renin activity and oestradiol parameters
To determine whether the increased hepatic angiotensinogen mRNA levels in prenatal
DEX-exposed female offspring were reflected in increased circulating RAS activities,
plasma renin activity and angiotensinogen levels were measured in 6-7 month old
offspring. Prenatal DEX-exposed female offspring displayed significantly elevated
levels of both plasma angiotensinogen and renin activity (see Table 4-3). Whilst
angiotensinogen is regulated by sex steroids as well as glucocorticoids, no differences in
plasma oestradiol levels between DEX and control offspring were found (see Table 4-3).
Levels of angiotensinogen and renin activity were similar to control in male DEX
offspring (see Table 4-3).
Table 4-3 Offspring plasma renin activity, angiotensinogen and oestradiol levels.
Adult plasma renin activity, angiotensinogen and oestradiol. Measurements were made
in ad-libitum-fed, 6-7 month-old male and female rat offspring, treated in utero during
the last week of pregnancy (embryonic days 14-21) with vehicle or DEX. Results are
mean ± S.E.M, n = 6-8 per group, 2-way ANOVA (prenatal treatment x gender) and
Student's t-test (for oestradiol), * p < 0.05 compared with vehicle group.
Plasma Parameter












4.3.7 Effect of prenatal DEX on hepatic GR expression in female offspring
Consistent with DEX-treated male offspring (Nyirenda et al. 1998), GR mRNA was
significantly increased in the liver of DEX-treated female offspring (Vehicle, 158 ± 51
estimated grains per hepatocyte versus DEX, 317 ± 44 estimated grains per hepatocyte;
n = 5 per group, Student's t-test, *p < 0.05).
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4.2 Discussion
Data presented in this chapter demonstrate that DEX administration in the last week of
gestation reduces offspring birth weight and programmes adult cardiovascular and
metabolic physiology in a sex specific manner. In male offspring, prenatal
glucocorticoid exposure programmes elevated basal circulating corticosterone, elevated
hepatic PEPCK activity, and produces adulthood postglucose hyperglycaemia and
hyperinsulinaemia. In female offspring, prenatal dexamethasone treatment programmes
elevated hepatic angiotensinogen mRNA expression, elevated plasma angiotensinogen
and renin activity, and produces hypertension.
Birth weight reduction and postnatal catch-up growth were observed in both males and
females in this study, whereas the adult 'programmed' phenotypes differed considerably.
This reinforces the current notion that birth weight is merely a relatively crude marker of
exposure to an adverse (late) gestational environment, rather than a specific cause of
pathophysiology in the offspring. Below specific aspects of the adult phenotype are
discussed.
HPA axis
As with some other antenatal challenges (stress, alcohol, etc), antenatal DEX exerts sex-
specific effects on the adult HPA axis. In males, last trimester DEX selectively increases
morning basal ACTH and corticosterone levels, findings in agreement with earlier
studies, which further showed decreased levels of the glucocorticoid and
mineralocorticoid receptors in the hippocampus, suggesting decreased HPA axis
feedback sensitivity (Levitt et al. 1996; Welberg et al. 2001). Female HPA function was
not altered by DEX. Two possible explanations occur; either females resist DEX
programming or the 'stress' of antenatal vehicle injections was sufficient to programme
the offspring HPA axis to the same extent as DEX in females. In support of the latter
explanation, many sexually dimorphic antenatal programming paradigms affecting the
HPA axis in rats are more marked in females (Weinstock et al. 1992; Osbom et al.
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1996), though this is by no means consistent (Kim et al. 1999; Koehl et al. 1999).
Moreover, female, but not male offspring rat HPA parameters can be programmed by
vehicle injections to a similar degree as last trimester DEX (Bakker et al. 1998).
Moreover, basal corticosterone and ACTH levels in the antenatal vehicle-injected
females were higher than seen in uninjected control females in our laboratory (personal
communication, Dr. Amanda Drake). In contrast, some data support different trajectories
for the development of HPA axis components in the rat, suggesting last trimester DEX
may impact upon different tissue sensitivity windows in males and females (Aird et al.
1997). In the guinea pig, similar sex specific programming of the HPA axis is also
observed (Liu et al. 2001). Whether CNS glucocorticoid receptor density is altered in
female DEX offspring remains the target of future studies. Nevertheless, the sex
difference in HPA axis programming by DEX is clear-cut.
Glucose-Insulin houteostasis
In agreement with previous observations (Nyirenda et al. 1998; Nyirenda et al. 2001),
DEX-treated male offspring were hyperglycaemic following an oral glucose load with
features suggestive of insulin resistance (higher 120 min insulin-to-glucose ratio). As
before, there was a permanent increase in hepatic PEPCK activity. None of these effects
were seen in female littermates. Similar gender-specific programming of insulin
resistance has been observed in the male offspring of protein restricted dams (Sugden &
Holness 2002), and the 2 antenatal challenges may be related as the diet reduces
placental 11P-HSD2 allowing excess fetal glucocorticoid exposure (Langley-Evans et al.
1996). It is tempting to speculate that the gender difference reflects the lack of HPA
programming in females. In support of this contention, raised hepatic PEPCK in males is
associated with permanently increased liver GR expression and hence increased
sensitivity of plasma glucose to circulating corticosterone levels, which are elevated in
males. Furthermore, this would explain why increased hepatic GR expression was not
associated with raised hepatic PEPCK activity in DEX-treated females. Alternatively, it
could be that insulin resistance (absent in the DEX-treated females) is necessary before
glucocorticoids can affect PEPCK activity (Reshef et al. 1970; Friedman et al. 1993).
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However, the control of PEPCK gene expression is complex and is only one part of the
myriad processes regulating glucose homeostasis. Alternative explanations, including
the role of oestradiol (though unaltered in this study), thyroid hormones and insulin (Hall
et al. 2000; Lucas et al. 1991), in modulating hepatic PEPCK and other genes, any of
which may be differentially altered in males and females, remain to be addressed.
Nonetheless, the parallels between programming (or not) of HPA hyperactivity and of
glucose dyshomeostasis remain intriguing.
Bloodpressure
Surprisingly, in the current study elevated systolic blood pressure was confined to DEX-
treated female offspring. Prior investigations have demonstrated higher blood pressures
in DEX-treated males, though there were differences in the prenatal treatment regime
(Benediktsson et al. 1993) and measurement technique used (Benediktsson et al. 1993;
Levitt et al. 1996). Interestingly, there is a suggestion that the timing of blood pressure
measurement may be important. Exposing dams to DEX, Ortiz et al found elevated
systolic blood pressure specifically confined to female offspring at 2 months of age, and
to male offspring at 6 months (Ortiz et al. 2003). In another study, the female offspring
of lard-fed dams did not reveal any elevation in blood pressure at 3 months of age but
did at 6 and 12 months, whilst the male offspring were normotensive at the selected time
points (Khan et al. 2003). Here offspring blood pressure was assessed at 6-7 months of
age, whereas our previous studies demonstrating hypertension in DEX-treated males
used younger animals (Benediktsson et al. 1993; Levitt et al. 1996). The reasons for the
disparity in these programming models are unknown.
Whatever the basis for the sex difference in this study, prenatal glucocorticoid
administration resulted in generalised activation of the RAS in the hypertensive female
but not the normotensive male littermate offspring. In rodents, angiotensinogen is a key
step determining RAS activation (Tamura et al. 1996) and it is a strong candidate gene
for hypertension in humans (Corvol et al. 1999). Thus, the higher hepatic
angiotensinogen mRNA levels and consequent elevation in plasma angiotensinogen
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concentrations in females may drive the hypertension. Non-hepatic sources of
angiotensinogen were not altered, emphasising the liver-specificity of this effect, (as on
other gene expression in this model; Nyirenda et al. 1998), in contrast to suggestions in
the sheep (Dodic et al. 2001). Moreover, their accompanying increase in PRA, is
consistent with the current notion that angiotensinogen is not merely a passive substrate
reservoir (Bohlender et al. 2000). Recent evidence suggests that the renin-
angiotensinogen complex acts to stabilise plasma renin concentrations (by increasing
renin's half life and decreasing its metabolic clearance rate), thereby regulating plasma
renin independently of renal renin secretion and Angll mediated feedback (Bohlender et
al. 2000). Thus, increased plasma angiotensinogen and PRA may co-exist to promote
hypertension. In contrast, prenatally DEX-treated males showed reduced hepatic
angiotensinogen mRNA levels, and unaltered plasma angiotensinogen and PRA.
Importantly, circulating oestradiol did not vary physiologically between the groups of
prenatally treated female offspring, though the naturally higher female levels could in
part underlie the gender differences in RAS programming.
In conclusion, prenatal DEX administration in the final week of gestation, results in
reduced birth weight, and subsequent gender specific abnormalities in cardiovascular
and metabolic physiology. Alterations within the RAS may, at least in part, underlie the
hypertension. Recent human data in preterm babies have suggested that brief prenatal
glucocorticoid treatment, commonly used in obstetric practice, is associated with
increased adolescent blood pressure (Doyle et al. 1999). These experimental
observations, in conjunction with others, highlight the necessity for meticulous follow-
up studies to ascertain whether antenatal glucocorticoid exposure in humans produces
these adverse effects, and to further determine whether they are gender specific.
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Prenatal dexamethasone, dietary sodium and
hypertension.
5.1 Introduction
Considerable research on the effects of dietary sodium on hypertension has generated a
wealth of contentious data, and as the debate ensues, one key question remains to the
fore; "how much to use in a healthful manner?" Conventional philosophy promotes the
beneficial blood pressure lowering effects of a low sodium diet; though its supporters
frequently cite studies utilising rodents that are predisposed to developing hypertension
when fed a sodium diet far in excess of normal nutritional requirements (Rapp 1982; Ely
1997). Moreover, the effectiveness of a low sodium diet is highly dependent on both the
stage of development and strain of rat used (Di Nicolantonio et al. 1990). Whilst these
very low sodium diets may reduce blood pressure (Ely et al. 1985), they are associated
with adverse effects such as hyperlipidaemia and insulin resistance (Fliser et al. 1995).
Furthermore, in certain experimental models, a low sodium diet actually increases blood
pressure: in uninephrectomised rats (Seymour et al. 1980) and those fed a low sodium
diet during weaning (Webb et al. 1987). As prenatal DEX has been demonstrated to
decrease nephron number (Oritz et al. 2002), this could possibly reduce renal function
thereby mimicking uninephrectomy. Most interestingly, low sodium diets have recently
been identified as programmers of low birth weight, and of hypertension in later life
(Roy-Clavel et al. 1999).
The mechanisms by which a low sodium diet may produce hypertension remain to be
fully elucidated, though alterations in vascular reactivity (Rossiter et al. 1995), renal
function and the RAS (Battista et al. 2002) have been implicated.
To our knowledge, no previous study has examined the effect of a low sodium diet on
the cardiovascular and metabolic physiology of a prenatally glucocorticoid programmed
Prenatal DEX, dietary sodium and hypertension? - 116-
Chapter 5
rat. Intriguingly, in one study, rats receiving daily injections of DEX and fed a sodium
deficient diet revealed significant increases in aldosterone synthase mRNA expression
when compared to those receiving: high salt, low salt, DEX, or DEX and a high salt diet
(Malee & Mellon 1991). With this in mind, we hypothesised that prenatal DEX would
result in a similar increase in aldosterone synthase gene expression when offspring were




Female offspring from both prenatal vehicle and DEX-treated dams were chosen from
the offspring cohorts generated in Chapter 4.
At 6 months of age, 12 female offspring from both cohorts were selected at random and
underwent 7 days of consecutive blood pressure measurement by tail-cuff
plethysmography, as outlined in Chapter 2.
At the end of the week, 6 females from both cohorts were placed on either a normal
(0.3%) or low (0.03%) sodium containing diet. Offspring were maintained on the diet for
14 days, and had their blood pressure measured by tail-cuff plethysmography every third
day for the first nine days, as outlined in Chapter 2.
5.2.2 Oral glucose tolerance test
11 days after initiation of the study, glucose and insulin were assayed in plasma samples
from offspring, collected during the OGTT, using the methods described in Chapter 2.
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5.2.3 Plasma renin activity, aldosterone and corticosterone levels
At the end of the study (day 14), renin activity, aldosterone and corticosterone were
assayed in plasma samples from offspring, collected from trunk blood during sacrifice,
as outlined in Chapter 2.
5.2.4 Re-evaluation of dietary sodium content
Due to the aberrant nature of the results generated throughout the course of this study,
the sodium content of the diets were re-assessed both independently by the Dept. of
Clinical Chemistry at Edinburgh's Western General Hospital, and by Special Diet
Services, the company which supplied the diets.
5.3 Results
5.3.1 Effect of dietary sodium on plasma renin activity, and plasma
aldosterone
A plasma renin activity (PRA) assay was performed 14 days after offspring had been
started on the sodium diets. As revealed by Figure 5-1, offspring fed the low sodium
diet had significantly lower PRA values; an absolutely counterintuitive finding given
that lower dietary sodium should increase PRA.
Furthermore, in association with lower PRA levels, those offspring fed a low sodium
diet also had lower, albeit not significant, plasma aldosterone levels, (normal sodium
diet: vehicle, 251 ±32 pmol /1 versus DEX, 267 ± 47 pmol / 1; low sodium diet: vehicle,
211 ± 19 pmol /1 versus DEX, 218 ± 24 pmol /1; 2-way ANOVA (prenatal treatment x
diet),/? = 0.5 compared with vehicle group).
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Figure 5-1 Effect of dietary sodium on plasma renin activity
Renin values were assayed in trunk plasma, collected at sacrifice in 6 month old female
vehicle and DEX-treated offspring, following 14 days on either a normal (0.3%) or low
(0.03%) sodium diet. All results are mean ± SEM, Student's t-test.
n = 6 per cohort, * p < 0.05 compared to normal sodium diet.
14
">
Vehicle 0.3% Vehicle 0.03% DEX 0.3% DEX 0.03%
5.3.2 Multiple re-analyses of dietary sodium content
Owing to the unexpected and counterintuitive PRA and aldosterone data, we decided to
re-evaluate the sodium content of the supplied diets. This was achieved both
independently by the Dept. of Clinical Chemistry, at the Western General Hospital, and
by returning some of the diets for re-analysis to Special Diet Services, the company
which supplied them to us. As Table 5-1 illustrates, there was an alarming disparity
between the dietary sodium content requested and those actually supplied and utilised
experimentally. Each re-evaluation concurred that the supposed 'normal 0.3%' sodium
containing diet actually contained sodium in the region of 0.09%, over 3 times less than
desired. Moreover, the supposed Tow 0.03%' sodium containing diet had more than 12
times the requested sodium content, implying the diet was more saline than standard
chow.
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Table 5-1 Re-evaluation of dietary sodium content
Following confounding experimental results, the sodium content of the diets utilised
throughout the course of the current study were re-analysed; both independently by the
Dept. of Clinical Chemistry, at Edinburgh's Western General Hospital and by Special
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5.3.3 Systolic blood pressure before and during manipulation
of dietary sodium content
Whilst on standard chow, DEX-treated females displayed significantly elevated systolic
blood pressure compared to controls; vehicle 131± 3 mmHg, DEX 147 ± 3 mmHg;
repeated measures analysis (prenatal treatment x diet x time), p = 0.0007. However,
when changed to the new SDS diets containing normal (0.36%) or low (0.09%) sodium
levels, blood pressure steadily increased in vehicle-treated animals, particularly those on
the low sodium containing diet, so that at the end of the experiment they had systolic
blood pressures analogous to DEX-treated offspring {p = 0.94, repeated measures
analysis (prenatal treatment x diet x time) see Figure 5-2}. Conversely, both cohorts of
DEX-treated offspring maintained blood pressures similar to those displayed whilst on
standard chow (see Figure 5-2).
Prenatal DEX, dietary sodium and hypertension? - 120-
Chapter 5
Figure 5-2 Blood pressure profiles of vehicle and DEX-treated females,
prior, and during changes in the sodium content of their diet
Systolic blood pressure, measured by tail-cuff plethysmography in 6 month old vehicle
and DEX-treated offspring on standard chow (n = 12 per group), and subsequently
placed on a normal (0.36%; n = 6 per group) or low (0.09%; n = 6 per group) sodium
diet for 9 days. All results are mean ± SEM, repeated measures ANOVA (prenatal
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5.3.4 Effect of dietary sodium on offspring body weight and glucose
homeostasis
All offspring continued to gain weight throughout the course of the experiment, with no
differences in the gain in body weight noted between offspring cohorts fed either sodium
diet (normal sodium diet: vehicle, 8 ± 2g versus DEX, 7 ± 2g; low sodium diet: vehicle
7.5 ± 2g versus DEX, 8 ± 1.5g; 2-way ANOVA (prenatal treatment x diet), p = 0.5).
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11 days after altering dietary sodium content, offspring underwent an OGTT. Both
offspring cohorts fed a low sodium diet had significantly higher basal fasting glucose
concentrations compared to those on the normal sodium diet (see Figure 5-3A).
Furthermore, after an oral glucose load, offspring cohorts fed a low sodium diet had
significantly higher 30-min plasma glucose concentrations compared to those fed a
normal sodium diet (see Figure 5-3A). There were no significant differences at 120 min.
Fasting plasma insulin levels were also significantly elevated in offspring cohorts fed a
low sodium diet and at 30 min following an oral glucose load when compared to
offspring fed a normal sodium diet (see Figure 5-3B). There were no significant
differences at 120 min.
Offspring of either prenatal treatment group fed a low sodium diet further showed
elevated basal (normal sodium diet, 0.57 ± 0.06 pg/mmol versus low sodium diet, 1.08 ±
0.08 pg/mmol; p < 0.05, 2-way ANOVA) and 30 min (normal sodium diet, 1.18 ± 0.09
pg/mmol versus low sodium diet, 1.52 ± 0.07 pg/mmol; 2-way ANOVA (prenatal
treatment x diet), p < 0.05) insulin-to-glucose ratios when compared to those offspring
fed a normal sodium diet. There were no significant differences at 120 min.
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Figure 5-3 Effect of dietary sodium on plasma glucose and insulin responses
to an oral glucose load
Offspring plasma glucose and insulin responses to an oral glucose load. 6 month old
female offspring of pregnant rats that received either vehicle or DEX during the last
trimester underwent an oral glucose tolerance test 11 days after being switched to a
0.36% (normal) or 0.09% (low) sodium diet. Plasma glucose (A) and insulin (B) was
measured at 0, 30 and 120 min after an oral glucose load. All results are mean ± SEM, 2-
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5.3.5 Effect of dietary sodium on offspring plasma corticosterone
As illustrated by Figure 5-4, no differences in plasma corticosterone were observed
between any of the groups at sacrifice.
Figure 5-4 Plasma corticosterone levels at sacrifice in female offspring fed
normal and low sodium diets
Plasma corticosterone levels in prenatally vehicle and DEX-treated female offspring,
measured in trunk blood taken at sacrifice 14 days post-feeding with either a low or



























This chapter relates data accumulated during a course of investigations intended to
examine the effects of a 10-fold lower sodium diet on the cardiovascular and metabolic
phenotype of the DEX-programmed rat. From the outset, results indicated that it was
necessary to re-analyse the diet. The verdict from a local laboratory and Special Diet
Services, the company that manufactured the low and normal sodium diets was
unanimous; the supposed Tow 0.03% sodium diet' contained 0.36% sodium, whilst the
'normal 0.3% sodium diet' contained 0.09% sodium. Following multiple and prolonged
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investigations, it was discovered that the manufacturers had not only incorrectly labeled
the supplied diets, but also failed to perform quality control tests on their produce.
Nonetheless, we were still left with diets composed of a normal (0.36%) and low
(0.09%) sodium content. In hindsight, this 4-fold difference in sodium content is
possibly more clinically and physiologically relevant when compared to the initially
proposed 10-fold sodium difference.
Systolic Blood Pressure
In accordance with previous studies (Levitt et al. 1996; Benediktsson et al. 1993) and
sibling offspring (Chapter 4), DEX-treated females displayed higher systolic blood
pressures when fed standard rat chow ( containing 0.3% sodium).
Vehicle offspring fed either the normal or low sodium diets displayed significantly
elevated blood pressure compared to when they were fed normal chow. This was
particularly evident in those offspring fed the low sodium diet, whose final blood
pressure was identical to that of the DEX-treated offspring. As previously discussed, the
hypertension-causing effects of dietary sodium are not unexpected. In terms of
mechanism for this hypertension, it is tempting to speculate that it was mediated by
dysregulation of the HPA-axis and/ or of the RAS. Indeed, vehicle treated offspring fed
either sodium diet displayed hypercorticosteronaemia and hypertension, whereas those
fed the low sodium diet also displayed elevated plasma renin activity (PRA) and even
higher blood pressure, consistent with this hypothesis.
Interestingly, modifications in dietary sodium did not significantly alter DEX-offspring
blood pressure, despite significantly elevated PRA in offspring fed the low sodium diet.
This could be explained by the fact that DEX- treated offspring fed a normal sodium diet
had analogous PRA and blood pressure values to the vehicle-treated offspring fed the
low sodium diet. In Chapter 4, it was demonstrated that an altered RAS (including
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increased PRA) mediates in part, the hypertension associated with prenatal DEX
treatment. Thus, although dietary sodium alters PRA in DEX-treated offspring, this does
not further impact on previously programmed events that cause blood pressure
dysregulation. It is tempting to speculate that this is due to the interactions ofDEX and a
low sodium diet on atrial natriuretic peptide (ANP). ANP, which is increased by DEX
treatment (Dananberg et al. 1992; Fullerton et al. 1991), has been demonstrated to lower
BP (by promoting diuresis and natriuresis) even in the face of increased PRA, but only
when subjects are fed a low sodium diet (Weidmann et al. 1986).
While it may be tempting to explain any blood pressures differences as a technical
artifact of measurement (see Chapters 2 and 6 for in-depth discussion); tail-cuff
plethysmography was sufficiently sensitive in detecting blood pressure differences when
the offspring were fed standard chow. Moreover, when rodents fed a low sodium diet
during weaning became hypertensive, measurements made in the tail correlated well
with measurements made simultaneously by an intra-arterial catheter (Webb et al. 1987).
Of course, fastidious blood pressure profiling could only be achieved by radio-telemetry
(see Chapters 2 and 6 for further comment).
Plasma renin activity andplasma aldosterone and corticosterone levels
In the present study low dietary sodium produced a significant increase in PRA in both
offspring, whilst the trend for plasma aldosterone to be higher did not reach significance.
As the supplied low sodium diet contained three times the desired low sodium
concentration, it is possible that whilst sufficiently low to increase PRA, our diet was
inadequate to stimulate a considerable increase in plasma aldosterone levels.
Alternatively, it could be that the assay (Cartledge and Lawson 2000), and indeed the
physiology of aldosterone are more variable. For example, the dietary and plasma levels
of potassium (a key stimulator of aldosterone secretion) and plasma ANP (known to
suppress aldosterone, even in the face of increased PRA, Weidmann et al. 1986) in the
current study are unknown. In one study (Malee & Mellon 1991), rats required a totally
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sodium deficient diet before alterations in aldosterone synthase were observed (although
plasma aldosterone levels were not examined). On the other hand, rodents fed a low
sodium diet during weaning displayed modified PRA and hypertension, without
alterations in plasma aldosterone (Webb et al. 1987), thereby mirroring our observations.
Moreover, our findings are in direct agreement with the 'low sodium diet' model of
prenatal programming (Battista et al. 2002), whose offspring also display
hypercorticosteronaemia and hypertension. Clearly, further investigations in our model
are warranted before we can reliably report on the nature of sodium-induced RAS
changes.
Elevated offspring corticosterone levels could be associated with hypertension as
previously discussed, and are possibly due to the well-documented stress associated with
dietary change (Hatton et al. 1987; Brindley et al. 1985).
Glucose homeostasis
Interestingly, both vehicle and DEX-treated offspring, fed a low sodium diet for 11 days
became glucose intolerant and insulin resistant, when compared to offspring fed a high
sodium diet. How could a low sodium diet 'overwrite' programming and render both
vehicle and DEX-treated offspring insulin resistant? Decreased insulin clearance as a
result of RAS activation (observed in both cohorts fed a low sodium diet) may be
responsible for this phenomenon (Lender et al. 1997). Indeed, decreased blood flow to
the liver as a result of Ang II (Ichikawa et al. 1979) can diminish insulin clearance
(Meland et al. 1994), and has been proposed to underlie the insulin resistance associated
with low salt diet feeding in wistar rats (Prada et al. 2000). Thus, it is tempting to
speculate that the increased basal plasma insulin levels observed in this study are related
to high plasma Ang II concentration. The association between a low sodium diet and
insulin resistance also concurs with human studies of both healthy volunteers and
patients with essential hypertension. (Fliser et al. 1995; Meland et al. 1997).
Additionally, insulin has been postulated to play a role in the pathophysiology of
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essential hypertension (see section 1.4.2e), and could therefore possibly contribute to
hypertension in this study.
Summary
This study reveals that a 4-fold reduction in dietary sodium results in hypertension in
prenatally vehicle treated animals, and supports a role for both the HPA and RAS in
mediating this. Conversely, whilst a lower sodium diet intensifies RAS dysregulation in
DEX-treated offspring, this does not exacerbate their programmed blood pressure
phenotype. Acute exposure to a lower sodium diet is sufficient to cause glucose
intolerance and insulin resistance in adult rats, irrespective of their prenatal treatment.
Repetition of many of these measurements under the initially proposed dietary
conditions, together with the addition of plasma Angll and ANP measurements and
radiotelemetric blood pressure monitoring, would be instructive in further elucidating
the phenotype of the DEX-programmed rat.
Incidentally
As a result of legal action arising from this study, Special Diet Services now ensures
independent testing of every bespoke diet, thereby sparing other researchers the
agonising experience of wasting time, animals and funds.
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Altered sympathetic responses mediate the stress-
induced hypertension associated with prenatal
dexamethasone in the rat
6.1 Introduction
In recent years, there has been growing evidence for an effect of intrauterine
development on disease risk in later life (Law et al. 2001; Curhan et al. 1996a; Curhan et
al. 1996b; Fall et al. 1998; Osmond et al. 1993; McCance et al. 1994; Barker et al. 1990;
Law et al. 1993; Yarbrough et al. 1998). Global epidemiological studies indicate that
low birth weight, a surrogate measure of an adverse intrauterine environment, is
associated with an increased risk of type 2 diabetes (McCance et al. 1994), hypertension
(Barker et al. 1990) and cardiovascular disease in adulthood (Barker 1999; Curhan et al.
1996b). To explain these findings, the physiological concept of prenatal 'programming'
has been developed, whereby a factor acting during critical periods of fetal life alters the
development of organs, resulting in permanently altered function and eventually disease
(Barker et al. 1993; Edwards et al. 1993).Whilst the pathophysiological mechanisms
underlying this relationship between low birth weight and subsequent adulthood disease
remain to be fully established, both fetal malnutrition (Barker et al. 1993) and in utero
overexposure to glucocorticoids (Benediktsson et al. 1993) have been proposed as
mediators of permanent programming of cardiovascular and metabolic phenotypes.
Fetal 'programming' may be investigated in a more controlled manner by using
laboratory animals that age rapidly and have similar genetic backgrounds. We and others
have long demonstrated in rats that prenatal exposure to the synthetic glucocorticoid
dexamethasone (DEX), commonly used in obstetric practice, produces permanently
impaired glucose intolerance, insulin resistance and hypertension in the adult offspring
(Levitt et al. 1996b; Nyirenda et al. 1998; Nyirenda et al. 2001; Langdown et al. 2001;
Sugden et al. 2001). Similarly, overexposure of endogenous maternal glucocorticoids by
inhibition of the feto-placental 'barrier enzyme', llbeta hydroxysteroid dehydrogenase
Prenatal DEX and increased SNS responsivity - 129 -
Chapter 6
type 2, programmes the same adulthood cardiovascular and metabolic pathologies
(Welberg et al. 2000; Lindsay et al. 1996a; Lindsay et al. 1996b). Although programmed
increases in the expression of key hepatic gluconeogenic enzymes may underpin later
hyperglycaemia (Nyirenda et al. 1998; Nyirenda et al. 2001), little is known of the
mechanisms by which glucocorticoids programme hypertension.
In rats, prenatal DEX, specifically in the last trimester, affects the development and
maturation of specific organs related to blood pressure control and maintenance; notably
the developing heart, kidney, vasculature and brain. Alterations in the activity or
responsivity of the sympathetic nervous system (SNS), either systemically or in one of
these specific regions, could provide one potential explanation for the manner in which
prenatal glucocorticoids promote adulthood hypertension. Indeed, in humans, increased
SNS activity has been proposed as a mechanism to explain the pathogenesis of
glucocorticoid-induced hypertension (Whitworth 1994; Whitworth et al. 1995; Saruta
1996). Consistent with this hypothesis, elevated SNS activity, established in utero, has
been demonstrated as one mechanism to link small size at birth with raised blood
pressure in adult life (Phillips & Barker 1997). In rats, prenatal DEX is known to
interfere with the development of cardiac, and central sympathetic innervation and
activity (Bian et al. 1993b; Slotkin et al. 1992), and to permanently alter the pattern and
expression of alpha and beta adrenergic receptors (Huff et al. 1991; Bian et al. 1992);
thereby possibly altering vascular responsivity to vasoconstrictors. Similar findings have
been reported with DEX administration during pregnancy in sheep, and are proposed to
mediate the increased cardiovascular responses in glucocorticoid treated fetuses (Tseng
et al. 1995; Padbury et al. 1995; Stein et al. 1994; Stein et al. 1993).
In the current study, we hypothesized that prenatal DEX-administration in the final
week of gestation increases blood pressure in the adult offspring by altering sympathetic
nerve responsivity; to investigate this, we used the method of radiotelemetry (Anderson
et al. 1999), which enables the remote recording of blood pressure in conscious,
unrestrained offspring. The pressor response of the mesenteric vasculature to
noradrenaline, vasopressin and potassium chloride, in both male and female offspring
were also assessed.




Female rats and their litters were maintained, bred, and administered with vehicle or
DEX during their third week of pregnancy as described in Chapter 2. The following
represent a new cohort of prenatally treated animals and are not the same as those
described in Chapter 4. Male and female offspring were weighed at 3, 7, 14 and 21 days
of age, and at three weekly intervals thereafter throughout postnatal life.
6.2.2 Radiotelemetric blood pressure measurement
Blood pressure (systolic, diastolic, and mean pressure), heart rate, and activity were
assessed by radiotelemetry in randomly selected littermates (5 male and 5 female, from 8
vehicle and 8 DEX litters) at 7-8 months of age, as outlined in Chapter 2.
6.2.3 Induction of stress by disturbance, weighing, and restraint procedure
To assess responses to stress, offspring were subjected to a series of graded stressors
from simple disturbance (a researcher entering their room), to being weighed, and placed
in a Perspex cylinder for 15 min. To evaluate the stress response to weighing,
haemodynamic measurements were recorded prior to removal of the rat from its cage,
and again immediately and at 5 min post-weighing, when the animal was replaced in its
home cage. For the restraint procedure, haemodynamic measurements were collected
prior to the rat being placed in the cylinder, throughout the 15 min restraint period, and
at 15 min post-restraint, when the animal was returned to its cage. A rest period of two
days was allowed between experiments.
6.2.4 Haemodynamic responses to alterations in catecholaminergic
mechanisms
Haemodynamic responses were analysed 2 hr following the depletion of catecholamines
by i.p. reserpine (O.Smg.kg"1), and during a 15 min restraint test, performed 4 hr post-
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reserpine administration. After a 1-week recovery period, haemodynamic responses were
collected for 15 min following a low dose of i.p. d-amphetamine (0.5mg.kg_1), aimed to
cause systemic catecholamine release.
6.2.5 Vascular responses to noradrenaline, vasopressin, and potassium
chloride
12 pairs of mesenteric vasculature preparations from both male and female offspring
aged between 4-4.5 months were simultaneously tested with increasing concentrations of
agonists in the following order: NA (0.1- 20pM; Sigma-Aldrich, UK), AVP (0.5- 20
nM; Sigma-Aldrich, UK) and KC1 (25-125mM), as described in Chapter 2.
6.2.6 Statistical analyses
All data are expressed as mean ± SEM.
Radiotelemetry data were compared using two-way or multiple ANOVA followed by a
LSD post-hoc multiple comparisons test where appropriate. Values were considered
significant when p < 0.05.
For each mesenteric preparation, the maximal response and the concentration of agonist
required for a 50% response (EC50) were determined. Differences in the mean log EC50
and maximal response values between vehicle and DEX-treated offspring mesenteric
vasculatures were compared using Student's unpaired t-test. Data were further analysed
by 2-way ANOVA (prenatal treatment x dose of agonist) followed by a LSD post-hoc
multiple comparisons; results were considered significant when p < 0.05.
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6.2 Results
6.3.1 Gestational weight gain, birth phenotype and catch-up growth
As outlined in Table 6-1, DEX administration throughout the final week of gestation
again resulted in a significant reduction in maternal weight gain, with no differences
noted in the length of gestation, litter size, ratio of male to female pups born or pup
viability. DEX treatment caused a significant reduction in the birth weight of offspring,
which was observed to the same degree in both male and female pups, consistent with
previous studies.
By weaning (postnatal day 21) and throughout adult life, the gain in body weight
ofmale and female offspring, treated with vehicle or DEX were similar, i.e. full catch-up
growth had occurred (data not shown).
Table 6-1 Comparison of gestational and birth parameters in vehicle
and DEX treated cohorts
Maternal weight before treatment, maternal weight gain during the last week of
pregnancy (days 15-21), gestation length, litter size, male: female ratio, and group, male,
and female offspring birth weight. Results are mean ± S.E.M, Student's t-test, * p < 0.05,
tP < 0.01 compared with vehicle group.
Maternal weight Maternal Gestation Litter Male: female Birth weight
before treatment weight gain length size ratio Group Male Female
(g) (g) (d) (g)
Vehicle 365 ±14 97 ±5 22 ±0 13 ±2.0 1.1 ±0.1 6.6 ±0.01 6.6 ±0.09 6.5 ±0.08
(n = 8) (n = 99) (n = 55) («= 44)
DEX 363 ±6 58 ±5* 22 ±0 12 ±1.8 1.2 ±0.2 5.7 ± 0.01 f 5.6 ± 0.08f 5.7±0.07|
(w = 9) (n = 108) (n = 56) («= 52)
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6.3.2 Radiotelemetry monitoring of offspring blood pressure, heart rate,
and activity under basal conditions
Circadian variations of blood pressure, heart rate, and activity were detected in all
offspring of the prenatal treatment groups; being highest early in the morning and falling
to their lowest during the afternoon (see Table 6-2 and Figure 6-1A). Both DEX-treated
male and female offspring had lower active (dark) phase systolic blood pressure when
compared to controls (see Table 6-2). Mean arterial blood pressure was also
significantly lower in DEX-treated offspring (see Figure 6-1A). There were no
significant differences between control and DEX-treated offspring in diastolic blood
pressure (see Table 6-2), heart rate (see Table 6-2 and Figure 6-1B) or activity (see
Table 6-2).
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Table 6-2 Offspring baseline cardiovascular and activity phenotypes
Cardiovascular parameters and activity measured under basal conditions in adult
offspring of vehicle and DEX-treated dams. Results are mean ± S.E.M, 2-way ANOVA
(prenatal treatment x gender), * p < 0.05, compared with vehicle group.
Vehicle $ Dex <$ Vehicle ^ Dex ^
Parameter (n = 5) (n = 5) (n= 4) (n = 5)
Systolic BP, mmHg
Night 153 ±7 143 ±10* 144 ±6 135 ±10*
Day 137 ±7 134 ±10 127 ±5 125 ±9
Diastolic BP, mmHg
Night 111 ±6 105 ±10 106 ±5 105 ±11
Day 102 ±5 98 ± 8 97 ± 5 95 ± 9
Heart Rate, bpm
Night 379 ± 13 378 ±37 414 ±17 410 ±24
Day 298 ±19 319 ±41 310 ± 12 323 ± 22
Activity
Night 4± 1 4± 1 9 ± 3 6±3
Day 1 ± 0.4 1 ±0.5 1.4 ±0.1 1.4 ±1
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Figure 6-1A Offspring basal mean arterial blood pressure patterns
Basal mean arterial blood pressure (MAP) in male and female offspring exposed to
vehicle (---) or DEX (—) during the last week of gestation. Data are expressed as 6-
hour rolling averages over 3 days. Values are mean ± s.E.M, 2-way ANOVA (prenatal
treatment x gender), n = 4 -5 of each sex per group, * p< 0.05 compared with vehicle
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Figure 6-1B Offspring basal heart rate patterns
Basal heart rate patterns in male and female offspring exposed to vehicle (—) or DEX
(—) during the last week of gestation. Data are expressed as 6-hour rolling averages
over 3 days. Values are mean ± s.E.M, 2-way ANOVA (prenatal treatment x gender),
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6.3.3 Offspring haemodynamic and activity responses to graded stressors
In utero exposure to DEX has been shown to cause a lifelong elevation in basal blood
pressure when measured by tail-cuff plethysmography and carotid cannulation. An
exaggerated stress response to these measurement techniques would account for this
hypertension. Therefore, we examined whether prenatal exposure to DEX was
associated with a hypertensive response to stress. As shown in Figure 6-2A, DEX-
treated offspring are exquisitely hypersensitive to stress, displaying graded hypertensive
responses when disturbed by a researcher entering their room, and when restrained. Even
weighing elicits a hypertensive response in DEX treated offspring (change in systolic
blood pressure, vehicle 10 ± 2 mmHg, DEX 19 ± 3 mmHg; p < 0.05). Moreover, DEX-
treated offspring maintain their hypertension for longer once released from restraint (see
Figure 6-2A), and after weighing ( change in systolic blood pressure 5 min post-
weighing, vehicle, 7 ± 5 mmHg, DEX 23 ± 5 mmHg ; p < 0.05). Dex-treated offspring
further displayed significantly increased changes in heart rate in response to being
weighed (vehicle 117 ± 17 bpm, DEX 156 ± 25 bpm; p < 0.05), and held in restraint
(vehicle 86 ± 11 bpm, DEX 136 ± 19 bpm; p < 0.05), which were not associated with
changes in activity (data not shown).
6.3.4 Offspring responses to alterations in catecholaminergic pathways
To assess the role of the sympathetic nervous system in mediating this stress induced
hypertension, we depleted nerve terminal catecholamines, using a low dose of reserpine.
DEX-treated offspring displayed a greater fall in mean arterial blood pressure and heart
rate (Table 3). Moreover, their previously demonstrated hypertensive responses pre-,
(vehicle -16 ± 3 mmHg, DEX 22 ± 4 mmHg; p = 0.1), during (vehicle 2 ± 5 mmHg,
DEX 1 ± 3 mmHg; p = 0.6) and post-restraint (vehicle -5 ± 2 mmHg, DEX -4 ± 3
mmHg; p = 0.86) were completely abolished (see Figure 6-2B). Conversely, a low dose
of d-amphetamine, to induce catecholamine release, resulted in a significantly greater
increase in DEX-treated offspring's mean arterial blood pressure and heart rate (see
Table 6-3). No significant differences in activity were noted between offspring's
response to either reserpine or d-amphetamine (see Table 6-3).
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Figure 6-2 Offspring blood pressure response to stress and inhibition
of catecholamine synthesis
A. Stress-induced mean arterial blood pressure changes in prenatal vehicle and DEX-
treated offspring, following disturbance, restraint, and at 15 min post- restraint. B.
Inhibiting catecholamine synthesis (reserpine; 0.5mg/kg) abolishes the exaggerated
stress-induced elevations in mean arterial blood pressure, previously displayed by
prenatal DEX-treated offspring during and post restraint. Values are mean ± S.E.M, 2-
way ANOVA (prenatal treatment x gender), n = 4-5 of each sex per group in A, and 3-4
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Table 6-3 Effect of reserpine and d-amphetamine on offspring
haemodynamic and activity patterns
Alterations in baseline haemodynamic parameters and activity post reserpine
(catecholamine synthesis inhibition) and d-amphetamine (catecholamine release)
administration, in adult offspring of vehicle and DEX-treated dams. Results are mean ±
S.E.M, 2-way ANOVA (prenatal treatment x gender), * p < 0.05, compared with vehicle
group.
Vehicle Offspring Dex Offspring
(n = 7; 4 (3\ 3 $) (n = 7;4^3?)
Reserpine
(0.5mg/kg; i.p.)
Delta MAP, mmHg -16 ±2 -24 ± 3*
Delta Heart Rate, bpm -74 ±16 -145 ±18*
Delta Activity -3 ±1.3 -2.5 ±1.2
D-amphetamine
(0.5mg/kg; i.p.)
Delta MAP, mmHg 14 ±0.5 26 ±3*
Delta Heart Rate, bpm 32 ±3 67 ± 11
Delta Activity 13 ± 2 13 ± 3
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6.3.5 Responsiveness of offspring mesenteric vasculature to
noradrenaline, vasopressin, and potassium chloride
Male Offspring
The responses of the mesenteric vasculature to the three agonists are shown in Figures
6-3A, B, and C. Basal perfusion pressures were similar in the two groups of rats.
Infusion of all agonists caused a concentration-dependent increase in perfusion
pressures, with plateaux reached in both groups at 5pM for noradrenaline, lOnM for
vasopressin, and 125mM for potassium chloride. However, tissues from DEX-treated
offspring were significantly more responsive; the maximal increments were greater to
each agonist tested, and the EC50 values were lower for both noradrenaline and
vasopressin (see Table 6-4).
Table 6-4 Mesenteric vascular function in vehicle and DEX-treated
male offspring
Maximal contraction and responsiveness to vascular agonists (as assessed by EC50), in
the mesenteric vasculature from vehicle and DEX-treated male offspring. Values are
mean ± S.E.M; n= 6 per group; Student's t-test,* p < 0.05, f P < 0-01, compared with
vehicle group
Vascular parametei Agonist Vehicle DEX
Maximal Contraction
(mmHg)
Noradrenaline 318± 12 371 ±25f
Vasopressin 260 ± 19 298±19*




0.5 ±0.06 0.4 ± 0.02f
Vasopressin
(nM)
3.0 ±0.20 2.5 ±0.30*
KC1
(mM)
63.0 ±5 67 ±3
(p = 0.27)
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Female Offspring
Similar basal perfusion pressures were noted in the two groups. Noradrenaline caused a
concentration-dependent increase in perfusion pressures, with plateaus reached at 2pM
in both treatment groups (see Figure 6-3D). However, the mesenteric vasculatures from
DEX-treated offspring were significantly more responsive to noradrenaline, (as analysed
by 2-way ANOVA), even though the maximal contraction (Vehicle, 344 ± 40mmHg
versus DEX, 373 ± 30; p = 0.16) and EC50 (Vehicle, 0.43 ± 0.02pM versus DEX, 0.39 ±
0.03pM; p = 0.16) values were similar for both treatment groups. DEX treatment did not
affect the pattern of responses to either vasopressin or potassium chloride. Maximal
responses in both groups were achieved at 5nM vasopressin, and 125mM potassium
chloride (data not shown).
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Figure 6-3 Constrictor responses of mesenteric vasculature from adult
male and female rats treated with vehicle or DEX in utero
Male offspring dose-response curves to noradrenaline (A), vasopressin (B) and
potassium chloride (C); and female offspring dose-response curve to noradrenaline (D),
in the isolated mesenteric vasculature from vehicle and DEX-treated rats. Results are
mean ± S.E.M, n = 6 per group, 2-way ANOVA (prenatal treatment x dose), f p < 0.01
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6.4 Discussion
The novelty of this study lies in the observation that prenatal DEX during the last week
of pregnancy actually results in lower basal blood pressure in the adult offspring; with
the hypertensive phenotype only being noted when these offspring are subjected to a
stressor. Moreover, DEX-treated offspring maintain this stress-induced hypertension for
longer following removal of the stressor. These hypertensive responses are mediated by
alterations in the responsivity of the SNS, being ameliorated by the inhibition of
catecholamine synthesis, and further exaggerated by the promotion of systemic
catecholamine release. Additionally, DEX-treated offspring display greater sensitivity to
a variety of vasoconstrictors in the isolated mesenteric vasculature.
Radiotelemetry, as a method of blood pressure measurement in rats has myriad
advantages over both tail-cuff plethysmography (TCP) and carotid cannulation (CC), as
it enables the recording of systolic and diastolic pressures in conscious, unrestrained, and
unanaesthetized animals. The majority of reports in which offspring blood pressure has
been assessed in rat models of fetal programming have relied on TCP (Langley-Evans
1997; Woodall et al. 1996; Langley & Jackson 1994) or CC (Levitt et al. 1996a;
Benediktsson et al. 1993). TCP, which only records systolic blood pressure, not only
involves preheating of the animal prior to measurement, but also requires considerable
restraint, as does CC. Naturally, both preheating and restraint could artifactually cause a
substantive elevation in basal blood pressure while failing to observe a selective increase
in pressor responses (Tonkiss et al. 1998). Furthermore, radiotelemetry also provides a
contrast between day (sleep) and the physiologically more accurate night (awake)
values, together with heart rate and an estimate of activity. Thus, serious stress effects,
together with the day-time recording of blood pressure, would account for the previously
demonstrated hypertension associated with prenatal glucocorticoid programming, when
assessed by TCP or CC. The observation in the current study that DEX-treated offspring
had reduced systolic and mean arterial blood pressure was completely unexpected.
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To the best of our knowledge, this is the first investigation to have undertaken a
comprehensive longitudinal study with the use of radiotelemetry for the measurement of
blood pressure in a prenatal glucocorticoid model of fetal programming. In rats, only two
previous dietary models of fetal programming (Tonkiss et al. 1998; Khan et al. 2003)
and one of intrauterine growth restriction have utilised radiotelemetry (Jansson &
Lambert 1999). In one, blood pressure was measured over a single 24-hour time period,
and uncovered a small (4mmHg) significant rise in the awake-phase diastolic blood
pressure in the male offspring of dams fed a diet with significantly reduced protein
content (by 19%) (Tonkiss et al. 1998). Female offspring were not studied. Interestingly,
in that study the offspring of the malnourished rats displayed a greater hypertensive
response to stress (ammonia odour) when compared to controls, thereby not only
highlighting the importance of recording in conscious unrestrained animals, but also
hinting at a potential cause ofprogrammable hypertension.
The impetus for examining pressor responses to stress stemmed not only from this
evidence, and the possible explanation for the hypertension uncovered by TCP or CC,
but also from the simple observation in the current study that merely entering the room
in which the offspring were housed was sufficient to drive hypertension selectively in
the DEX-treated offspring. When further subjected to a moderate stressor (weighing)
and the more severe restraint stress, similar to that used in TCP, the pressor responses of
the male and female DEX-treated offspring were significantly augmented, suggesting
increased sensitivity to environmental stress. An increased reactivity to stressful
environmental stimuli may lead to established hypertension through frequent transient
blood pressure elevations (Folkow & Hallback 1978), and whether these offspring would
eventually become permanently hypertensive warrants further study. Indeed, the DEX-
treated offspring maintained their hypertension longer after the removal of each stressor.
Insight into the potential mechanisms of this stress-induced hypertension may be gained
from the observation that DEX-treated offspring had higher heart rates (i.e. a marker,
although indirect, of cardiovascular adrenergic drive) associated with each of their
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hypertensive stress responses, indicating increased sympathetic nerve activity and/or
responsivity. Depletion of nerve terminal catecholamine stores with reserpine (an
Uptake-1 inhibitor) was sufficient to abolish the effect of DEX on the hypertensive
response and accompanying tachycardia pre- and post-restraint stress, whilst the same
dose of d-amphetamine led to a greater increase in these basal haemodynamic
parameters, further strengthening the evidence for a more responsive SNS. The SNS
participates in several stress responses, even in fetal life (McMillen et al. 2001), and
therefore, prenatal exposure to various stressors might affect the development of
sympathetic innervation or its regulation. For example, in rats, the offspring of prenatal
DEX-treated dams have increased noradrenaline turnover (a measure of neuronal
impulse) in central brain regions concerned with blood pressure control (Slotkin et al.
1992), whilst cardiac noradrenaline levels and turnover are suppressed (Bian et al.
1993a). In line with these observations, continuous gestational exposure to nicotine
impaired the maturation of both central and peripheral catecholaminergic pathways in
rats (Navarro et al. 1988), and a study on the offspring of rats kept in hypoxia during
pregnancy showed altered development of sympathetic centers involved in blood
pressure regulation (Peyronnet et al. 2002). Most interestingly, in the latter study, the
adverse effects on blood pressure regulation persisted throughout adulthood. Similarly,
ligation of the umbilical artery, an experimental model of fetal malnutrition, resulted in
alterations in SNS activity in both the newborn sheep (Oyama et al. 1992) and adult
female rat offspring (Jansson & Lambert 1999). Taken together, these animal data firmly
indicate that adverse influences in utero are capable of impairing the development and
function of the SNS. A recent study in low birth weight adults proposed that their lower
resting muscle sympathetic nerve activities were a function of altered SNS development
(Weitz et al. 2003). It is tempting to speculate that the demonstrated augmented SNS
responsivity observed in our DEX-treated offspring is a function of altered regulation of
adrenergic receptor density and coupling to or functional activity of signal transduction
mechanisms, though this remains to be elucidated.
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Increases in peripheral vascular resistance and cardiac output may also contribute to the
stress-induced hypertension observed in our prenatal DEX-treated offspring and have
been postulated to mediate the increases in blood pressure during glucocorticoid
treatment both pre- and post-natally (Derks et al. 1997). Studies using synthetic
glucocorticoids, such as DEX or bethasmethasone, suggest that the increased blood
pressure is independent ofmineralocorticoid-mediated effects, such as sodium retention
or volume expansion (Grunfeld 1990). Rather, it appears that glucocorticoids directly
alter vascular responsiveness to circulating vasoactive agents. In the present study, the
pattern of dose-response curves in the mesenteric vasculature of DEX-treated offspring
showed greater in vitro pressor responses to noradrenaline in male and females, and to
vasopressin and a depolarizing potassium solution in males only. The in vitro perfusion
preparation used in these studies was separated from other in vivo systems known to
regulate vascular tone, suggesting therefore, that a change in receptor binding or
alterations in the production of local vasorelaxants/constrictors underlies the increased
vascular sensitivity. Glucocorticoids may regulate the synthesis of vasoactive
compounds, such as prostaglandins or nitric oxide, which in turn modulate peripheral
vascular reactivity. Indeed, inhibition of nitric oxide synthesis (Wallerath et al. 1999)
and decreased levels of both prostaglandin and its mediator adenylate cyclase (Handa et
al. 1984; Handa et al. 1983) have been demonstrated in adult rats with DEX-induced
hypertension. Similarly increased mesenteric vasculature sensitivity to noradrenaline has
been observed in rats treated with low doses of DEX (Russo et al. 1990). Notably, these
animals were at a pre-hypertensive stage, and had alterations in both prostaglandin
synthesis and in the neuronal uptake of noradrenaline. The gender differences noted in
the mesenteric vasculature responses of DEX-treated offspring to both vasopressin and
potassium chloride are intriguing, and could possibly reflect changes in vascular
reactivity during the reproductive cycle (Dalle Lucca et al. 2000), and the effect of sex
steroids on vascular smooth muscle sensitivity (Garcia-Villalon et al. 1996).
Interestingly, as in this study, gender has been previously demonstrated to have no effect
on the sensitivity to noradrenaline in both the rat tail artery and aorta (Garcia-Villalon et
al. 1996; Fulton et al. 2002).
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Antenatal glucocorticoids have well documented and very substantial immediate benefits
in threatened pre-mature labour (Crowley 2003; Crowley 2000). However, there is ever
increasing interest regarding the non-pulmonary effects of glucocorticoid exposure to the
fetus (O'Regan et al. 2001). Indeed, recent data have suggested that a short antenatal
glucocorticoid exposure in preterm infants is associated with increased blood pressure at
adolescence (Doyle et al. 1999). The present study, though somewhat small in sample
number and duration, advances our knowledge of the nature and mechanisms of
glucocorticoid-induced alterations in postnatal blood pressure. As the prenatal
glucocorticoid exposure models extend our understanding of the fetal origins
phenomena, it is clear that there is a real need for replication and extended studies in
humans. Only then, will we be better equipped to understand both the immediate and
long-term consequences of antenatal glucocorticoid treatment.
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Mechanisms ofglucocorticoid programmed disease
7.1 Background and aims
When glucocorticoids were first employed therapeutically almost 50 years ago, they
were administered with great gusto, including during pregnancy. From the outset, results
showed that the offspring of women treated with glucocorticoids when pregnant had
reduced birth weight, an effect that is reflected in numerous experimental animals
(reviewed in O' Regan et al. 2001). Repeated global epidemiological studies have linked
low birth weight and other markers of restrained growth in early life with a considerable
increased risk of hypertension, type II diabetes and ischaemic heart disease (Barker
1998). Given the growth-retarding effects of glucocorticoids, their key role in
determining the trajectory of organ maturation and their direct hypertensive and
hyperglycaemic effects in vivo, some investigators questioned whether glucocorticoids
might underlie these epidemiological links (Edwards et al. 1993; Seckl et al. 1999).
Subsequent studies in rats, sheep and guinea pigs showed that brief glucocorticoid
exposure during specific 'developmental windows' of foetal life could permanently
programme or 'hardwire' tissue responses, leading to persistent elevations of blood
pressure and blood glucose and insulin levels in adult life. Now, research is focused on
identifying the underlying mechanisms that are involved in the glucocorticoid
programming of disease.
To this end, research in this thesis was aimed at primarily determining the nature and
mechanism(s) of glucocorticoid programmed hypertension, and to further determine
whether programmed cardiovascular and metabolic events are sexually dimorphic. It




7.2 Gender specific programming of cardiovascular and
metabolic abnormalities
7.2.1 Metabolic phenotypes
The results presented in Chapter 4 of this thesis adds further weight to the hypothesis
that in utero over-exposure to glucocorticoids programmes increased hepatic glucose
output, thereby producing glucose intolerance and insulin resistance throughout adult
life. Evidence is presented that none of these effects occur in female offspring, even
though treatment involved the same gestational window and indeed dams as the males,
and birth weight was similarly reduced in both sexes.
Analogous findings have been made in an alternative model of programmed insulin
resistance i.e. only the male offspring of protein restricted dams have elevated PEPCK
activity (Desai et al. 1997b) and are insulin resistant ( Desai et al. 1997a; Sugden &
Holness 2002). Interestingly, the two prenatal challenges may be related as dietary
protein restriction reduces placental 11P-HSD type II, allowing excess foetal
glucocorticoid exposure (Langley-Evans et al. 1996).
Furthermore, the evidence that only DEX-treated male offspring display a hyperactive
HPA-axis provides one mechanism to explain the sex-specific cause of their glucose
dyshomeostasis.
The male-specific metabolic response to prenatal DEX programming may be important
in relation to other studies showing increased vulnerability of male rats, compared to
females, to the later development of obesity (Anguita et al. 1993),
hypercholesterolemia (Lucas et al. 1996) and triacylglycerolaemia (Lucas et al. 1996)
as a result of early protein restriction. At each stage during adulthood, the DEX-treated
males in our studies were considerably heavier than their female siblings, despite being
similarly intra-uterine growth retarded. Thus, could the combination of IUGR and excess
weight gain in adult life be particularly detrimental to male rats? This suggestion would
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be consistent with observations in humans that show IUGR men to be more insulin
resistant than women (Phillips et al. 1994). It is further known that the distribution of
body fat is important in the etiology of insulin resistance, and men have greater fat
deposition around the waist (intra-abdominal obesity) associated with greater insulin
resistance (Ferrannini 1995; Ludvik et al. 1995). Interestingly, corticosterone treatment
of male rats has been demonstrated to uniquely increase intra-abdominal fat depots
(Rebuffe-Scrive et al. 1992), though the effect of prenatal DEX on body fat distribution
remains to be determined in our model. Additionally, it is only women with a relative
hyperandrogenicity that are statistically associated with a centralisation of body fat and
insulin resistance (Nilsson et al. 1998). Thus, it is also possible that the higher male
androgen levels drive body fat centralisiation and promote insulin resistance. Consistent
with this hypothesis, female rat pups imprinted with androgens display increased intra¬
abdominal fat depots and insulin resistance (Nilsson et al. 1998). Furthermore, it is
tempting to speculate that the DEX-treated male increase in insulin resistance may
operate in tandem with their higher basal glucocorticoid levels to increase PEPCK
activity (Friedman et al. 1997; Reshef et al. 1970).
7.2.2 Cardiovascular phenotypes
Data presented in Chapter 4 also reinforces the notion that prenatal DEX treatment
results in adult offspring with elevated blood pressure (Benediktsson et al. 1993; Levitt
et al. 1996b). In contrast to previous studies (Benediktsson et al. 1993), the evidence
presented here suggests that this characteristic was female-specific.
Similar female-specific elevations in blood pressure have been made in other prenatal
glucocorticoid (Ortiz et al. 2003) and dietary (Khan et al. 2003) programming models,
although as illustrated by Chapter 6 and others (Ortiz et al. 2003), these data may reflect
the inherent problems of single time-point measurement techniques.
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Whatever the basis for the sex difference in this study, prenatal glucocorticoid
administration resulted in generalised activation of the RAS in the hypertensive female
but not the normotensive male littermate offspring; with the higher hepatic
angiotensinogen mRNA levels and consequent elevation in plasma angiotensinogen
concentrations probably driving female hypertension.
Angiotensinogen is a key step determining RAS activation in rodents (Tamura et al.
1996), has been implicated to underlie in part the glucocorticoid programmed
hypertension in sheep (Dodic et al. 2001), and is a strong candidiate gene for
hypertension in humans (Corvol et al. 1999; Martinez et al. 2002; Procopciuc et al.
2002).
Importantly, circulating oestradiol did not vary physiologically between the groups of
prenatally treated offspring, though the naturally higher female levels could account for
the gender differences in RAS programming.
7.3 Nature and mechanisms of glucocorticoid programmed
hypertension
Results presented in Chapter 6 illustrate that prenatal DEX during the last week of
pregnancy actually results in lower basal blood pressure in the adult offspring; with the
previously reported hypertensive phenotype only being noted when these offspring are
subjected to any stressor, regardless of its apparent banality. Moreover, DEX-treated
offspring maintain this stress-induced hypertension for longer following removal of the
stressor. These hypertensive responses are mediated by alterations in the responsivity of
the SNS, being ameliorated by the inhibition of catecholamine synthesis, and further
exaggerated by the promotion of systemic catecholamine release. Additionally, evidence
is presented that DEX-treated offspring display greater sensitivity to a variety of
vasoconstrictors in the isolated mesenteric vasculature.
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Collectively, all the findings in this thesis reinforce the early life origins of disease
hypothesis. They provide further evidence, and more importantly, mechanisms for the
programming of metabolic and cardiovascular pathophysiology, over and above those
derived from epidemiological associations. Furthermore, genes identified as being
differentially expressed between prenatally glucocorticoid treated and control animals
(e.g. angiotensinogen), could become targets for therapeutic intervention. By targeting
these genes in individuals deemed at risk because of low weight or thinness at birth, it
may be possible to ameliorate or prevent the development of adulthood hypertension and
insulin resistance. For example, in rodents, early postnatal treatment with an inhibitor of
the RAS prevents the subsequent development of adulthood hypertension in the
offspring ofprotein restricted dams (Sherman & Langley-Evans 1998).
These findings may be of relevance to humans, as antenatal glucocorticoids have
extensive therapeutic use prenatally. Despite their apparent benefits to the preterm infant
(Crowley 2000; Crowley 2003), there is ever increasing interest regarding the non-
pulmonary effects of glucocorticoid exposure to the foetus (O' Regan et al. 2001).
Indeed, recent data have suggested that a short antenatal glucocorticoid exposure in
preterm infants is associated with increased blood pressure at adolescence (Doyle et al.
1999). The present thesis provides novel information regarding the nature and
mechanisms of glucocorticoid-induced alterations in postnatal blood pressure. Moreover,
it may shape future clinical studies, by highlighting the absolute necessity for
ambulatory BP monitoring, as to avoid stress artifacts or 'white-coat' hypertension in
low birth weight subjects. Alternatively, it is tempting to speculate that these findings
provide a mechanistic basis for 'white-coat' hypertension; and it would be interesting to
elucidate whether those susceptible to the condition are in fact 'programmed'. As the
'disturbance' stress studies in Chapter 6 illustrate, prenatally DEX-treated animals are
unable to adapt to their environment, and ambulatory BP measurements would provide
valuable and detailed BP profiles about low birth weight human subjects as they go
about their everyday lives. As the prenatal glucocorticoid exposure model continues to
extend our understanding of the early-life origins phenomena, it is clear that there is a
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real need for replication and extended studies in humans. Only then, will we be better
equipped to understand both the immediate and long-term consequences of antenatal
glucocorticoid treatment. In the interim, the further evidence presented in this thesis
recommends that caution is required in the use of these interventions; whilst some
glucocorticoid is good, more is not necessarily better.
7.4 Dietary effects on programming
Data presented in Chapter 5 revealed that a 4-fold reduction in dietary sodium results in
hypertension in prenatally vehicle treated animals; and supports a role for both the HPA
and RAS in mediating this. Conversely, whilst a lower sodium diet intensified the pre¬
existing RAS dysregulation in DEX-treated offspring, it did not exacerbate their
programmed blood pressure phenotype, and it is tempting to speculate that ANP may
play a role in preventing further hypertension (see section 5.3; Weidmann et al. 1986).
Furthermore, evidence is presented that acute exposure to a low sodium diet is sufficient
to cause glucose intolerance and insulin resistance in adult rats, irrespective of their
prenatal treatment. By activating the RAS, a low sodium diet can reduce blood flow to
the liver (Ichikawa et al. 1979) thereby decreasing insulin clearance (Meland et al. 1994;
Prada et al. 2000); thus providing one mechanism to explain this phenomenon.
7.5 Perinatal stress effects on programming
Results presented in Chapter 3 clearly illustrate the power of perinatal environmental
noise stress to alter the phenotype of prenatally vehicle and DEX- treated offspring (see
Table 3-2). The programming effects of stress alone on metabolic and cardiovascular
physiology remain to be elucidated, but are most probably mediated through increased
glucocorticoid secretion, and would therefore be expected to exacerbate the effects of
prenatal vehicle or DEX treatment.
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Vehicle and DEX-treated birth phenotypes normally observed in this paradigm (see
Table 3-2) were altered, and the previously demonstrated differences in adult phenotype
were completely abolished. Given that the birth phenotypes were affected, it is likely
that the environmental noise stress was present during the prenatal period. Reviewing
the absolute values for each investigated physiological parameter indicates that the
phenotype of vehicle-treated offspring had been shifted towards that of the DEX-treated
animals, with little if any deviation of the latter (see Table 3-2). This not only supports
the above assertion, but further implies that there is an 'upper-limit' for the
programming effects of stress and glucocorticoids.
7.6 Signposting future frontiers
Excitingly, many frontiers remain to be investigated before we fully comprehend the
mechanisms of prenatal glucocorticoid programmed disease; and elements of the work
presented in this thesis not only signpost these areas, but also indicate those worth
revisiting.
Amongst the latter, include aspects of the work presented in Chapter 5. Repetition of
many of the measurements under the initially proposed dietary conditions, with the
addition of: a high (3%) sodium diet, plasma Angll and ANP measurements, and
radiotelemetric blood pressure monitoring, would be instructive in further elucidating
the phenotypc of the DEX-programmed rat.
Data presented in this thesis strengthen previous results that the last week of gestation is
the crucial 'developmental window' in the rat during which glucose dyshomeostasis
(Nyirenda et al. 1998) and hypertension (Levitt et al. 1996a) can be programmed.
However, there is scope for this window to be further defined, as administration ofDEX
during the last two days of pregnancy alone did not result in adult hyperglycaemia
(Nyirenda et al. 2001), whereas constant treatment throughout pregnancy has resulted in
hypertension (Benediktsson et al. 1993). Epidemiological studies have suggested that
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infant size and proportion, and the nature of subsequent programmed events varies
according to the trimester during which the insult occurred (Osmond & Barker 2000;
Roseboom et al. 2001). The nature of the systems susceptible to DEX treatment during
discrete developmental windows will be dependent on the foetal gene expression and
biochemistry at that time, and could possibly underlie some of the observed sex
differences.
Further elucidation of the role of the SNS in this model is also warranted.
Charaterisation of a- and P-adrenoreceptors in prenatally treated offspring would
establish whether receptor subtype(s) underlie the increased catecholaminergic
responsitivity associated with prenatal DEX-treatment. Furthermore, given the key role
of the SNS in regulating the internal milieu, it would be of great interest to ascertain
whether SNS dysfunction underlies other programmed phenotypes. For example, does
increased programmed SNS responsivity, associated with prenatally DEX-treated
offspring, contribute to their glucose dyshomeostasis? Treatment with the catecholamine
synthesis inhibitor, reserpine, prior to commencement of an OGTT could address this.
Given the importance of programmed alterations in both the peripheral RAS and SNS to
the cardiovascular phenotype of prenatally DEX-treated offspring, there is a clear need
to extend investigations to those central regions governing blood pressure control. In the
brain, there is great interplay between both systems, with Angll being a well
documented stimulator of the SNS (Segar et al. 2001). On this basis, an obvious first
candidate to characterise would be Angll receptors in central sympathetic areas.
Several epidemiological studies advocate a positive correlation between maternal BP
during pregnancy and BP in children (Himmelmann et al. 1994; Himmelmann 1994).
Examination of this association in the DEX-model would obviously be worthwhile, in
order to determine if prenatal treatment has any adverse affects on maternal BP, and if it
is these alterations that contribute either wholly or in part to offspring BP, rather than the
prenatal treatment per se. Using radiotelemetry, it would be possible to accurately profile
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maternal BP prior to pregnancy, during prenatal treatment and the early postnatal period;
subsequent radiotelemetric BP recordings could then be made in her adult offspring.
The emerging role of gender in determining programmed outcomes is very intriguing,
and as previously discussed (see section 7.2), the mechanisms underlying this sexual
dimorphism in the effect of prenatal DEX on postnatal physiology clearly requires
further investigation.
Additionally, there remain several key topics to be addressed in our prenatal
glucocorticoid over-exposure model. As yet, no-one has examined whether RAS
inhibitors administered early in the postnatal period could ameliorate or prevent later
offspring hypertension, as in other prenatal programming models (Sherman & Langley-
Evans 1998). Furthermore, it has yet to be determined whether programmed alterations
in the pancreas of prenatal DEX-treated rats contribute to their glucose dyshomeostasis.
Epidemiological studies and other programming studies in rodents have associated low
birth weight with impaired immune function (McDade et al. 2001a; McDade et al.
2001b; Bakker et al. 1998), and renal impairment (Eriksson et al. 2000; Ortiz et al.
2003). Whether these abnormalities are associated with our prenatal DEX programming
model remains to be investigated.
Finally, recent evidence further emphasising the importance of early life events suggest
that they may also affect the health of subsequent generations. A clear inverse
correlation has been demonstrated between maternal birth weight and offspring BP that
is independent of offspring birth weight (Barker et al. 2000). Moreover, in rodents,
intrauterine maternal malnutrition has resulted in F2 adult offspring with pronounced
insulin resistance (Martin et al. 2000). The potential for prenatal DEX to influence the
metabolic and cardiovascular physiology of subsequent generations is the focus of
current research in our laboratory.
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7.7 Summary
Much of the world's population is challenged by increasing rates of adult-onset diabetes
and cardiovascular disease. Prevention of these chronic illnesses requires a search for the
origins of disease extending beyond the traditional limits of medical research and
practice. This thesis adds weight to the hypothesis that in utero over-exposure to
glucocorticoids can programme alterations in metabolic and cardiovascular physiology
that persist throughout adult life (summarised in Figure 7-1). Moreover, it seems that
prenatal DEX treatment produces hypertension that is specifically stress-induced, and
support a role for both the RAS and SNS in mediating this. Additionally, it appears that
the programming of cardiovascular physiology may reflect distinct processes in each
gender, whilst the programming of metabolic physiology is male specific. These
findings may prove valuable in directing future scientific and clinical investigations that
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